NZ620411B2 - Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors - Google Patents
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors Download PDFInfo
- Publication number
- NZ620411B2 NZ620411B2 NZ620411A NZ62041112A NZ620411B2 NZ 620411 B2 NZ620411 B2 NZ 620411B2 NZ 620411 A NZ620411 A NZ 620411A NZ 62041112 A NZ62041112 A NZ 62041112A NZ 620411 B2 NZ620411 B2 NZ 620411B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- alkyl
- optionally substituted
- group
- heteroaryl
- alkenyl
- Prior art date
Links
- 230000027455 binding Effects 0.000 title claims abstract description 262
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title claims abstract description 172
- 230000003042 antagnostic Effects 0.000 title claims abstract description 166
- 239000005557 antagonist Substances 0.000 title claims abstract description 166
- 201000011510 cancer Diseases 0.000 title claims abstract description 88
- 108060007796 SPATA2 Proteins 0.000 claims abstract description 50
- 101710011976 PDCD1LG2 Proteins 0.000 claims abstract description 46
- 102100007289 PDCD1LG2 Human genes 0.000 claims abstract description 46
- 201000011231 colorectal cancer Diseases 0.000 claims abstract description 11
- 206010025650 Malignant melanoma Diseases 0.000 claims abstract description 10
- 201000001441 melanoma Diseases 0.000 claims abstract description 10
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 6
- 206010066476 Haematological malignancy Diseases 0.000 claims abstract description 6
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims abstract description 6
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims abstract description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 6
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims abstract description 6
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims abstract description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 783
- 102000004965 antibodies Human genes 0.000 claims description 274
- 108090001123 antibodies Proteins 0.000 claims description 274
- 229910052739 hydrogen Inorganic materials 0.000 claims description 166
- 125000001072 heteroaryl group Chemical group 0.000 claims description 152
- 125000000623 heterocyclic group Chemical group 0.000 claims description 134
- 239000001257 hydrogen Substances 0.000 claims description 128
- 125000003342 alkenyl group Chemical group 0.000 claims description 126
- 125000005843 halogen group Chemical group 0.000 claims description 120
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 110
- 150000002431 hydrogen Chemical class 0.000 claims description 95
- 229910052799 carbon Inorganic materials 0.000 claims description 88
- 125000004946 alkenylalkyl group Chemical group 0.000 claims description 75
- -1 cyano, amino Chemical group 0.000 claims description 74
- 125000003118 aryl group Chemical group 0.000 claims description 72
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 71
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 69
- 125000000304 alkynyl group Chemical group 0.000 claims description 65
- 125000005038 alkynylalkyl group Chemical group 0.000 claims description 65
- 239000000427 antigen Substances 0.000 claims description 65
- 108091007172 antigens Proteins 0.000 claims description 65
- 102000038129 antigens Human genes 0.000 claims description 65
- 102100007290 CD274 Human genes 0.000 claims description 63
- 101710012053 CD274 Proteins 0.000 claims description 63
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 62
- 229910052757 nitrogen Inorganic materials 0.000 claims description 60
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 59
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 58
- 125000006448 cycloalkyl cycloalkyl group Chemical group 0.000 claims description 58
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 claims description 58
- 125000003107 substituted aryl group Chemical group 0.000 claims description 58
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 54
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 53
- 239000003814 drug Substances 0.000 claims description 52
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 51
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 49
- 102100019764 PDCD1 Human genes 0.000 claims description 48
- 210000001744 T-Lymphocytes Anatomy 0.000 claims description 48
- 125000001188 haloalkyl group Chemical group 0.000 claims description 47
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 43
- 210000004027 cells Anatomy 0.000 claims description 38
- 230000002708 enhancing Effects 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 36
- 239000011780 sodium chloride Substances 0.000 claims description 36
- 125000004350 aryl cycloalkyl group Chemical group 0.000 claims description 34
- 238000004519 manufacturing process Methods 0.000 claims description 33
- 150000001875 compounds Chemical group 0.000 claims description 31
- 230000002401 inhibitory effect Effects 0.000 claims description 30
- 125000005466 alkylenyl group Chemical group 0.000 claims description 28
- 229910052717 sulfur Inorganic materials 0.000 claims description 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 27
- 125000005842 heteroatoms Chemical group 0.000 claims description 25
- 125000004043 oxo group Chemical group O=* 0.000 claims description 25
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 24
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 23
- 125000001424 substituent group Chemical group 0.000 claims description 23
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 23
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 21
- 230000004044 response Effects 0.000 claims description 21
- 239000012453 solvate Substances 0.000 claims description 20
- 125000004429 atoms Chemical group 0.000 claims description 19
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 19
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- 230000035772 mutation Effects 0.000 claims description 18
- 230000036737 immune function Effects 0.000 claims description 17
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 17
- 230000035693 Fab Effects 0.000 claims description 16
- 230000004913 activation Effects 0.000 claims description 16
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 16
- 239000003112 inhibitor Substances 0.000 claims description 15
- 210000004443 Dendritic Cells Anatomy 0.000 claims description 14
- 230000001965 increased Effects 0.000 claims description 14
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 14
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 claims description 12
- 230000003213 activating Effects 0.000 claims description 12
- 125000003282 alkyl amino group Chemical group 0.000 claims description 12
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 12
- 230000002829 reduced Effects 0.000 claims description 12
- 230000002459 sustained Effects 0.000 claims description 12
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 11
- 125000004104 aryloxy group Chemical group 0.000 claims description 11
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 11
- 102100004328 BRAF Human genes 0.000 claims description 10
- 101700004551 BRAF Proteins 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 150000001721 carbon Chemical group 0.000 claims description 9
- 125000006456 halo alkyl cycloalkyl group Chemical group 0.000 claims description 9
- 230000037361 pathway Effects 0.000 claims description 9
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 125000002837 carbocyclic group Chemical group 0.000 claims description 7
- 230000020411 cell activation Effects 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 206010069755 K-ras gene mutation Diseases 0.000 claims description 6
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 6
- 230000035800 maturation Effects 0.000 claims description 6
- 108020005497 Nuclear hormone receptors Proteins 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 239000000460 chlorine Chemical group 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 230000001461 cytolytic Effects 0.000 claims description 5
- 102200055464 BRAF V600E Human genes 0.000 claims description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 4
- 108090000174 Interleukin-10 Proteins 0.000 claims description 4
- 102000003814 Interleukin-10 Human genes 0.000 claims description 4
- 108090001007 Interleukin-8 Proteins 0.000 claims description 4
- 210000002966 Serum Anatomy 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 102100019451 CD80 Human genes 0.000 claims description 3
- 101700080477 CD80 Proteins 0.000 claims description 3
- 102100008186 CD83 Human genes 0.000 claims description 3
- 101700013105 CD83 Proteins 0.000 claims description 3
- 125000005090 alkenylcarbonyl group Chemical group 0.000 claims description 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 3
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 3
- 230000003281 allosteric Effects 0.000 claims description 3
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 3
- 125000000732 arylene group Chemical group 0.000 claims description 3
- 125000002393 azetidinyl group Chemical group 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 230000002860 competitive Effects 0.000 claims description 3
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 claims description 3
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 3
- 125000005549 heteroarylene group Chemical group 0.000 claims description 3
- 238000002513 implantation Methods 0.000 claims description 3
- 238000001764 infiltration Methods 0.000 claims description 3
- 230000003834 intracellular Effects 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims 33
- 125000005418 aryl aryl group Chemical group 0.000 claims 28
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 26
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 26
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 25
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 21
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 20
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 20
- 229910052736 halogen Inorganic materials 0.000 claims 20
- 150000002367 halogens Chemical group 0.000 claims 20
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 15
- 150000002829 nitrogen Chemical group 0.000 claims 14
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 8
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 8
- 150000002148 esters Chemical compound 0.000 claims 6
- 125000004434 sulfur atoms Chemical group 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 4
- 239000011737 fluorine Chemical group 0.000 claims 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical group [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 4
- 101700041762 hizr-1 Proteins 0.000 claims 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- 230000002463 transducing Effects 0.000 claims 1
- 102100013504 RPL17 Human genes 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 description 144
- 239000000203 mixture Substances 0.000 description 39
- 206010028980 Neoplasm Diseases 0.000 description 34
- 201000010099 disease Diseases 0.000 description 32
- 102000018358 Immunoglobulins Human genes 0.000 description 25
- 108060003951 Immunoglobulins Proteins 0.000 description 25
- 230000035492 administration Effects 0.000 description 22
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 108010038807 Oligopeptides Proteins 0.000 description 17
- 102000015636 Oligopeptides Human genes 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 230000011664 signaling Effects 0.000 description 17
- 238000002560 therapeutic procedure Methods 0.000 description 17
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 12
- 108010087819 Fc receptors Proteins 0.000 description 11
- 102000009109 Fc receptors Human genes 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 10
- 230000003247 decreasing Effects 0.000 description 10
- 229960000060 monoclonal antibodies Drugs 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 229910052720 vanadium Inorganic materials 0.000 description 10
- 230000000259 anti-tumor Effects 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 108091007229 NSP3 Papain-like protease domain Proteins 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037240 fusion proteins Human genes 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 230000001404 mediated Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 230000036039 immunity Effects 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 230000004064 dysfunction Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000001225 therapeutic Effects 0.000 description 6
- 210000004881 tumor cells Anatomy 0.000 description 6
- 229960005486 vaccines Drugs 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102100014838 FCGRT Human genes 0.000 description 5
- 101710003435 FCGRT Proteins 0.000 description 5
- 210000004408 Hybridomas Anatomy 0.000 description 5
- 102000004851 Immunoglobulin G Human genes 0.000 description 5
- 108090001095 Immunoglobulin G Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 108091006028 chimera Proteins 0.000 description 5
- 230000000875 corresponding Effects 0.000 description 5
- 201000009910 diseases by infectious agent Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000003902 lesions Effects 0.000 description 5
- 230000004083 survival Effects 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 206010063836 Atrioventricular septal defect Diseases 0.000 description 4
- 230000037250 Clearance Effects 0.000 description 4
- BSMCAPRUBJMWDF-KRWDZBQOSA-N Cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 4
- 229960002271 Cobimetinib Drugs 0.000 description 4
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 4
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 108091008153 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 230000000890 antigenic Effects 0.000 description 4
- 230000035512 clearance Effects 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000006011 modification reaction Methods 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 230000036961 partial Effects 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
- 230000004043 responsiveness Effects 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 229910052727 yttrium Inorganic materials 0.000 description 4
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 3
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 229940001468 Citrate Drugs 0.000 description 3
- ACSIXWWBWUQEHA-UHFFFAOYSA-N Clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 229960004679 Doxorubicin Drugs 0.000 description 3
- 229960002949 Fluorouracil Drugs 0.000 description 3
- 229960002258 Fulvestrant Drugs 0.000 description 3
- 229940088597 Hormone Drugs 0.000 description 3
- 102000004854 Immunoglobulin M Human genes 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229960001592 Paclitaxel Drugs 0.000 description 3
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 3
- 229960004622 Raloxifene Drugs 0.000 description 3
- 229960004528 Vincristine Drugs 0.000 description 3
- XRASPMIURGNCCH-UHFFFAOYSA-N Zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- QKJSVPBYHKEILK-UHFFFAOYSA-N cyclohexene Chemical group C1CCC=[C]C1 QKJSVPBYHKEILK-UHFFFAOYSA-N 0.000 description 3
- NRADQUVNXZVPHN-UHFFFAOYSA-N cyclopentene Chemical group C1C[C]=CC1 NRADQUVNXZVPHN-UHFFFAOYSA-N 0.000 description 3
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000001086 cytosolic Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical class C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical group C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 101710044770 sll1951 Proteins 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000004936 stimulating Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- 229960004276 zoledronic acid Drugs 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N Aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 229960003437 Aminoglutethimide Drugs 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N Azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- 210000003719 B-Lymphocytes Anatomy 0.000 description 2
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 2
- 102100007493 CNTF Human genes 0.000 description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N Calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 229960004117 Capecitabine Drugs 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Natural products C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 229920000453 Consensus sequence Polymers 0.000 description 2
- 229960004397 Cyclophosphamide Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 102100010782 EGFR Human genes 0.000 description 2
- 101700039191 EGFR Proteins 0.000 description 2
- 102100016692 ESR1 Human genes 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N Gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229960001101 Ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 102100007033 JCHAIN Human genes 0.000 description 2
- 101710026201 JCHAIN Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 229960004338 Leuprorelin Drugs 0.000 description 2
- 210000004698 Lymphocytes Anatomy 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 101710027479 MAP2K1 Proteins 0.000 description 2
- 102100006473 MAP2K1 Human genes 0.000 description 2
- 101710027476 MAP2K2 Proteins 0.000 description 2
- 102100015877 MAP2K2 Human genes 0.000 description 2
- 101700028785 MEK1 Proteins 0.000 description 2
- 101700053443 MKK1 Proteins 0.000 description 2
- 101700052154 MPK1 Proteins 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- 206010027476 Metastasis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229960001156 Mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical class C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- QZGIWPZCWHMVQL-UIYAJPBUSA-N Neocarzinostatin Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 2
- 108010019706 Nivolumab Proteins 0.000 description 2
- 102000007399 Nuclear hormone receptors Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 210000001672 Ovary Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000012271 PD-L1 inhibitor Substances 0.000 description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940095743 Selective estrogen receptor modulators Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229960001603 Tamoxifen Drugs 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 229960005454 Thioguanine Drugs 0.000 description 2
- 229960001196 Thiotepa Drugs 0.000 description 2
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N Toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- 229960004355 Vindesine Drugs 0.000 description 2
- 101700009925 WNK1 Proteins 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000001833 anti-estrogenic Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 125000004069 aziridinyl group Chemical group 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 230000000139 costimulatory Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 229960000255 exemestane Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101700068005 hbhA Proteins 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001506 immunosuppresive Effects 0.000 description 2
- 230000001771 impaired Effects 0.000 description 2
- 230000001976 improved Effects 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 210000004962 mammalian cells Anatomy 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 229940113083 morpholine Drugs 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene Chemical class C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic Effects 0.000 description 2
- 244000052769 pathogens Species 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 101700034429 prsG Proteins 0.000 description 2
- 101700032180 psaA Proteins 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- 229960000759 risedronic acid Drugs 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 229930003347 taxol Natural products 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- 229960005026 toremifene Drugs 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QZPQTZZNNJUOLS-UHFFFAOYSA-N β-lapachone Chemical compound C12=CC=CC=C2C(=O)C(=O)C2=C1OC(C)(C)CC2 QZPQTZZNNJUOLS-UHFFFAOYSA-N 0.000 description 2
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2R,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N (2R,3S,4R,5S)-1,6-dibromohexane-2,3,4,5-tetrol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- VGGGPCQERPFHOB-RDBSUJKOSA-N (2S)-2-[[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-RDBSUJKOSA-N 0.000 description 1
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2S)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1R,2R)-1,2-dimethanidylcyclohexane;5-fluoro-1H-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N (2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)butan-2-yl]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2S)-2-[[4-[1-(2-amino-4-oxo-1H-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
- KGGVWMAPBXIMEM-ZRTAFWODSA-N (3S,5R)-5-[(11R)-11-hydroxy-11-[(2R,5R)-5-[(2R,5R)-5-[(1S)-1-hydroxyundecyl]oxolan-2-yl]oxolan-2-yl]undecyl]-3-(2-oxopropyl)oxolan-2-one Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@H]2OC(=O)[C@H](CC(C)=O)C2)CC1 KGGVWMAPBXIMEM-ZRTAFWODSA-N 0.000 description 1
- XOZIUKBZLSUILX-GIQCAXHBSA-N (4S,7R,8S,9S,13Z,16S)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 1
- DLWOTOMWYCRPLK-UVTDQMKNSA-N (4Z)-5-amino-6-(7-amino-6-methoxy-5,8-dioxoquinolin-2-yl)-4-(4,5-dimethoxy-6-oxocyclohexa-2,4-dien-1-ylidene)-3-methyl-1H-pyridine-2-carboxylic acid Chemical compound C1=CC(OC)=C(OC)C(=O)\C1=C\1C(N)=C(C=2N=C3C(=O)C(N)=C(OC)C(=O)C3=CC=2)NC(C(O)=O)=C/1C DLWOTOMWYCRPLK-UVTDQMKNSA-N 0.000 description 1
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5R,6R,7R,8R)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- JXVAMODRWBNUSF-KZQKBALLSA-N (7S,9R,10R)-7-[(2R,4S,5S,6S)-5-[[(2S,4aS,5aS,7S,9S,9aR,10aR)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2S,4S,5S,6S)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBJBKNOSA-N (7S,9S)-7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C1CC(N)C(O)C(C)O1 MWWSFMDVAYGXBV-FGBJBKNOSA-N 0.000 description 1
- RCFNNLSZHVHCEK-IMHLAKCZSA-N (7S,9S)-7-(4-amino-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C1CC([NH3+])CC(C)O1 RCFNNLSZHVHCEK-IMHLAKCZSA-N 0.000 description 1
- NOPNWHSMQOXAEI-PUCKCBAPSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-(2,3-dihydropyrrol-1-yl)-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCC=C1 NOPNWHSMQOXAEI-PUCKCBAPSA-N 0.000 description 1
- KMSKQZKKOZQFFG-YXRRJAAWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1CCCCO1 KMSKQZKKOZQFFG-YXRRJAAWSA-N 0.000 description 1
- AESVUZLWRXEGEX-GJPCMZTKSA-N (7S,9S)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;iron(3+) Chemical compound [Fe+3].O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1C[C@@H](N)[C@@H](O)[C@@H](C)O1 AESVUZLWRXEGEX-GJPCMZTKSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8S,11R,13R,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (E)-1-[(2S)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- AZFZKANGXPSDEA-NVNXTCNLSA-N (Z)-3-(4-bromophenyl)-N-methyl-3-pyridin-3-ylprop-2-en-1-amine Chemical compound C=1C=CN=CC=1C(=C/CNC)\C1=CC=C(Br)C=C1 AZFZKANGXPSDEA-NVNXTCNLSA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8S)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3H-pyrrolo[3,2-e]indole-6-carbonyl]-1H-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- YYSJNACCWYRKMK-UHFFFAOYSA-N 1,5-didehydro-2,4-dihydroimidazol-1-ium-3-ide Chemical group C1[N-]C[N+]#C1 YYSJNACCWYRKMK-UHFFFAOYSA-N 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical group C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1H-pyrazole Chemical group C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6H-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N 2-Imidazoline Chemical group C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-N-[(3S,6S,7R,10S,16S)-3-[(2S)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-N-[(3S,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- VNBAOSVONFJBKP-UHFFFAOYSA-N 2-chloro-N,N-bis(2-chloroethyl)propan-1-amine;hydrochloride Chemical compound Cl.CC(Cl)CN(CCCl)CCCl VNBAOSVONFJBKP-UHFFFAOYSA-N 0.000 description 1
- SYNHCENRCUAUNM-UHFFFAOYSA-N 2-chloro-N-(2-chloroethyl)-N-methylethanamine oxide;hydron;chloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical group C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N 3-(3-methylsulfonyloxypropylamino)propyl methanesulfonate Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-N,N-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-M 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GHOKWGTUZJEAQD-ZETCQYMHSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical group C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1H-pyrazole Chemical group C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 description 1
- YIMDLWDNDGKDTJ-ABYLTEMBSA-N 4-[(2S,3S,4S)-3-hydroxy-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]morpholine-3-carbonitrile Chemical compound N1([C@H]2CC(O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-ABYLTEMBSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N 5-ethynyl-1H-pyrimidine-2,4-dione Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- DHMYGZIEILLVNR-UHFFFAOYSA-N 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione;1H-pyrimidine-2,4-dione Chemical compound O=C1C=CNC(=O)N1.O=C1NC(=O)C(F)=CN1C1OCCC1 DHMYGZIEILLVNR-UHFFFAOYSA-N 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purin-2-amine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 1
- 229950004955 ADOZELESIN Drugs 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- 229940030495 ANTIANDROGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- 229940028652 Abraxane Drugs 0.000 description 1
- ZOZKYEHVNDEUCO-XUTVFYLZSA-N Aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
- 229950002684 Aceglatone Drugs 0.000 description 1
- 229940037127 Actonel Drugs 0.000 description 1
- BYRVKDUQDLJUBX-UHFFFAOYSA-N Adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3CC4CC44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-UHFFFAOYSA-N 0.000 description 1
- 210000004100 Adrenal Glands Anatomy 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- TXUZVZSFRXZGTL-QPLCGJKRSA-N Afimoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 TXUZVZSFRXZGTL-QPLCGJKRSA-N 0.000 description 1
- 229940062527 Alendronate Drugs 0.000 description 1
- 229940045714 Alkyl sulfonate alkylating agents Drugs 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 229960003896 Aminopterin Drugs 0.000 description 1
- 229960001220 Amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N Anthracene Chemical class C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 229940046836 Anti-estrogens Drugs 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 229940078010 Arimidex Drugs 0.000 description 1
- 229940087620 Aromasin Drugs 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 229940046844 Aromatase inhibitors Drugs 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 229960002756 Azacitidine Drugs 0.000 description 1
- 229950011321 Azaserine Drugs 0.000 description 1
- 229950006844 BIZELESIN Drugs 0.000 description 1
- 108010090685 BMS-936559 Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N Betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- QGJZLNKBHJESQX-CASBDLHJSA-N Betulinic acid Natural products O=C(O)[C@@]12[C@@H]([C@@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC1)CC2 QGJZLNKBHJESQX-CASBDLHJSA-N 0.000 description 1
- 108010005144 Bevacizumab Proteins 0.000 description 1
- 108010071919 Bispecific Antibodies Proteins 0.000 description 1
- 229940112871 Bisphosphonate drugs affecting bone structure and mineralization Drugs 0.000 description 1
- OYVAGSVQBOHSSS-WXFSZRTFSA-O Bleomycin Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-WXFSZRTFSA-O 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108010007539 Blocking Antibodies Proteins 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- MBABCNBNDNGODA-LUVUIASKSA-N Bullatacin Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-LUVUIASKSA-N 0.000 description 1
- MBABCNBNDNGODA-LTGLSHGVSA-N Bullatacin Natural products O=C1C(C[C@H](O)CCCCCCCCCC[C@@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)=C[C@H](C)O1 MBABCNBNDNGODA-LTGLSHGVSA-N 0.000 description 1
- KGGVWMAPBXIMEM-JQFCFGFHSA-N Bullatacinone Natural products O=C(C[C@H]1C(=O)O[C@H](CCCCCCCCCC[C@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)C1)C KGGVWMAPBXIMEM-JQFCFGFHSA-N 0.000 description 1
- 229960005064 Buserelin Acetate Drugs 0.000 description 1
- PYMDEDHDQYLBRT-DRIHCAFSSA-N Buserelin acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 PYMDEDHDQYLBRT-DRIHCAFSSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OUFUAQXCSKICMF-UHFFFAOYSA-L C(C1(C(C=CC2=CC=CC=C12)O)C(=O)[O-])C1(C(C=CC2=CC=CC=C12)O)C(=O)[O-] Chemical class C(C1(C(C=CC2=CC=CC=C12)O)C(=O)[O-])C1(C(C=CC2=CC=CC=C12)O)C(=O)[O-] OUFUAQXCSKICMF-UHFFFAOYSA-L 0.000 description 1
- 210000004899 C-terminal region Anatomy 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N CARUBICIN Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229950001725 CARUBICIN Drugs 0.000 description 1
- BBZDXMBRAFTCAA-AREMUKBSSA-N CARZELESIN Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 1
- 102100019461 CD28 Human genes 0.000 description 1
- 101700033362 CD28 Proteins 0.000 description 1
- 101700078950 CD44 Proteins 0.000 description 1
- 102100003735 CD44 Human genes 0.000 description 1
- 229950009908 Cactinomycin Drugs 0.000 description 1
- 229940088954 Camptosar Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229950007509 Carzelesin Drugs 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010022830 Cetuximab Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229950008249 Chlornaphazine Drugs 0.000 description 1
- XCDXSSFOJZZGQC-UHFFFAOYSA-N Chlornaphazine Chemical compound C1=CC=CC2=CC(N(CCCl)CCCl)=CC=C21 XCDXSSFOJZZGQC-UHFFFAOYSA-N 0.000 description 1
- MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
- 230000036849 Clc Effects 0.000 description 1
- 229960002286 Clodronic Acid Drugs 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N Cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- 229960000684 Cytarabine Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 229940104302 Cytosine Drugs 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-Galacturonic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- NNJPGOLRFBJNIW-HNNXBMFYSA-N Demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- 229950003913 Detorubicin Drugs 0.000 description 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N Dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- AUGQEEXBDZWUJY-NMAPUUFXSA-N Diacetoxyscirpenol Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)C)O2 AUGQEEXBDZWUJY-NMAPUUFXSA-N 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N Dialin Chemical class C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Didronel Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 230000036947 Dissociation constant Effects 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N Dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229940115080 Doxil Drugs 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 229950004203 Droloxifene Drugs 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N Duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- AFMYMMXSQGUCBK-AKMKHHNQSA-N Dynemicin A Chemical compound C1#C\C=C/C#C[C@@H]2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3[C@@]34O[C@]32[C@@H](C)C(C(O)=O)=C(OC)[C@H]41 AFMYMMXSQGUCBK-AKMKHHNQSA-N 0.000 description 1
- 229940121647 EGFR inhibitors Drugs 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- 102000027760 ERBB2 Human genes 0.000 description 1
- 101700025368 ERBB2 Proteins 0.000 description 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N ESORUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N Eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- XOPYFXBZMVTEJF-PDACKIITSA-N Eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 1
- 229940053594 Eligard Drugs 0.000 description 1
- 229950000549 Elliptinium acetate Drugs 0.000 description 1
- 229940120655 Eloxatin Drugs 0.000 description 1
- 229950010213 Eniluracil Drugs 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 229950011487 Enocitabine Drugs 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 Erlotinib Drugs 0.000 description 1
- 229950002017 Esorubicin Drugs 0.000 description 1
- LJQQFQHBKUKHIS-WJHRIEJJSA-N Esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 1
- 229960001842 Estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229940009626 Etidronate Drugs 0.000 description 1
- 229960005237 Etoglucid Drugs 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Etoglucid Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- 229940085363 Evista Drugs 0.000 description 1
- 229950011548 FADROZOLE Drugs 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N Fadrozole Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- 229940043168 Fareston Drugs 0.000 description 1
- 229940087861 Faslodex Drugs 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229940087476 Femara Drugs 0.000 description 1
- 210000003754 Fetus Anatomy 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 Floxuridine Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960000304 Folic Acid Drugs 0.000 description 1
- 229940001490 Fosamax Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940014259 Gelatin Drugs 0.000 description 1
- 229940020967 Gemzar Drugs 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N Gentisic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- 229940097043 Glucuronic Acid Drugs 0.000 description 1
- 229940049906 Glutamate Drugs 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229960003690 Goserelin Acetate Drugs 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 1
- 229940088013 Hycamtin Drugs 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100018955 IL1A Human genes 0.000 description 1
- 229940015872 Ibandronate Drugs 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010041012 Integrin alpha4 Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N Irinotecan hydrochloride Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N Isoindoline Chemical group C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 102100001056 KITLG Human genes 0.000 description 1
- 210000002510 Keratinocytes Anatomy 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 101700081293 LMX1A Proteins 0.000 description 1
- CIEYTVIYYGTCCI-UHFFFAOYSA-N Lapachol Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(O)C(=O)C2=C1 CIEYTVIYYGTCCI-UHFFFAOYSA-N 0.000 description 1
- CWPGNVFCJOPXFB-UHFFFAOYSA-N Lapachol Chemical compound C1=CC=C2C(=O)C(=O)C(CC=C(C)C)=C(O)C2=C1 CWPGNVFCJOPXFB-UHFFFAOYSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 229940089022 Leuprolide Acetate Drugs 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N Losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 Losoxantrone Drugs 0.000 description 1
- 229940087857 Lupron Drugs 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N Lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 Lurtotecan Drugs 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 101700067074 MAPK Proteins 0.000 description 1
- 101710041325 MAPKAPK2 Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N Maitansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N Mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229940099262 Marinol Drugs 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- 229960004296 Megestrol Acetate Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229960003539 Mitoguazone Drugs 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- 229960000350 Mitotane Drugs 0.000 description 1
- 210000001616 Monocytes Anatomy 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229960000951 Mycophenolic Acid Drugs 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- UWYXLGUQQFPJRI-UHFFFAOYSA-N N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 UWYXLGUQQFPJRI-UHFFFAOYSA-N 0.000 description 1
- XGXNTJHZPBRBHJ-UHFFFAOYSA-N N-phenylpyrimidin-2-amine Chemical class N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 description 1
- 229940086322 Navelbine Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N Nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N Nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 229940085033 Nolvadex Drugs 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 229950011093 Onapristone Drugs 0.000 description 1
- 229940043515 Other immunoglobulins in ATC Drugs 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 229940116315 Oxalic Acid Drugs 0.000 description 1
- 229950003180 PEPLOMYCIN Drugs 0.000 description 1
- 101710038828 PRKCA Proteins 0.000 description 1
- 102100007893 PRKCA Human genes 0.000 description 1
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N PUROMYCIN Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 1
- 229950010131 PUROMYCIN Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- VREZDOWOLGNDPW-ALTGWBOUSA-N Pancratistatin Chemical compound C1=C2[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H]3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-ALTGWBOUSA-N 0.000 description 1
- VREZDOWOLGNDPW-MYVCAWNPSA-N Pancratistatin Natural products O=C1N[C@H]2[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]2c2c1c(O)c1OCOc1c2 VREZDOWOLGNDPW-MYVCAWNPSA-N 0.000 description 1
- 229940055729 Papain Drugs 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N Pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960002340 Pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N Pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N Podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 231100000614 Poison Toxicity 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 102000000034 Programmed Cell Death 1 Receptor Human genes 0.000 description 1
- 108010080196 Programmed Cell Death 1 Receptor Proteins 0.000 description 1
- 229940087463 Proleukin Drugs 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N Pyrazoline Chemical group C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N Rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 229940089617 Risedronate Drugs 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229950004892 Rodorubicin Drugs 0.000 description 1
- NSFWWJIQIKBZMJ-PAGWOCKZSA-N Roridin A Chemical compound C([C@@]12[C@]3(C)[C@H]4C[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)[C@@H](O)[C@H](C)CCO[C@H](\C=C\C=C/C(=O)O4)[C@H](O)C)O2 NSFWWJIQIKBZMJ-PAGWOCKZSA-N 0.000 description 1
- HXCHCVDVKSCDHU-SNTWSMTASA-N S-[(2R,3S,4S,6S)-6-[[(2R,3S,4S,5R,6R)-5-[(2S,4S,5S)-5-(ethylamino)-4-methoxyoxan-2-yl]oxy-4-hydroxy-6-[[(2S,5E,9S,13E)-9-hydroxy-12-(methoxycarbonylamino)-13-[2-(methyltrisulfanyl)ethylidene]-11-oxo-2-bicyclo[7.3.1]trideca-1(12),5-dien-3,7-diynyl]oxy]-2-m Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C/C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-SNTWSMTASA-N 0.000 description 1
- 229950001403 SIZOFIRAN Drugs 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N Selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- 229940112726 Skelid Drugs 0.000 description 1
- 229950006315 Spirogermanium Drugs 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 229960001052 Streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- BXFOFFBJRFZBQZ-QYWOHJEZSA-N T-2 mycotoxin Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@H]1[C@]3(COC(C)=O)C[C@@H](C(=C1)C)OC(=O)CC(C)C)O2 BXFOFFBJRFZBQZ-QYWOHJEZSA-N 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N TAXOL® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 229950000212 TRIOXIFENE Drugs 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N Tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 229940061353 Temodar Drugs 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- KLBSRSYHIIAQTG-PZICIZFRSA-N Tenuazonic acid Chemical compound CC[C@H](C)[C@@H]1NC(=O)C(C(C)=O)C1=O KLBSRSYHIIAQTG-PZICIZFRSA-N 0.000 description 1
- 229940033529 Tetrahydrocannabinol Drugs 0.000 description 1
- 229950011457 Tiamiprine Drugs 0.000 description 1
- 229940019375 Tiludronate Drugs 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 229950001353 Tretamine Drugs 0.000 description 1
- 229960001727 Tretinoin Drugs 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N Triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229960004560 Triaziquone Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N Trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N Trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 Trimetrexate Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N Trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- RXRGZNYSEHTMHC-BQBZGAKWSA-N Troxacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N Tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 229950009811 UBENIMEX Drugs 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N Uramustine Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N Vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 229940053867 Xeloda Drugs 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Yamafur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 229940002005 Zometa Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N Zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R,2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[(2R,3S,4S)-3-hydroxy-5-[[(2S,3R)-3-hydroxy-1-oxo-1-[2-[4-[4-[3-[[(1S)-1-phenylethyl] Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- QTQAWLPCGQOSGP-DVKIRIBLSA-N [(3R,5R,6S,7R,8E,10R,11R,12E,14E)-6-hydroxy-5,11,21-trimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate Chemical class N1C(=O)\C(C)=C\C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C\[C@@H](C)[C@H](O)[C@H](OC)C[C@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-DVKIRIBLSA-N 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8R,9S,13S,14S,17S)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
- XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N [3-[4-(3-methylsulfonyloxypropanoyl)piperazin-1-yl]-3-oxopropyl] methanesulfonate Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- IKDXDQDKCZPQSZ-JHYYTBFNSA-N acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopro Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 IKDXDQDKCZPQSZ-JHYYTBFNSA-N 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N aldehydo-D-arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N aminolevulinic acid Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic Effects 0.000 description 1
- 230000003388 anti-hormone Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045687 antimetabolites Folic acid analogs Drugs 0.000 description 1
- 239000002257 antimetastatic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000002238 attenuated Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003542 behavioural Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical group C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- GNTFBMAGLFYMMZ-UHFFFAOYSA-N bicyclo[3.2.2]nonane Chemical group C1CC2CCC1CCC2 GNTFBMAGLFYMMZ-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 108010047060 carzinophilin Proteins 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001889 chemoattractant Effects 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000002113 chemopreventative Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229960001480 chlorozotocin Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 108010089438 cryptophycin 1 Proteins 0.000 description 1
- 108010090203 cryptophycin 8 Proteins 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000002074 deregulated Effects 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished Effects 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 229940042397 direct acting antivirals Cyclic amines Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 210000003162 effector T lymphocyte Anatomy 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 229950007539 elliptinium Drugs 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 description 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 description 1
- 229930013356 epothilones Natural products 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2S)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N ethyl N-[2,5-bis(aziridin-1-yl)-4-(ethoxycarbonylamino)-3,6-dioxocyclohexa-1,4-dien-1-yl]carbamate Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 125000005469 ethylenyl group Chemical group 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N imidazolidine Chemical group C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003392 indanyl group Chemical class C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical class C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000002147 killing Effects 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229960001320 lapatinib ditosylate Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 239000012035 limiting reagent Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 150000002680 magnesium Chemical class 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 210000003071 memory T lymphocyte Anatomy 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VJRAUFKOOPNFIQ-TVEKBUMESA-N methyl (1R,2R,4S)-4-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-[(2S,4S,5S,6S)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylat Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 VJRAUFKOOPNFIQ-TVEKBUMESA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000005445 natural product Substances 0.000 description 1
- 229930014626 natural products Natural products 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MAZYQGHSTXUZJF-ZBRHGPMOSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](O)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@]5(C)C[C@H](C[C@@H](O5)CC4=C3C3=O)N(C)C)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 MAZYQGHSTXUZJF-ZBRHGPMOSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical group C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- 229930001140 podophyllotoxin Natural products 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920000740 poly(D-lysine) polymer Polymers 0.000 description 1
- 229920005589 poly(ferrocenylsilane) Polymers 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 150000003109 potassium Chemical class 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000003623 progesteronic Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 200000000025 progressive disease Diseases 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M pyridine-4-carboxylate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000000284 resting Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 101710004466 rgy Proteins 0.000 description 1
- 101710030364 rgy1 Proteins 0.000 description 1
- 101710030359 rgy2 Proteins 0.000 description 1
- 101710024887 rl Proteins 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 101700045897 spk-1 Proteins 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000005503 thioxanyl group Chemical group 0.000 description 1
- 229960005324 tiludronic acid Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000003327 trichothecene derivatives Chemical class [H][C@]12O[C@]3([H])[C@H]([*])[C@@H]([*])[C@@](C)(C33CO3)C1(C[*])C([*])C([*])C(C)=C2 0.000 description 1
- 229930013292 trichothecenes Natural products 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- 229950010147 troxacitabine Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- KDQAABAKXDWYSZ-JKDPCDLQSA-N vincaleukoblastine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 KDQAABAKXDWYSZ-JKDPCDLQSA-N 0.000 description 1
- COFJBSXICYYSKG-FJFFLIEUSA-N vindesine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 COFJBSXICYYSKG-FJFFLIEUSA-N 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- CILBMBUYJCWATM-IJDPFCGHSA-N vinorelbine L-tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-IJDPFCGHSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N β-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 1
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
Abstract
The disclosure relates the use of an effective amount of a PD-1 axis binding antagonist and a MEK inhibitor for treating or delaying progression of cancer in an individual. The PD-1 axis binding antagonist may be a PD-1 binding antagonist, a PD-L 1 binding antagonist or a PD-L2 binding antagonist and may further be MDX-1106, Merck 3745, CT-011, AMP-224, YW243.55.S70, MPOL3280A or MDX-1105. The MEK inhibitor may be G02442104, G38963, G02443714, G00039805, GOC-0973 or formula (I) - (VII). The cancer may be colorectal cancer, melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, pancreatic cancer, a haematological malignancy, or renal cell carcinoma. d may further be MDX-1106, Merck 3745, CT-011, AMP-224, YW243.55.S70, MPOL3280A or MDX-1105. The MEK inhibitor may be G02442104, G38963, G02443714, G00039805, GOC-0973 or formula (I) - (VII). The cancer may be colorectal cancer, melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, pancreatic cancer, a haematological malignancy, or renal cell carcinoma.
Description
METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS
AND MEK INHIBITORS
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the priority benefit of U.S. provisional application Serial No.
61/574,406, filed August 1, 2011, the contents of which are incorporated herein by reference in
its entirety.
BACKGROUND OF THE INVENTION
The provision of two distinct signals to T-cells is a widely accepted model for
lymphocyte activation of resting T lymphocytes by antigen-presenting cells (APCs). Lafferty et
al, Aust. J. Exp. Biol. Med. ScL 53: 27-42 (1975). This model further provides for the
discrimination of self from non-self and immune tolerance. Bretscher et al, Science 169: 1042-
1049 (1970); Bretscher, P.A., P.N.A.S. USA 96: 185-190 (1999); Jenkins et al, J. Exp. Med.
165: 302-319 (1987). The primary signal, or antigen specific signal, is transduced through the
T- cell receptor (TCR) following recognition of foreign antigen peptide presented in the context
of the major histocompatibility-complex (MHC). The second or co-stimulatory signal is
delivered to T-cells by co-stimulatory molecules expressed on antigen-presenting cells (APCs),
and induce T-cells to promote clonal expansion, cytokine secretion and effector function.
Lenschow et al., Ann. Rev. Immunol. 14:233 (1996). In the absence of co-stimulation, T-cells
can become refractory to antigen stimulation, do not mount an effective immune response, and
further may result in exhaustion or tolerance to foreign antigens.
In the two-signal model T-cells receive both positive and negative secondary co-
stimulatory signals. The regulation of such positive and negative signals is critical to maximize
the host's protective immune responses, while maintaining immune tolerance and preventing
autoimmunity. Negative secondary signals seem necessary for induction of T-cell tolerance,
while positive signals promote T-cell activation. While the simple two-signal model still
provides a valid explanation for naive lymphocytes, a host's immune response is a dynamic
process, and co- stimulatory signals can also be provided to antigen-exposed T-cells. The
mechanism of co-stimulation is of therapeutic interest because the manipulation of co-
stimulatory signals has shown to provide a means to either enhance or terminate cell-based
immune response. Recently, it has been discovered that T cell dysfunction or anergy occurs
concurrently with an induced and sustained expression of the inhibitory receptor, programmed
death 1 polypeptide (PD-1). As a result, therapeutic targeting of PD-1 and other molecules
which signal through interactions with PD-1, such as programmed death ligand 1 (PD-Ll) and
programmed death ligand 2 (PD-L2) are an area of intense interest.
PD-L1 is overexpressed in many cancers and is often associated with poor prognosis
(Okazaki T et al., Intern. Immun. 2007 19(7):813) (Thompson RH et al., Cancer Res 2006,
66(7):3381). Interestingly, the majority of tumor infiltrating T lymphocytes predominantly
express PD-1, in contrast to T lymphocytes in normal tissues and peripheral blood T
lymphocytes indicating that up-regulation of PD-1 on tumor-reactive T cells can contribute to
impaired antitumor immune responses (Blood 2009 114(8):1537). This may be due to
exploitation of PD-L1 signaling mediated by PD-L1 expressing tumor cells interacting with PD-
1 expressing T cells to result in attenuation of T cell activation and evasion of immune
surveillance (Sharpe et al., Nat Rev 2002) (Keir ME et al., 2008 Annu. Rev. Immunol. 26:677).
Therefore, inhibition of the PD-L1/PD-1 interaction may enhance CD8+ T cell-mediated killing
of tumors.
The inhibition of PD-1 axis signaling through its direct ligands (e.g., PD-Ll, PD-L2)
has been proposed as a means to enhance T cell immunity for the treatment of cancer (e.g.,
tumor immunity). Moreover, similar enhancements to T cell immunity have been observed by
inhibiting the binding of PD-L1 to the binding partner B7-1. Furthermore, combining inhibition
of PD-1 signaling with other signaling pathways (e.g. MAPK pathway, “MEK”) that are
deregulated in tumor cells may further enhance treatment efficacy. However, an optimal
therapeutic treatment would combine blockade of PD-1 receptor/ligand interaction with an agent
that directly inhibited tumor growth, optionally further including unique immune enhancing
properties not provided by PD-1 blockade alone. There remains a need for such an optimal
therapy for treating, stabilizing, preventing, and/or delaying development of various cancers.
All references, publications, and patent applications disclosed herein are hereby
incorporated by reference in their entirety.
BRIEF SUMMARY OF THE INVENTION
The present invention generally describes a combination treatment comprising a MEK
inhibitor (which has direct tumor targeted effects and immune enhancing properties) and a PD-1
axis binding antagonist.
[0007a] In one aspect, the invention relates to the use of a PD-1 axis binding antagonist and a
MEK inhibitor in the manufacture of a medicament for treating or delaying progression of
cancer in an individual.
[0007b] In another aspect, the invention relates to the use of a PD-1 axis binding antagonist in
the manufacture of a medicament for treating or delaying progression of cancer in an individual,
wherein the PD-1 axis binding agent is for use in combination with a MEK inhibitor.
[0007c] In another aspect, the invention relates to the use of a MEK inhibitor in the
manufacture of a medicament for treating or delaying progression of cancer in an individual,
wherein the MEK inhibitor is for use in combination with a PD-1 axis binding antagonist.
[0007d] In another aspect, the invention relates to the use of a PD-1 axis binding antagonist and
a MEK inhibitor in the manufacture of a medicament for enhancing immune function in an
individual having cancer.
[0007e] In another aspect, the invention relates to the use of an effective amount of a PD-1 axis
binding antagonist in the manufacture of a medicament for enhancing immune function in an
individual having cancer, wherein the PD-1 axis binding agent is for use in combination with a
MEK inhibitor.
[0007f] In another aspect, the invention relates to the use of an effective amount of a MEK
inhibitor in the manufacture of a medicament for enhancing immune function in an individual
having cancer, wherein the MEK inhibitor is for use in combination with a PD-1 axis binding
antagonist.
[0007g] In another aspect, the invention relates to the use of a kit comprising a PD-1 axis
binding antagonist in the manufacture of a medicament for treating or delay progression of
cancer in an individual, wherein the PD-1 axis binding antagonist is for use in combination with
a MEK inhibitor.
[0007h] In another aspect, the invention relates to the use of a kit comprising a PD-1 axis
binding antagonist and a MEK inhibitor in the manufacture of a medicament for treating or delay
progression of cancer in an individual.
[0007h] In another aspect, the invention relates to the use of a kit comprising a MEK inhibitor
in the manufacture of a medicament for treating or delay progression of cancer in an individual,
wherein the MEK inhibitor is for use in combination with a PD-1 axis binding antagonist.
[0007i] Certain statements that appear below are broader than what appears in the statements of
the invention above. These statements are provided in the interests of providing the reader with
a better understanding of the invention and its practice. The reader is directed to the
accompanying claim set which defines the scope of the invention.
Described are are methods for treating cancer or slowing progression of cancer in an
individual comprising administering to the individual an effective amount of a PD-1 axis binding
antagonist and a MEK inhibitor.
Also described herein is use of a PD-1 axis binding antagonist in the manufacture of a
medicament for treating or delaying progression of cancer in an individual in combination with a
MEK inhibitor. Also described herein is use of a MEK inhibitor in the manufacture of a
medicament for treating or delaying progression of cancer in an individual in combination with a
PD-1 axis binding antagonist. Also described herein is use of a PD-1 axis binding antagonist
and a MEK inhibitor in the manufacture of medicaments for treating or delaying progression of
cancer in an individual. Also described herein is a manufacturing process of medicaments for
treating or delaying progression of cancer in an individual, characterized by the use of a PD-1
axis binding antagonist and a MEK inhibitor. Also described herein is a PD-1 axis binding
antagonist for use in combination with a MEK inhibitor for treating or delaying progression of
cancer in the individual. Also described herein is a MEK inhibitor for use in combination with a
PD-1 axis binding antagonist for treating or delaying progression of cancer in the individual.
The cancer treated may contain a BRAF V600E mutation, a BRAF wildtype, a KRAS
wildtype, or an activating KRAS mutation. The cancer may be a melanoma, a colorectal cancer,
a non-small cell lung cancer, an ovarian cancer, a breast cancer, a prostate cancer, a pancreatic
cancer, hematological malignancy or a renal cell carcinoma. The cancer may be at early stage or
at late stage. In some embodiments, the individual treated is a human.
In some embodiments, the treatment results in sustained response in the individual after
cessation of the treatment. In some embodiments, the treatment produces a complete response, a
partial response, or stable disease in the individual.
Also described herein are methods of enhancing immune function in an individual
having cancer comprising administering an effective amount of a PD-1 axis binding antagonist
and a MEK inhibitor. In some embodiments, the individual is a human.
Also described herein is use of a PD-1 axis binding antagonist in the manufacture of a
medicament for enhancing immune function in an individual having cancer in combination with
a MEK inhibitor. Also described herein is use of a MEK inhibitor in the manufacture of a
medicament for enhancing immune described in an individual having cancer in combination
with a PD-1 axis binding antagonist. Also provided herein is use of a PD-1 axis binding
antagonist and a MEK inhibitor in the manufacture of medicaments for enhancing immune
function in the individual having cancer. Also described herein is a manufacturing process of
medicaments for enhancing immune function in an individual, characterized by the use of a PD-
1 axis binding antagonist and a MEK inhibitor. Also described herein is a PD-1 axis binding
antagonist for use in combination with a MEK inhibitor for enhancing immune function in the
individual having cancer. Also described herein is a MEK inhibitor for use in combination with
a PD-1 axis binding antagonist for enhancing immune function in the individual having cancer.
In some embodiments, the individual is a human.
In some embodiments, the PD-1 axis binding antagonist is a PD-1 binding antagonist, a
PD-L1 binding antagonist or a PD-L2 binding antagonist. In some embodiments, the PD-1
binding antagonist inhibits binding of PD-1 to PD-L1 and/or binding of PD-1 to PD-L2. In
some embodiments, the PD-1 binding antagonist is an antibody (e.g., antibody MDX-1106, CT-
011 and Merck 3745 described herein), an antigen binding fragments thereof, an immunoadhesin,
a fusion protein, or an oligopeptide. In some embodiments, the PD-1 binding antagonist is an
immunoadhesin comprising a PD-L2 extracellular domain fused to a Fc domain (e.g., AMP-224
described herein). In some embodiments, the PD-L1 binding antagonist inhibits binding of PD-
L1 to PD-1 and/or binding of PD-L1 to B7-1. In some embodiments, the PD-L1 binding
antagonist is an antibody (e.g., antibody YW243.55.S70, MPDL3280A and MDX-1105
described herein), an antigen binding fragments thereof, an immunoadhesin, a fusion protein, or
an oligopeptide. In some embodiments, the PD-L2 binding antagonist inhibits binding of PD-L2
to PD-1. In some embodiments, the PD-L2 binding antagonist is an antibody, an antigen
binding fragments thereof, an immunoadhesin, a fusion protein, or an oligopeptide.
In some embodiments, the MEK inhibitor is a compound of the formula (I), (II), (III),
(IV), (V), or (VI) as described here below, or a pharmaceutically acceptable salt or solvate
thereof.
In some embodiments, the MEK inhibitor is a competitive inhibitor of MEK. In some
embodiments, the MEK inhibitor is more selective against activating KRAS mutation. In some
embodiments, the MEK inhibitor is an allosteric inhibitor of MEK. In some embodiments, the
MEK inhibitor is more selective against an activating BRAF mutation. In some embodiments,
the MEK inhibitor is selected from the group consisting of G02442104, G-38963, G02443714,
G00039805, and GDC-0973, or a pharmaceutically acceptable salt or solvate thereof.
In some embodiments, the MEK inhibitor is administered continuously or
intermittently. In some embodiments, the MEK inhibitor is administered before administration
of the PD-1 axis binding antagonist, simultaneously with administration of the PD-1 axis
binding antagonist, or after administration of the PD-1 axis binding antagonist. In some
embodiments, the MEK inhibitor and the PD-1 axis binding antagonist are administered with
different dosing frequency.
In another embodiment, described is a kit comprising a PD-1 axis binding antagonist
and/or a MEK inhibitor for treating or delaying progression of a cancer in an individual or
enhancing immune function in an individual having cancer. The kit may comprise a PD-1 axis
binding antagonist and a package insert comprising instructions for using the PD-1 axis binding
antagonist in combination with a MEK inhibitor to treat or delay progression of cancer in an
individual, or enhancing immune function in an individual having cancer. The kit may comprise
a MEK inhibitor and a package insert comprising instructions for using the MEK inhibitor in
combination with a PD-1 axis binding antagonist to treat or delay progression of cancer in an
individual, or to enhance immune function in an individual having cancer. The kit may
comprise a PD-1 axis binding antagonist and a MEK inhibitor, and a package insert comprising
instructions for using the PD-1 axis binding antagonist and the MEK inhibitor to treat or delay
progression of cancer in an individual, or to enhance immune function in an individual having
cancer.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows enhanced MHC I surface expression on melanoma and colorectal
tumor cell lines upon treatment with MEK inhibitor. (A) Histogram showing increased MHC I
expression on the surface of human tumor cell lines treated with MEK inhibitor. (B) Histogram
showing increased MHC I expression on the surface of mouse tumor cell lines treated with MEK
inhibitor.
Figure 2 is a histogram showing that treatment of human melanoma cell lines (5/8 cell
lines of which were BRAF mutant; BRAF wild-type cells indicated with asterisk) with BRAF
inhibitor did not upregulate MHC I surface expression.
Figure 3 shows that treatment of human peripheral blood mononuclear cells with MEK
inhibitor did not upregulate MHC I surface expression. (A-D) Histogram showing unaltered
MHC I surface expression in CD4+ T cells, CD8+ T cells, B cells, or monocytes upon MEK
inhibitor treatment.
Figure 4 demonstrates that co-stimulatory signals make T cells responsive despite
MEK inhibitor treatment. (A) Graph of CD8 T cells levels shows that MEK inhibitor treatment
reduced T cell proliferation and activation normally induced by stimulation of CD3. (B) Graph
of CD8 T cells show that co-stimulation of CD3 and CD28 was sufficient to overcome the
inhibitory effect of MEK inhibitor treatment.
Figure 5 shows that MEK inhibitor treatment enhanced maturation and activation of
dendritic cells stimulated with anti-CD40 antibodies. (A-C) Histogram showing dendritic cells
stimulated with anti-CD40 antibodies and treated with MEK or BRAF inhibitor. MEK inhibitor
enhanced DC activation as evidenced by upregulation of DC surface activation markers CD83,
MHC II and CD86. (D-F) Graphs of activated dendritic cell levels demonstrates that MEK
inhibitor enhanced DC activation in a dose dependent manner.
Figure 6 is a graph showing reduced serum levels of immunosuppressive and pro-
tumor cytokines in in vivo models of cancer. (A and C) Immunosuppressive cytokine IL-10 was
decreased 7 days following co-treatment with anti-PD-L1 antibodies and MEK inhibitor as
compared to treatment with anti-PD-L1 or MEK inhibitor treatment alone. (B and D) The pro-
tumor chemokine KC was decreased upon co-treatment with anti-PD-L1 antibodies and MEK
inhibitor as compared to treatment with anti-PD-L1 or MEK inhibitor treatment alone.
Figure 7 demonstrates that MEK inhibitor treatment enhanced anti-tumor activity of
anti-PD-L1 antibodies in in vivo models of colorectal cancer. (A) Graph depicting changes in
tumor volume with anti-PD-L1 antibodies and MEK inhibitor co-treatment demonstrate a
significant reduction of early stage tumor growth and sustained anti-tumor effect as compared to
anti-PD-L1 antibodies or MEK inhibitor treatment alone. (B) Graph depicting changes in tumor
volume with anti-PD-L1 antibodies and MEK inhibitor co-treatment demonstrate a significant
inhibition of late stage tumor growth as compared to anti-PD-L1 antibodies or MEK inhibitor
treatment alone.
Figure 8 is a series of graphs demonstrating that MEK inhibitor doses were more
effective when used in combination with anti-PD-L1 antibody for treatment in in vivo models of
colorectal cancer. (A) Graph depicting reduction in tumor volume with increasing doses of
MEK inhibitor GDC-0973 treatment. (B) Graph depicting reduction in tumor volume upon
administration of anti-PD-L1 antibody in combination with different doses of MEK inhibitor
GDC-0973. Mpk indicates milligrams per kilogram (mg/kg).
Figure 9 is a graph demonstrating that treatment with MEK inhibitor G02443714
enhanced the anti-tumor activity of anti-PD-L1 antibodies in in vivo models of colorectal cancer.
An enhanced reduction in tumor volume with anti-PD-L1 antibody and MEK inhibitor
combination treatment was observed as compared to treatment with anti-PD-L1 antibody or
MEK inhibitor G02443714 alone.
Figure 10 is a graph demonstrating that treatment with MEK inhibitor G02442104
enhanced the anti-tumor activity of anti-PD-L1 antibodies in in vivo models of colorectal cancer.
An enhanced reduction in tumor volume with anti-PD-L1 antibody and MEK inhibitor
combination treatment was observed as compared to treatment with anti-PD-L1 antibody or
MEK inhibitor G02442104 alone.
Figure 11 is a graph demonstrating that treatment with MEK inhibitor G00039805
enhanced the anti-tumor activity of anti-PD-L1 antibodies in in vivo models of colorectal cancer.
An enhanced reduction in tumor volume with anti-PD-L1 antibody and MEK inhibitor
combination treatment was observed as compared to treatment with anti-PD-L1 antibody or
MEK inhibitor G00039805 alone.
Figure 12 demonstrates that MEK inhibitor treatment enhanced anti-tumor activity of
anti-PD-L1 antibodies in in vivo models of melanoma. (A and B) Graph depicting changes in
tumor volume with anti-PD-L1 antibodies and MEK inhibitor co-treatment demonstrates
significantly reduced tumor growth as compared to anti-PD-L1 antibodies or MEK inhibitor
treatment alone.
Figure 13 is a graph demonstrating that co-treatment with anti-PD-L1 antibodies and a
chemotherapeutic agent Temodar did not reduce tumor growth in an in vivo model of melanoma.
Therefore, the anti-tumor effect of MEK inhibitor and anti-PD-L1 antibodies is specific.
Figure 14 is a graph demonstrating that co-treatment with anti-OX40 antibodies and a
MEK inhibitor did not reduce tumor growth in an in vivo colorectal model. Therefore, the anti-
tumor effect of MEK inhibitor and anti-PD-L1 antibodies is specific.
Figure 15 contains several graphs showing that MEK inhibitor increased activation of
dendritic cells independently of anti-PD-L1 antibody treatment. (A) Graph demonstrating that
anti-PD-L1 antibody treatment slightly increased MHC I surface expression. MEK inhibitor
treatment significantly enhanced MHCI expression, however co-treatment with anti-PD-L1
antibodies did not enhance the effect of MEK inhibitor treatment. (B-D) Graphs demonstrating
that anti-PD-L1 antibody treatment did not increase expression of dendritic cell activation
markers MHC II, CD80, and CD86. In contrast MEK inhibitor treatment significantly enhanced
expression of dendritic cell activation markers. Co-treatment with anti-PD-L1 antibodies did not
enhance the effect of MEK inhibitor treatment. (E-H) Graphs demonstrating that stimulation of
dendritic cells with anti-CD40 antibodies did not alter the effect of MEK inhibitor and anti-PD-
L1 co-treatment on dendritic cell activation.
DETAILED DESCRIPTION OF THE INVENTION
I. General techniques
The techniques and procedures described or referenced herein are generally well
understood and commonly employed using conventional methodology by those skilled in the art,
such as, for example, the widely utilized methodologies described in Sambrook et al., Molecular
Cloning: A Laboratory Manual 3d edition (2001) Cold Spring Harbor Laboratory Press, Cold
Spring Harbor, N.Y.; Current Protocols in Molecular Biology (F.M. Ausubel, et al. eds.,
(2003)); the series Methods in Enzymology (Academic Press, Inc.): PCR 2: A Practical
Approach (M.J. MacPherson, B.D. Hames and G.R. Taylor eds. (1995)), Harlow and Lane, eds.
(1988) Antibodies, A Laboratory Manual, and Animal Cell Culture (R.I. Freshney, ed. (1987));
Oligonucleotide Synthesis (M.J. Gait, ed., 1984); Methods in Molecular Biology, Humana Press;
Cell Biology: A Laboratory Notebook (J.E. Cellis, ed., 1998) Academic Press; Animal Cell
Culture (R.I. Freshney), ed., 1987); Introduction to Cell and Tissue Culture (J.P. Mather and
P.E. Roberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (A. Doyle,
J.B. Griffiths, and D.G. Newell, eds., 1993-8) J. Wiley and Sons; Handbook of Experimental
Immunology (D.M. Weir and C.C. Blackwell, eds.); Gene Transfer Vectors for Mammalian
Cells (J.M. Miller and M.P. Calos, eds., 1987); PCR: The Polymerase Chain Reaction, (Mullis
et al., eds., 1994); Current Protocols in Immunology (J.E. Coligan et al., eds., 1991); Short
Protocols in Molecular Biology (Wiley and Sons, 1999); Immunobiology (C.A. Janeway and P.
Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: A Practical Approach (D. Catty., ed.,
IRL Press, 1988-1989); Monoclonal Antibodies: A Practical Approach (P. Shepherd and C.
Dean, eds., Oxford University Press, 2000); Using Antibodies: A Laboratory Manual (E. Harlow
and D. Lane (Cold Spring Harbor Laboratory Press, 1999); The Antibodies (M. Zanetti and J. D.
Capra, eds., Harwood Academic Publishers, 1995); and Cancer: Principles and Practice of
Oncology (V.T. DeVita et al., eds., J.B. Lippincott Company, 1993).
II. Definitions
The term ‘comprising’ as used in this specification and claims means ‘consisting at
least in part of’. When interpreting statements in this specification and claims which includes
the ‘comprising’, other features besides the features prefaced by this term in each statement can
also be present. Related terms such as ‘comprise’ and ‘comprised’ are to be interpreted in
similar manner.
[0035a] The term “PD-1 axis binding antagonist" is a molecule that inhibits the interaction of a
PD-1 axis binding partner with either one or more of its binding partner, so as to remove T-cell
dysfunction resulting from signaling on the PD-1 signaling axis – with a result being to restore
or enhance T-cell function (e.g., proliferation, cytokine production, target cell killing). As used
herein, a PD-1 axis binding antagonist includes a PD-1 binding antagonist, a PD-L1 binding
antagonist and a PD-L2 binding antagonist.
The term “PD-1 binding antagonists” is a molecule that decreases, blocks, inhibits,
abrogates or interferes with signal transduction resulting from the interaction of PD-1 with one
or more of its binding partners, such as PD-L1, PD-L2. In some embodiments, the PD-1 binding
antagonist is a molecule that inhibits the binding of PD-1 to its binding partners. In a specific
embodiment, the PD-1 binding antagonist inhibits the binding of PD-1 to PD-L1 and/or PD-L2.
For example, PD-1 binding antagonists include anti-PD-1 antibodies, antigen binding fragments
thereof, immunoadhesins, fusion proteins, oligopeptides and other molecules that decrease,
block, inhibit, abrogate or interfere with signal transduction resulting from the interaction of PD-
1 with PD-L1 and/or PD-L2. In one embodiment, a PD-1 binding antagonist reduces the
negative co-stimulatory signal mediated by or through cell surface proteins expressed on T
lymphocytes mediated signaling through PD-1 so as render a dysfunctional T-cell less
dysfunctional (e.g., enhancing effector responses to antigen recognition). In some embodiments,
the PD-1 binding antagonist is an anti-PD-1 antibody. In a specific embodiment, a PD-1 binding
antagonist is MDX-1106 described herein. In another specific embodiment, a PD-1 binding
antagonist is Merck 3745 described herein. In another specific embodiment, a PD-1 binding
antagonist is CT-011 described herein.
The term “PD-L1 binding antagonists” is a molecule that decreases, blocks, inhibits,
abrogates or interferes with signal transduction resulting from the interaction of PD-L1 with
either one or more of its binding partners, such as PD-1, B7-1. In some embodiments, a PD-L1
binding antagonist is a molecule that inhibits the binding of PD-L1 to its binding partners. In a
specific embodiment, the PD-L1 binding antagonist inhibits binding of PD-L1 to PD-1 and/or
B7-1. In some embodiments, the PD-L1 binding antagonists include anti-PD-L1 antibodies,
antigen binding fragments thereof, immunoadhesins, fusion proteins, oligopeptides and other
molecules that decrease, block, inhibit, abrogate or interfere with signal transduction resulting
from the interaction of PD-L1 with one or more of its binding partners, such as PD-1, B7-1. In
one embodiment, a PD-L1 binding antagonist reduces the negative co-stimulatory signal
mediated by or through cell surface proteins expressed on T lymphocytes mediated signaling
through PD-L1 so as to render a dysfunctional T-cell less dysfunctional (e.g., enhancing effector
responses to antigen recognition). In some embodiments, a PD-L1 binding antagonist is an anti-
PD-L1 antibody. In a specific embodiment, an anti-PD-L1 antibody is YW243.55.S70 described
herein. In another specific embodiment, an anti-PD-L1 antibody is MDX-1105 described herein.
In still another specific embodiment, an anti-PD-L1 antibody is MPDL3280A described herein.
The term “PD-L2 binding antagonists” is a molecule that decreases, blocks, inhibits,
abrogates or interferes with signal transduction resulting from the interaction of PD-L2 with
either one or more of its binding partners, such as PD-1. In some embodiments, a PD-L2
binding antagonist is a molecule that inhibits the binding of PD-L2 to its binding partners. In a
specific embodiment, the PD-L2 binding antagonist inhibits binding of PD-L2 to PD-1. In some
embodiments, the PD-L2 antagonists include anti-PD-L2 antibodies, antigen binding fragments
thereof, immunoadhesins, fusion proteins, oligopeptides and other molecules that decrease,
block, inhibit, abrogate or interfere with signal transduction resulting from the interaction of PD-
L2 with either one or more of its binding partners, such as PD-1. In one embodiment, a PD-L2
binding antagonist reduces the negative co-stimulatory signal mediated by or through cell
surface proteins expressed on T lymphocytes mediated signaling through PD-L2 so as render a
dysfunctional T-cell less dysfunctional (e.g., enhancing effector responses to antigen
recognition). In some embodiments, a PD-L2 binding antagonist is an immunoadhesin.
The term “dysfunction” in the context of immune dysfunction, refers to a state of
reduced immune responsiveness to antigenic stimulation. The term includes the common
elements of both exhaustion and/or anergy in which antigen recognition may occur, but the
ensuing immune response is ineffective to control infection or tumor growth.
The term “dysfunctional”, as used herein, also includes refractory or unresponsive to
antigen recognition, specifically, impaired capacity to translate antigen recognition into down-
stream T-cell effector functions, such as proliferation, cytokine production (e.g., IL-2) and/or
target cell killing.
The term “anergy” refers to the state of unresponsiveness to antigen stimulation
resulting from incomplete or insufficient signals delivered through the T-cell receptor (e.g.
increase in intracellular Ca in the absence of ras-activation). T cell anergy can also result upon
stimulation with antigen in the absence of co-stimulation, resulting in the cell becoming
refractory to subsequent activation by the antigen even in the context of costimulation. The
unresponsive state can often be overriden by the presence of Interleukin-2. Anergic T-cells do
not undergo clonal expansion and/or acquire effector functions.
The term “exhaustion” refers to T cell exhaustion as a state of T cell dysfunction that
arises from sustained TCR signaling that occurs during many chronic infections and cancer. It is
distinguished from anergy in that it arises not through incomplete or deficient signaling, but
from sustained signaling. It is defined by poor effector function, sustained expression of
inhibitory receptors and a transcriptional state distinct from that of functional effector or
memory T cells. Exhaustion prevents optimal control of infection and tumors. Exhaustion can
result from both extrinsic negative regulatory pathways (e.g., immunoregulatory cytokines) as
well as cell intrinsic negative regulatory (costimulatory) pathways (PD-1, B7-H3, B7-H4, etc.).
“Enhancing T-cell function” means to induce, cause or stimulate a T-cell to have a
sustained or amplified biological function, or renew or reactivate exhausted or inactive T-cells.
Examples of enhancing T-cell function include: increased secretion of g-interferon from CD8
T-cells, increased proliferation, increased antigen responsiveness (e.g., viral, pathogen, or tumor
clearance) relative to such levels before the intervention. In one embodiment, the level of
enhancement is as least 50%, alternatively 60%, 70%, 80%, 90%, 100%, 120%, 150%, 200%.
The manner of measuring this enhancement is known to one of ordinary skill in the art.
A “T cell dysfunctional disorder” is a disorder or condition of T-cells characterized by
decreased responsiveness to antigenic stimulation. In a particular embodiment, a T-cell
dysfunctional disorder is a disorder that is specifically associated with inappropriate increased
signaling through PD-1. In another embodiment, a T-cell dysfunctional disorder is one in which
T-cells are anergic or have decreased ability to secrete cytokines, proliferate, or execute cytolytic
activity. In a specific embodiment, the decreased responsiveness results in ineffective control of
a pathogen or tumor expressing an immunogen. Examples of T cell dysfunctional disorders
characterized by T-cell dysfunction include unresolved acute infection, chronic infection and
tumor immunity.
“Tumor immunity” refers to the process in which tumors evade immune recognition
and clearance. Thus, as a therapeutic concept, tumor immunity is “treated” when such evasion is
attenuated, and the tumors are recognized and attacked by the immune system. Examples of
tumor recognition include tumor binding, tumor shrinkage and tumor clearance.
“Immunogenecity” refers to the ability of a particular substance to provoke an immune
response. Tumors are immunogenic and enhancing tumor immunogenicity aids in the clearance
of the tumor cells by the immune response. Examples of enhancing tumor immunogenicity
include treatment with anti-PDL antibodies and a MEK inhibitor.
“Sustained response” refers to the sustained effect on reducing tumor growth after
cessation of a treatment. For example, the tumor size may remain to be the same or smaller as
compared to the size at the beginning of the administration phase. In some embodiments, the
sustained response has a duration at least the same as the treatment duration, at least 1.5X, 2.0X,
2.5X, or 3.0X length of the treatment duration.
The term “antibody” includes monoclonal antibodies (including full length antibodies
which have an immunoglobulin Fc region), antibody compositions with polyepitopic specificity,
multispecific antibodies (e.g., bispecific antibodies, diabodies, and single-chain molecules, as
well as antibody fragments (e.g., Fab, F(ab') , and Fv). The term “immunoglobulin” (Ig) is used
interchangeably with “antibody” herein.
The basic 4-chain antibody unit is a heterotetrameric glycoprotein composed of two
identical light (L) chains and two identical heavy (H) chains. An IgM antibody consists of 5 of
the basic heterotetramer units along with an additional polypeptide called a J chain, and contains
antigen binding sites, while IgA antibodies comprise from 2-5 of the basic 4-chain units
which can polymerize to form polyvalent assemblages in combination with the J chain. In the
case of IgGs, the 4-chain unit is generally about 150,000 daltons. Each L chain is linked to an H
chain by one covalent disulfide bond, while the two H chains are linked to each other by one or
more disulfide bonds depending on the H chain isotype. Each H and L chain also has regularly
spaced intrachain disulfide bridges. Each H chain has at the N-terminus, a variable domain (V )
followed by three constant domains (C ) for each of the a and g chains and four C domains for
m and e isotypes. Each L chain has at the N-terminus, a variable domain (V ) followed by a
constant domain at its other end. The V is aligned with the V and the C is aligned with the
L H L
first constant domain of the heavy chain (C 1). Particular amino acid residues are believed to
form an interface between the light chain and heavy chain variable domains. The pairing of a
V and V together forms a single antigen-binding site. For the structure and properties of the
different classes of antibodies, see e.g., Basic and Clinical Immunology, 8th Edition, Daniel P.
Sties, Abba I. Terr and Tristram G. Parsolw (eds), Appleton & Lange, Norwalk, CT, 1994, page
71 and Chapter 6. The L chain from any vertebrate species can be assigned to one of two clearly
distinct types, called kappa and lambda, based on the amino acid sequences of their constant
domains. Depending on the amino acid sequence of the constant domain of their heavy chains
(CH), immunoglobulins can be assigned to different classes or isotypes. There are five classes
of immunoglobulins: IgA, IgD, IgE, IgG and IgM, having heavy chains designated a, d, e, g and
m, respectively. The g and a classes are further divided into subclasses on the basis of relatively
minor differences in the CH sequence and function, e.g., humans express the following
subclasses: IgG1, IgG2A, IgG2B, IgG3, IgG4, IgA1 and IgA2.
The “variable region” or “variable domain” of an antibody refers to the amino-
terminal domains of the heavy or light chain of the antibody. The variable domains of the heavy
chain and light chain may be referred to as “VH” and “VL”, respectively. These domains are
generally the most variable parts of the antibody (relative to other antibodies of the same class)
and contain the antigen binding sites.
The term "variable" refers to the fact that certain segments of the variable domains
differ extensively in sequence among antibodies. The V domain mediates antigen binding and
defines the specificity of a particular antibody for its particular antigen. However, the variability
is not evenly distributed across the entire span of the variable domains. Instead, it is
concentrated in three segments called hypervariable regions (HVRs) both in the light-chain and
the heavy chain variable domains. The more highly conserved portions of variable domains are
called the framework regions (FR). The variable domains of native heavy and light chains each
comprise four FR regions, largely adopting a beta-sheet configuration, connected by three
HVRs, which form loops connecting, and in some cases forming part of, the beta-sheet structure.
The HVRs in each chain are held together in close proximity by the FR regions and, with the
HVRs from the other chain, contribute to the formation of the antigen binding site of antibodies
(see Kabat et al., Sequences of Immunological Interest, Fifth Edition, National Institute of
Health, Bethesda, MD (1991)). The constant domains are not involved directly in the binding of
antibody to an antigen, but exhibit various effector functions, such as participation of the
antibody in antibody-dependent cellular toxicity.
The term “monoclonal antibody” as used herein refers to an antibody obtained from a
population of substantially homogeneous antibodies, i.e., the individual antibodies comprising
the population are identical except for possible naturally occurring mutations and/or post-
translation modifications (e.g., isomerizations, amidations) that may be present in minor
amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic
site. In contrast to polyclonal antibody preparations which typically include different antibodies
directed against different determinants (epitopes), each monoclonal antibody is directed against
a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies
are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other
immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being
obtained from a substantially homogeneous population of antibodies, and is not to be construed
as requiring production of the antibody by any particular method. For example, the monoclonal
antibodies to be used in accordance with the present description may be made by a variety of
techniques, including, for example, the hybridoma method (e.g., Kohler and Milstein., Nature,
256:495-97 (1975); Hongo et al., Hybridoma, 14 (3): 253-260 (1995), Harlow et al., Antibodies:
A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2 ed. 1988); Hammerling et al.,
in: Monoclonal Antibodies and T-Cell Hybridomas 563-681 (Elsevier, N.Y., 1981)),
recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567), phage-display technologies
(see, e.g., Clackson et al., Nature, 352: 624-628 (1991); Marks et al., J. Mol. Biol. 222: 581-597
(1992); Sidhu et al., J. Mol. Biol. 338(2): 299-310 (2004); Lee et al., J. Mol. Biol. 340(5): 1073-
1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34): 12467-12472 (2004); and Lee et al.,
J. Immunol. Methods 284(1-2): 119-132 (2004), and technologies for producing human or
human-like antibodies in animals that have parts or all of the human immunoglobulin loci or
genes encoding human immunoglobulin sequences (see, e.g., ; WO
1996/34096; ; ; Jakobovits et al., Proc. Natl. Acad. Sci. USA
90: 2551 (1993); Jakobovits et al., Nature 362: 255-258 (1993); Bruggemann et al., Year in
Immunol. 7:33 (1993); U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425;
and 5,661,016; Marks et al., Bio/Technology 10: 779-783 (1992); Lonberg et al., Nature 368:
856-859 (1994); Morrison, Nature 368: 812-813 (1994); Fishwild et al., Nature Biotechnol. 14:
845-851 (1996); Neuberger, Nature Biotechnol. 14: 826 (1996); and Lonberg and Huszar,
Intern. Rev. Immunol. 13: 65-93 (1995).
The term “naked antibody” refers to an antibody that is not conjugated to a cytotoxic
moiety or radiolabel.
The terms “full-length antibody,” “intact antibody” or “whole antibody” are used
interchangeably to refer to an antibody in its substantially intact form, as opposed to an antibody
fragment. Specifically whole antibodies include those with heavy and light chains including an
Fc region. The constant domains may be native sequence constant domains (e.g., human native
sequence constant domains) or amino acid sequence variants thereof. In some cases, the intact
antibody may have one or more effector functions.
An “antibody fragment” comprises a portion of an intact antibody, preferably the
antigen binding and/or the variable region of the intact antibody. Examples of antibody
fragments include Fab, Fab', F(ab') and Fv fragments; diabodies; linear antibodies (see U.S.
Patent 5,641,870, Example 2; Zapata et al., Protein Eng. 8(10): 1057-1062 [1995]); single-chain
antibody molecules and multispecific antibodies formed from antibody fragments. Papain
digestion of antibodies produced two identical antigen-binding fragments, called "Fab"
fragments, and a residual "Fc" fragment, a designation reflecting the ability to crystallize readily.
The Fab fragment consists of an entire L chain along with the variable region domain of the H
chain (V ), and the first constant domain of one heavy chain (C 1). Each Fab fragment is
monovalent with respect to antigen binding, i.e., it has a single antigen-binding site. Pepsin
treatment of an antibody yields a single large F(ab') fragment which roughly corresponds to two
disulfide linked Fab fragments having different antigen-binding activity and is still capable of
cross-linking antigen. Fab' fragments differ from Fab fragments by having a few additional
residues at the carboxy terminus of the C 1 domain including one or more cysteines from the
antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine
residue(s) of the constant domains bear a free thiol group. F(ab') antibody fragments originally
were produced as pairs of Fab' fragments which have hinge cysteines between them. Other
chemical couplings of antibody fragments are also known.
The Fc fragment comprises the carboxy-terminal portions of both H chains held
together by disulfides. The effector functions of antibodies are determined by sequences in the
Fc region, the region which is also recognized by Fc receptors (FcR) found on certain types of
cells.
“Fv” is the minimum antibody fragment which contains a complete antigen-recognition
and -binding site. This fragment consists of a dimer of one heavy- and one light-chain variable
region domain in tight, non-covalent association. From the folding of these two domains
emanate six hypervariable loops (3 loops each from the H and L chain) that contribute the amino
acid residues for antigen binding and confer antigen binding specificity to the antibody.
However, even a single variable domain (or half of an Fv comprising only three HVRs specific
for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the
entire binding site.
“Single-chain Fv” also abbreviated as “sFv” or “scFv” are antibody fragments that
comprise the V and V antibody domains connected into a single polypeptide chain.
Preferably, the sFv polypeptide further comprises a polypeptide linker between the V and V
domains which enables the sFv to form the desired structure for antigen binding. For a review
of the sFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg
and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).
“Functional fragments” of the antibodies as described comprise a portion of an intact
antibody, generally including the antigen binding or variable region of the intact antibody or the
Fc region of an antibody which retains or has modified FcR binding capability. Examples of
antibody fragments include linear antibody, single-chain antibody molecules and multispecific
antibodies formed from antibody fragments.
The term “diabodies” refers to small antibody fragments prepared by constructing sFv
fragments (see preceding paragraph) with short linkers (about 5-10) residues) between the V
and V domains such that inter-chain but not intra-chain pairing of the V domains is achieved,
thereby resulting in a bivalent fragment, i.e., a fragment having two antigen-binding sites.
Bispecific diabodies are heterodimers of two "crossover" sFv fragments in which the VH and VL
domains of the two antibodies are present on different polypeptide chains. Diabodies are
described in greater detail in, for example, EP 404,097; WO 93/11161; Hollinger et al., Proc.
Natl. Acad. Sci. USA 90: 6444-6448 (1993).
The monoclonal antibodies herein specifically include "chimeric" antibodies
(immunoglobulins) in which a portion of the heavy and/or light chain is identical with or
homologous to corresponding sequences in antibodies derived from a particular species or
belonging to a particular antibody class or subclass, while the remainder of the chain(s) is(are)
identical with or homologous to corresponding sequences in antibodies derived from another
species or belonging to another antibody class or subclass, as well as fragments of such
antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567;
Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). Chimeric antibodies of
interest herein include PRIMATIZED antibodies wherein the antigen-binding region of the
antibody is derived from an antibody produced by, e.g., immunizing macaque monkeys with an
antigen of interest. As used herein, “humanized antibody” is used a subset of “chimeric
antibodies.”
"Humanized" forms of non-human (e.g., murine) antibodies are chimeric antibodies
that contain minimal sequence derived from non-human immunoglobulin. In one embodiment, a
humanized antibody is a human immunoglobulin (recipient antibody) in which residues from an
HVR (hereinafter defined) of the recipient are replaced by residues from an HVR of a non-
human species (donor antibody) such as mouse, rat, rabbit or non-human primate having the
desired specificity, affinity, and/or capacity. In some instances, framework (“FR”) residues of
the human immunoglobulin are replaced by corresponding non-human residues. Furthermore,
humanized antibodies may comprise residues that are not found in the recipient antibody or in
the donor antibody. These modifications may be made to further refine antibody performance,
such as binding affinity. In general, a humanized antibody will comprise substantially all of at
least one, and typically two, variable domains, in which all or substantially all of the
hypervariable loops correspond to those of a non-human immunoglobulin sequence, and all or
substantially all of the FR regions are those of a human immunoglobulin sequence, although the
FR regions may include one or more individual FR residue substitutions that improve antibody
performance, such as binding affinity, isomerization, immunogenicity, etc. The number of these
amino acid substitutions in the FR are typically no more than 6 in the H chain, and in the L
chain, no more than 3. The humanized antibody optionally will also comprise at least a portion
of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For
further details, see, e.g., Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature
332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992). See also, for
example, Vaswani and Hamilton, Ann. Allergy, Asthma & Immunol. 1:105-115 (1998); Harris,
Biochem. Soc. Transactions 23:1035-1038 (1995); Hurle and Gross, Curr. Op. Biotech. 5:428-
433 (1994); and U.S. Pat. Nos. 6,982,321 and 7,087,409.
A “human antibody” is an antibody that possesses an amino-acid sequence
corresponding to that of an antibody produced by a human and/or has been made using any of
the techniques for making human antibodies as disclosed herein. This definition of a human
antibody specifically excludes a humanized antibody comprising non-human antigen-binding
residues. Human antibodies can be produced using various techniques known in the art,
including phage-display libraries. Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991);
Marks et al., J. Mol. Biol., 222:581 (1991). Also available for the preparation of human
monoclonal antibodies are methods described in Cole et al., Monoclonal Antibodies and Cancer
Therapy, Alan R. Liss, p. 77 (1985); Boerner et al., J. Immunol., 147(1):86-95 (1991). See also
van Dijk and van de Winkel, Curr. Opin. Pharmacol., 5: 368-74 (2001). Human antibodies can
be prepared by administering the antigen to a transgenic animal that has been modified to
produce such antibodies in response to antigenic challenge, but whose endogenous loci have
been disabled, e.g., immunized xenomice (see, e.g., U.S. Pat. Nos. 6,075,181 and 6,150,584
regarding XENOMOUSE technology). See also, for example, Li et al., Proc. Natl. Acad. Sci.
USA, 103:3557-3562 (2006) regarding human antibodies generated via a human B-cell
hybridoma technology.
The term “hypervariable region,” “HVR,” or “HV,” when used herein refers to the
regions of an antibody variable domain which are hypervariable in sequence and/or form
structurally defined loops. Generally, antibodies comprise six HVRs; three in the VH (H1, H2,
H3), and three in the VL (L1, L2, L3). In native antibodies, H3 and L3 display the most
diversity of the six HVRs, and H3 in particular is believed to play a unique role in conferring
fine specificity to antibodies. See, e.g., Xu et al., Immunity 13:37-45 (2000); Johnson and Wu,
in Methods in Molecular Biology 248:1-25 (Lo, ed., Human Press, Totowa, NJ, 2003). Indeed,
naturally occurring camelid antibodies consisting of a heavy chain only are functional and stable
in the absence of light chain. See, e.g., Hamers-Casterman et al., Nature 363:446-448 (1993);
Sheriff et al., Nature Struct. Biol. 3:733-736 (1996).
A number of HVR delineations are in use and are encompassed herein. The Kabat
Complementarity Determining Regions (CDRs) are based on sequence variability and are the
most commonly used (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed.
Public Health Service, National Institutes of Health, Bethesda, MD. (1991)). Chothia refers
instead to the location of the structural loops (Chothia and Lesk, J. Mol. Biol. 196:901-917
(1987)). The AbM HVRs represent a compromise between the Kabat HVRs and Chothia
structural loops, and are used by Oxford Molecular's AbM antibody modeling software. The
“contact” HVRs are based on an analysis of the available complex crystal structures. The
residues from each of these HVRs are noted below.
Loop Kabat AbM Chothia Contact
L1 L24-L34 L24-L34 L26-L32 L30-L36
L2 L50-L56 L50-L56 L50-L52 L46-L55
L3 L89-L97 L89-L97 L91-L96 L89-L96
H1 H31-H35B H26-H35B H26-H32 H30-H35B (Kabat numbering)
H1 H31-H35 H26-H35 H26-H32 H30-H35 (Chothia numbering)
H2 H50-H65 H50-H58 H53-H55 H47-H58
H3 H95-H102 H95-H102 H96-H101 H93-H101
HVRs may comprise “extended HVRs” as follows: 24-36 or 24-34 (L1), 46-56 or 50-
56 (L2) and 89-97 or 89-96 (L3) in the VL and 26-35 (H1), 50-65 or 49-65 (H2) and 93-102, 94-
102, or 95-102 (H3) in the VH. The variable domain residues are numbered according to Kabat
et al., supra, for each of these definitions.
The expression “variable-domain residue-numbering as in Kabat” or “amino-acid-
position numbering as in Kabat,” and variations thereof, refers to the numbering system used for
heavy-chain variable domains or light-chain variable domains of the compilation of antibodies in
Kabat et al., supra. Using this numbering system, the actual linear amino acid sequence may
contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a FR
or HVR of the variable domain. For example, a heavy-chain variable domain may include a
single amino acid insert (residue 52a according to Kabat) after residue 52 of H2 and inserted
residues (e.g. residues 82a, 82b, and 82c, etc. according to Kabat) after heavy-chain FR residue
82. The Kabat numbering of residues may be determined for a given antibody by alignment at
regions of homology of the sequence of the antibody with a “standard” Kabat numbered
sequence.
"Framework" or "FR" residues are those variable-domain residues other than the HVR
residues as herein defined.
A “human consensus framework” or “acceptor human framework” is a framework that
represents the most commonly occurring amino acid residues in a selection of human
immunoglobulin VL or VH framework sequences. Generally, the selection of human
immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences.
Generally, the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of
Immunological Interest, 5 Ed. Public Health Service, National Institutes of Health, Bethesda,
MD (1991). Examples include for the VL, the subgroup may be subgroup kappa I, kappa II,
kappa III or kappa IV as in Kabat et al., supra. Additionally, for the VH, the subgroup may be
subgroup I, subgroup II, or subgroup III as in Kabat et al., supra. Alternatively, a human
consensus framework can be derived from the above in which particular residues, such as when
a human framework residue is selected based on its homology to the donor framework by
aligning the donor framework sequence with a collection of various human framework
sequences. An acceptor human framework “derived from” a human immunoglobulin framework
or a human consensus framework may comprise the same amino acid sequence thereof, or it
may contain pre-existing amino acid sequence changes. In some embodiments, the number of
pre-existing amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4
or less, 3 or less, or 2 or less.
A “VH subgroup III consensus framework” comprises the consensus sequence obtained
from the amino acid sequences in variable heavy subgroup III of Kabat et al., supra. In one
embodiment, the VH subgroup III consensus framework amino acid sequence comprises at least
a portion or all of each of the following sequences: EVQLVESGGGLVQPGGSLRLSCAAS
(HC-FR1)(SEQ ID NO:4), WVRQAPGKGLEWV (HC-FR2), (SEQ ID NO:5),
RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR (HC-FR3, SEQ ID NO:6),
WGQGTLVTVSA (HC-FR4), (SEQ ID NO:7).
A “VL kappa I consensus framework” comprises the consensus sequence obtained from
the amino acid sequences in variable light kappa subgroup I of Kabat et al., supra. In one
embodiment, the VH subgroup I consensus framework amino acid sequence comprises at least a
portion or all of each of the following sequences: DIQMTQSPSSLSASVGDRVTITC (LC-FR1)
(SEQ ID NO:11), WYQQKPGKAPKLLIY (LC-FR2) (SEQ ID NO:12),
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (LC-FR3)(SEQ ID NO:13), FGQGTKVEIKR
(LC-FR4)(SEQ ID NO:14).
An “amino-acid modification” at a specified position, e.g. of the Fc region, refers to the
substitution or deletion of the specified residue, or the insertion of at least one amino acid
residue adjacent the specified residue. Insertion “adjacent” to a specified residue means
insertion within one to two residues thereof. The insertion may be N-terminal or C-terminal to
the specified residue. The preferred amino acid modification herein is a substitution.
An “affinity-matured” antibody is one with one or more alterations in one or more
HVRs thereof that result in an improvement in the affinity of the antibody for antigen, compared
to a parent antibody that does not possess those alteration(s). In one embodiment, an affinity-
matured antibody has nanomolar or even picomolar affinities for the target antigen. Affinity-
matured antibodies are produced by procedures known in the art. For example, Marks et al.,
Bio/Technology 10:779-783 (1992) describes affinity maturation by VH- and VL-domain
shuffling. Random mutagenesis of HVR and/or framework residues is described by, for
example: Barbas et al. Proc Nat. Acad. Sci. USA 91:3809-3813 (1994); Schier et al. Gene
169:147-155 (1995); Yelton et al. J. Immunol. 155:1994-2004 (1995); Jackson et al., J.
Immunol. 154(7):3310-9 (1995); and Hawkins et al, J. Mol. Biol. 226:889-896 (1992).
As use herein, the term "specifically binds to" or is "specific for" refers to measurable
and reproducible interactions such as binding between a target and an antibody, which is
determinative of the presence of the target in the presence of a heterogeneous population of
molecules including biological molecules. For example, an antibody that specifically binds to a
target (which can be an epitope) is an antibody that binds this target with greater affinity,
avidity, more readily, and/or with greater duration than it binds to other targets. In one
embodiment, the extent of binding of an antibody to an unrelated target is less than about 10% of
the binding of the antibody to the target as measured, e.g., by a radioimmunoassay (RIA). In
certain embodiments, an antibody that specifically binds to a target has a dissociation constant
(Kd) of ≤ 1 μM, ≤ 100 nM, ≤ 10 nM, ≤ 1 nM, or ≤ 0.1 nM. In certain embodiments, an antibody
specifically binds to an epitope on a protein that is conserved among the protein from different
species. In another embodiment, specific binding can include, but does not require exclusive
binding.
As used herein, the term “immunoadhesin” designates antibody-like molecules which
combine the binding specificity of a heterologous protein (an “adhesin”) with the effector
functions of immunoglobulin constant domains. Structurally, the immunoadhesins comprise a
fusion of an amino acid sequence with the desired binding specificity which is other than the
antigen recognition and binding site of an antibody (i.e., is “heterologous”), and an
immunoglobulin constant domain sequence. The adhesin part of an immunoadhesin molecule
typically is a contiguous amino acid sequence comprising at least the binding site of a receptor
or a ligand. The immunoglobulin constant domain sequence in the immunoadhesin may be
obtained from any immunoglobulin, such as IgG-1, IgG-2 (including IgG2A and IgG2B), IgG-3,
or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM. The Ig fusions
preferably include the substitution of a domain of a polypeptide or antibody described herein in
the place of at least one variable region within an Ig molecule. In a particularly preferred
embodiment, the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CH1,
CH2 and CH3 regions of an IgG1 molecule. For the production of immunoglobulin fusions see
also US Patent No. 5,428,130 issued June 27, 1995. For example, useful immunoadhesins as
second medicaments useful for combination therapy herein include polypeptides that comprise
the extracellular or PD-1 binding portions of PD-L1 or PD-L2 or the extracellular or PD-L1 or
PD-L2 binding portions of PD-1, fused to a constant domain of an immunoglobulin sequence,
such as a PD-L1 ECD – Fc, a PD-L2 ECD – Fc, and a PD-1 ECD - Fc, respectively.
Immunoadhesin combinations of Ig Fc and ECD of cell surface receptors are sometimes termed
soluble receptors.
A “fusion protein” and a “fusion polypeptide” refer to a polypeptide having two
portions covalently linked together, where each of the portions is a polypeptide having a
different property. The property may be a biological property, such as activity in vitro or in vivo.
The property may also be simple chemical or physical property, such as binding to a target
molecule, catalysis of a reaction, etc. The two portions may be linked directly by a single
peptide bond or through a peptide linker but are in reading frame with each other.
A “PD-1 oligopeptide,” “PD-L1 oligopeptide,” or “PD-L2 oligopeptide” is an
oligopeptide that binds, preferably specifically, to a PD-1, PD-L1 or PD-L2 negative
costimulatory polypeptide, respectively, including a receptor, ligand or signaling component,
respectively, as described herein. Such oligopeptides may be chemically synthesized using
known oligopeptide synthesis methodology or may be prepared and purified using recombinant
technology. Such oligopeptides are usually at least about 5 amino acids in length, alternatively
at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54,
55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80,
81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 amino acids in
length or more. Such oligopeptides may be identified using well known techniques. In this
regard, it is noted that techniques for screening oligopeptide libraries for oligopeptides that are
capable of specifically binding to a polypeptide target are well known in the art (see, e.g., U.S.
Patent Nos. 5,556,762, 5,750,373, 4,708,871, 4,833,092, 5,223,409, 5,403,484, 5,571,689,
,663,143; PCT Publication Nos. WO 84/03506 and WO84/03564; Geysen et al., Proc. Natl.
Acad. Sci. U.S.A., 81:3998-4002 (1984); Geysen et al., Proc. Natl. Acad. Sci. U.S.A., 82:178-182
(1985); Geysen et al., in Synthetic Peptides as Antigens, 130-149 (1986); Geysen et al., J. Immunol.
Meth., 102:259-274 (1987); Schoofs et al., J. Immunol., 140:611-616 (1988), Cwirla, S. E. et al.
Proc. Natl. Acad. Sci. USA, 87:6378 (1990); Lowman, H.B. et al. Biochemistry, 30:10832 (1991);
Clackson, T. et al. Nature, 352: 624 (1991); Marks, J. D. et al., J. Mol. Biol., 222:581 (1991); Kang,
A.S. et al. Proc. Natl. Acad. Sci. USA, 88:8363 (1991), and Smith, G. P., Current Opin. Biotechnol.,
2:668 (1991).
A “blocking” antibody or an “antagonist” antibody is one that inhibits or reduces a
biological activity of the antigen it binds. In some embodiments, blocking antibodies or
antagonist antibodies substantially or completely inhibit the biological activity of the antigen.
The anti-PD-L1 antibodies useful in the invention block the signaling through PD-1 so as to
restore a functional response by T-cells (e.g., proliferation, cytokine production, target cell
killing) from a dysfunctional state to antigen stimulation.
An “agonist” or activating antibody is one that enhances or initiates signaling by the
antigen to which it binds. In some embodiments, agonist antibodies cause or activate signaling
without the presence of the natural ligand.
The term “Fc region” herein is used to define a C-terminal region of an
immunoglobulin heavy chain, including native-sequence Fc regions and variant Fc regions.
Although the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the
human IgG heavy-chain Fc region is usually defined to stretch from an amino acid residue at
position Cys226, or from Pro230, to the carboxyl-terminus thereof. The C-terminal lysine
(residue 447 according to the EU numbering system) of the Fc region may be removed, for
example, during production or purification of the antibody, or by recombinantly engineering the
nucleic acid encoding a heavy chain of the antibody. Accordingly, a composition of intact
antibodies may comprise antibody populations with all K447 residues removed, antibody
populations with no K447 residues removed, and antibody populations having a mixture of
antibodies with and without the K447 residue. Suitable native-sequence Fc regions for use in
the antibodies as described include human IgG1, IgG2 (IgG2A, IgG2B), IgG3 and IgG4.
“Fc receptor” or “FcR” describes a receptor that binds to the Fc region of an antibody.
The preferred FcR is a native sequence human FcR. Moreover, a preferred FcR is one which
binds an IgG antibody (a gamma receptor) and includes receptors of the FcgRI, FcgRII, and
FcgRIII subclasses, including allelic variants and alternatively spliced forms of these receptors,
FcgRII receptors include FcgRIIA (an "activating receptor") and FcgRIIB (an "inhibiting
receptor"), which have similar amino acid sequences that differ primarily in the cytoplasmic
domains thereof. Activating receptor FcgRIIA contains an immunoreceptor tyrosine-based
activation motif (ITAM) in its cytoplasmic domain. Inhibiting receptor FcgRIIB contains an
immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic domain. (see M.
Daëron, Annu. Rev. Immunol. 15:203-234 (1997). FcRs are reviewed in Ravetch and Kinet,
Annu. Rev. Immunol. 9: 457-92 (1991); Capel et al., Immunomethods 4: 25-34 (1994); and de
Haas et al., J. Lab. Clin. Med. 126: 330-41 (1995). Other FcRs, including those to be identified
in the future, are encompassed by the term "FcR" herein.
The term “Fc receptor” or “FcR” also includes the neonatal receptor, FcRn, which is
responsible for the transfer of maternal IgGs to the fetus. Guyer et al., J. Immunol. 117: 587
(1976) and Kim et al., J. Immunol. 24: 249 (1994). Methods of measuring binding to FcRn are
known (see, e.g., Ghetie and Ward, Immunol. Today 18: (12): 592-8 (1997); Ghetie et al., Nature
Biotechnology 15 (7): 637-40 (1997); Hinton et al., J. Biol. Chem. 279 (8): 6213-6 (2004); WO
2004/92219 (Hinton et al.). Binding to FcRn in vivo and serum half-life of human FcRn high-
affinity binding polypeptides can be assayed, e.g., in transgenic mice or transfected human cell
lines expressing human FcRn, or in primates to which the polypeptides having a variant Fc
region are administered. (Presta) describes antibody variants which improved
or diminished binding to FcRs. See also, e.g., Shields et al., J. Biol. Chem. 9(2): 6591-6604
(2001).
The phrase “substantially reduced,” or “substantially different,” as used herein, denotes
a sufficiently high degree of difference between two numeric values (generally one associated
with a molecule and the other associated with a reference/comparator molecule) such that one of
skill in the art would consider the difference between the two values to be of statistical
significance within the context of the biological characteristic measured by said values (e.g., Kd
values). The difference between said two values is, for example, greater than about 10%, greater
than about 20%, greater than about 30%, greater than about 40%, and/or greater than about 50%
as a function of the value for the reference/comparator molecule.
The term “substantially similar” or “substantially the same,” as used herein, denotes a
sufficiently high degree of similarity between two numeric values (for example, one associated
with an antibody as described herein and the other associated with a reference/comparator
antibody), such that one of skill in the art would consider the difference between the two values
to be of little or no biological and/or statistical significance within the context of the biological
characteristic measured by said values (e.g., Kd values). The difference between said two values
is, for example, less than about 50%, less than about 40%, less than about 30%, less than about
%, and/or less than about 10% as a function of the reference/comparator value.
"Carriers" as used herein include pharmaceutically acceptable carriers, excipients, or
stabilizers that are nontoxic to the cell or mammal being exposed thereto at the dosages and
concentrations employed. Often the physiologically acceptable carrier is an aqueous pH
buffered solution. Examples of physiologically acceptable carriers include buffers such as
phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular
weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or
immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as
glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other
carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar
alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic
surfactants such as TWEEN™, polyethylene glycol (PEG), and PLURONICS™.
A “package insert” refers to instructions customarily included in commercial packages
of medicaments that contain information about the indications customarily included in
commercial packages of medicaments that contain information about the indications, usage,
dosage, administration, contraindications, other medicaments to be combined with the packaged
product, and/or warnings concerning the use of such medicaments, etc.
As used herein, the term “treatment” refers to clinical intervention designed to alter the
natural course of the individual or cell being treated during the course of clinical pathology.
Desirable effects of treatment include decreasing the rate of disease progression, ameliorating or
palliating the disease state, and remission or improved prognosis. For example, an individual is
successfully “treated” if one or more symptoms associated with cancer are mitigated or
eliminated, including, but are not limited to, reducing the proliferation of (or destroying)
cancerous cells, decreasing symptoms resulting from the disease, increasing the quality of life
of those suffering from the disease, decreasing the dose of other medications required to treat the
disease, delaying the progression of the disease, and/or prolonging survival of individuals.
As used herein, “delaying progression of a disease” means to defer, hinder, slow, retard,
stabilize, and/or postpone development of the disease (such as cancer). This delay can be of
varying lengths of time, depending on the history of the disease and/or individual being treated.
As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass
prevention, in that the individual does not develop the disease. For example, a late stage cancer,
such as development of metastasis, may be delayed.
An “effective amount” is at least the minimum concentration required to effect a
measurable improvement or prevention of a particular disorder. An effective amount herein may
vary according to factors such as the disease state, age, sex, and weight of the patient, and the
ability of the antibody to elicit a desired response in the individual. An effective amount is also
one in which any toxic or detrimental effects of the treatment are outweighed by the
therapeutically beneficial effects. For prophylactic use, beneficial or desired results include
results such as eliminating or reducing the risk, lessening the severity, or delaying the onset of
the disease, including biochemical, histological and/or behavioral symptoms of the disease, its
complications and intermediate pathological phenotypes presenting during development of the
disease. For therapeutic use, beneficial or desired results include clinical results such as
decreasing one or more symptoms resulting from the disease, increasing the quality of life of
those suffering from the disease, decreasing the dose of other medications required to treat the
disease, enhancing effect of another medication such as via targeting, delaying the progression
of the disease, and/or prolonging survival. In the case of cancer or tumor, an effective amount of
the drug may have the effect in reducing the number of cancer cells; reducing the tumor size;
inhibiting (i.e., slow to some extent or desirably stop) cancer cell infiltration into peripheral
organs; inhibit (i.e., slow to some extent and desirably stop) tumor metastasis; inhibiting to some
extent tumor growth; and/or relieving to some extent one or more of the symptoms associated
with the disorder. An effective amount can be administered in one or more administrations. For
purposes described herein, an effective amount of drug, compound, or pharmaceutical
composition is an amount sufficient to accomplish prophylactic or therapeutic treatment either
directly or indirectly. As is understood in the clinical context, an effective amount of a drug,
compound, or pharmaceutical composition may or may not be achieved in conjunction with
another drug, compound, or pharmaceutical composition. Thus, an “effective amount” may be
considered in the context of administering one or more therapeutic agents, and a single agent
may be considered to be given in an effective amount if, in conjunction with one or more other
agents, a desirable result may be or is achieved.
As used herein, “in conjunction with” refers to administration of one treatment
modality in addition to another treatment modality. As such, “in conjunction with” refers to
administration of one treatment modality before, during, or after administration of the other
treatment modality to the individual.
As used herein, “complete response” or “CR” refers to disappearance of all target
lesions; “partial response” or “PR” refers to at least a 30% decrease in the sum of the longest
diameters (SLD) of target lesions, taking as reference the baseline SLD; and “stable disease” or
“SD” refers to neither sufficient shrinkage of target lesions to qualify for PR, nor sufficient
increase to qualify for PD, taking as reference the smallest SLD since the treatment started.
As used herein, “progressive disease” or “PD” refers to at least a 20% increase in the
SLD of target lesions, taking as reference the smallest SLD recorded since the treatment started
or the presence of one or more new lesions.
As used herein, “progression free survival” (PFS) refers to the length of time during
and after treatment during which the disease being treated (e.g., cancer) does not get worse.
Progression-free survival may include the amount of time patients have experienced a complete
response or a partial response, as well as the amount of time patients have experienced stable
disease.
As used herein, "overall response rate" (ORR) refers to the sum of complete response
(CR) rate and partial response (PR) rate.
As used herein, "overall survival" refers to the percentage of individuals in a group
who are likely to be alive after a particular duration of time.
A “chemotherapeutic agent” is a chemical compound useful in the treatment of cancer.
Examples of chemotherapeutic agents include alkylating agents such as thiotepa and
cyclophosphamide (CYTOXAN®); alkyl sulfonates such as busulfan, improsulfan, and
piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines
and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide,
triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and
bullatacinone); deltatetrahydrocannabinol (dronabinol, MARINOL®); beta-lapachone;
lapachol; colchicines; betulinic acid; a camptothecin (including the synthetic analogue topotecan
(HYCAMTIN®), CPT-11 (irinotecan, CAMPTOSAR®), acetylcamptothecin, scopolectin, and
9-aminocamptothecin); bryostatin; pemetrexed; callystatin; CC-1065 (including its adozelesin,
carzelesin and bizelesin synthetic analogues); podophyllotoxin; podophyllinic acid; teniposide;
cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin
(including the synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancratistatin;
TLK-286; CDP323, an oral alpha-4 integrin inhibitor; a sarcodictyin; spongistatin; nitrogen
mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide,
mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin,
phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine,
chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the
enediyne antibiotics (e. g., calicheamicin, especially calicheamicin gamma1I and calicheamicin
omegaI1 (see, e.g., Nicolaou et al., Angew. Chem Intl. Ed. Engl., 33: 183-186 (1994));
dynemicin, including dynemicin A; an esperamicin; as well as neocarzinostatin chromophore
and related chromoprotein enediyne antibiotic chromophores), aclacinomysins, actinomycin,
authramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin,
chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazooxo-L-norleucine,
doxorubicin (including ADRIAMYCIN®, morpholino-doxorubicin, cyanomorpholino-
doxorubicin, 2-pyrrolino-doxorubicin, doxorubicin HCl liposome injection (DOXIL®) and
deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as
mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin,
puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex,
zinostatin, zorubicin; anti-metabolites such as methotrexate, gemcitabine (GEMZAR®), tegafur
(UFTORAL®), capecitabine (XELODA®), an epothilone, and 5-fluorouracil (5-FU); folic acid
analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as
fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine,
azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine,
floxuridine, and imatinib (a 2-phenylaminopyrimidine derivative), as well as other c-Kit
inhibitors; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher
such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil;
amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone;
elfornithine; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine;
maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol;
nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; 2-ethylhydrazide; procarbazine;
PSK® polysaccharide complex (JHS Natural Products, Eugene, OR); razoxane; rhizoxin;
sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine;
trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine
(ELDISINE®, FILDESIN®); dacarbazine; mannomustine; mitobronitol; mitolactol;
pipobroman; gacytosine; arabinoside ("Ara-C"); thiotepa; taxoids, e.g., paclitaxel (TAXOL®),
albumin-engineered nanoparticle formulation of paclitaxel (ABRAXANE ), and doxetaxel
(TAXOTERE®); chloranbucil; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs
such as cisplatin and carboplatin; vinblastine (VELBAN®); platinum; etoposide (VP-16);
ifosfamide; mitoxantrone; vincristine (ONCOVIN®); oxaliplatin; leucovovin; vinorelbine
(NAVELBINE®); novantrone; edatrexate; daunomycin; aminopterin; ibandronate;
topoisomerase inhibitor RFS 2000; difluorometlhylornithine (DMFO); retinoids such as retinoic
acid; pharmaceutically acceptable salts, acids or derivatives of any of the above; as well as
combinations of two or more of the above such as CHOP, an abbreviation for a combined
therapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone, and FOLFOX, an
abbreviation for a treatment regimen with oxaliplatin (ELOXATIN ) combined with 5-FU and
leucovovin.
Additional examples of chemotherapeutic agents include anti-hormonal agents that act
to regulate, reduce, block, or inhibit the effects of hormones that can promote the growth of
cancer, and are often in the form of systemic, or whole-body treatment. They may be hormones
themselves. Examples include anti-estrogens and selective estrogen receptor modulators
(SERMs), including, for example, tamoxifen (including NOLVADEX® tamoxifen), raloxifene
(EVISTA®), droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone,
and toremifene (FARESTON®); anti-progesterones; estrogen receptor down-regulators (ERDs);
estrogen receptor antagonists such as fulvestrant (FASLODEX®); agents that function to
suppress or shut down the ovaries, for example, leutinizing hormone-releasing hormone (LHRH)
agonists such as leuprolide acetate (LUPRON® and ELIGARD®), goserelin acetate, buserelin
acetate and tripterelin; anti-androgens such as flutamide, nilutamide and bicalutamide; and
aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in
the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, megestrol acetate
(MEGASE®), exemestane (AROMASIN®), formestanie, fadrozole, vorozole (RIVISOR®),
letrozole (FEMARA®), and anastrozole (ARIMIDEX®). In addition, such definition of
chemotherapeutic agents includes bisphosphonates such as clodronate (for example,
BONEFOS® or OSTAC®), etidronate (DIDROCAL®), NE-58095, zoledronic acid/zoledronate
(ZOMETA®), alendronate (FOSAMAX®), pamidronate (AREDIA®), tiludronate (SKELID®),
or risedronate (ACTONEL®); as well as troxacitabine (a 1,3-dioxolane nucleoside cytosine
analog); anti-sense oligonucleotides, particularly those that inhibit expression of genes in
signaling pathways implicated in abherant cell proliferation, such as, for example, PKC-alpha,
Raf, H-Ras, and epidermal growth factor receptor (EGF-R); vaccines such as THERATOPE®
vaccine and gene therapy vaccines, for example, ALLOVECTIN® vaccine, LEUVECTIN®
vaccine, and VAXID® vaccine; topoisomerase 1 inhibitor (e.g., LURTOTECAN®); an anti-
estrogen such as fulvestrant; a Kit inhibitor such as imatinib or EXEL-0862 (a tyrosine kinase
inhibitor); EGFR inhibitor such as erlotinib or cetuximab; an anti-VEGF inhibitor such as
bevacizumab; arinotecan; rmRH (e.g., ABARELIX®); lapatinib and lapatinib ditosylate (an
ErbB-2 and EGFR dual tyrosine kinase small-molecule inhibitor also known as GW572016);
17AAG (geldanamycin derivative that is a heat shock protein (Hsp) 90 poison), and
pharmaceutically acceptable salts, acids or derivatives of any of the above.
As used herein, the term “cytokine” refers generically to proteins released by one cell
population that act on another cell as intercellular mediators or have an autocrine effect on the
cells producing the proteins. Examples of such cytokines include lymphokines, monokines;
interleukins (“ILs”) such as IL-1, IL-1 α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL10, IL-
11, IL-12, IL-13, IL-15, IL-17A-F, IL-18 to IL-29 (such as IL-23), IL-31, including
PROLEUKIN rIL-2; a tumor-necrosis factor such as TNF- α or TNF- β, TGF-b1-3; and other
polypeptide factors including leukemia inhibitory factor (“LIF”), ciliary neurotrophic factor
(“CNTF”), CNTF-like cytokine (“CLC”), cardiotrophin (“CT”), and kit ligand (“KL”).
As used herein, the term "chemokine" refers to soluble factors (e.g., cytokines) that
have the ability to selectively induce chemotaxis and activation of leukocytes. They also trigger
processes of angiogenesis, inflammation, wound healing, and tumorigenesis. Example
chemokines include IL-8, a human homolog of murine keratinocyte chemoattractant (KC).
As used herein and in the appended claims, the singular forms “a,” “or,” and “the”
include plural referents unless the context clearly dictates otherwise.
Reference to “about” a value or parameter herein includes (and describes) variations
that are directed to that value or parameter per se. For example, description referring to “about
X” includes description of “X”.
The term "alkyl" as used herein refers to a saturated linear or branched-chain
monovalent hydrocarbon radical of one to twelve carbon atoms. Examples of alkyl groups
include, but are not limited to, methyl (Me, -CH ), ethyl (Et, -CH CH ), 1-propyl (n-Pr, n-
3 2 3
propyl, -CH CH CH ), 2-propyl (i-Pr, i-propyl, -CH(CH ) ), 1-butyl (n-Bu, n-butyl, -
2 2 3 3 2
CH CH CH CH ), 2-methylpropyl (i-Bu, i-butyl, -CH CH(CH ) ), 2-butyl (s-Bu, s-butyl, -
2 2 2 3 2 3 2
CH(CH )CH CH ), 2-methylpropyl (t-Bu, t-butyl, -C(CH ) ), 1-pentyl (n-pentyl, -
3 2 3 3 3
CH CH CH CH CH ), 2-pentyl (-CH(CH )CH CH CH ), 3-pentyl (-CH(CH CH ) ), 2-methyl-
2 2 2 2 3 3 2 2 3 2 3 2
2-butyl (-C(CH ) CH CH ), 3-methylbutyl (-CH(CH )CH(CH ) ), 3-methylbutyl (-
3 2 2 3 3 3 2
CH CH CH(CH ) ), 2-methylbutyl (-CH CH(CH )CH CH ), 1-hexyl (-
2 2 3 2 2 3 2 3
CH CH CH CH CH CH ), 2-hexyl (-CH(CH )CH CH CH CH ), 3-hexyl (-
2 2 2 2 2 3 3 2 2 2 3
CH(CH CH )(CH CH CH )), 2-methylpentyl (-C(CH ) CH CH CH ), 3-methylpentyl (-
2 3 2 2 3 3 2 2 2 3
CH(CH )CH(CH )CH CH ), 4-methylpentyl (-CH(CH )CH CH(CH ) ), 3-methylpentyl (-
3 3 2 3 3 2 3 2
C(CH )(CH CH ) ), 2-methylpentyl (-CH(CH CH )CH(CH ) ), 2,3-dimethylbutyl (-
3 2 3 2 2 3 3 2
C(CH ) CH(CH ) ), 3,3-dimethylbutyl (-CH(CH )C(CH ) , 1-heptyl, 1-octyl, and the like.
3 2 3 2 3 3 3
The term "alkenyl" refers to linear or branched-chain monovalent hydrocarbon radical
of two to twelve carbon atoms with at least one site of unsaturation, i.e., a carbon-carbon, sp
double bond, wherein the alkenyl radical includes radicals having "cis" and "trans" orientations,
or alternatively, "E" and "Z" orientations. Examples include, but are not limited to, ethylenyl or
vinyl (-CH=CH ), allyl (-CH CH=CH ), and the like.
2 2 2
The term "alkynyl" refers to a linear or branched monovalent hydrocarbon radical of
two to twelve carbon atoms with at least one site of unsaturation, i.e., a carbon-carbon, sp triple
bond. Examples include, but are not limited to, ethynyl (-C”CH), propynyl
(propargyl, -CH2C”CH), and the like.
The terms "carbocycle", "carbocyclyl", "carbocyclic ring" and "cycloalkyl" refer to a
monovalent non-aromatic, saturated or partially unsaturated ring having 3 to 12 carbon atoms as
a monocyclic ring or 7 to 12 carbon atoms as a bicyclic ring. Bicyclic carbocycles having 7 to
12 atoms can be arranged, for example, as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, and
bicyclic carbocycles having 9 or 10 ring atoms can be arranged as a bicyclo [5,6] or [6,6]
system, or as bridged systems such as bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane and
bicyclo[3.2.2]nonane. Examples of monocyclic carbocycles include, but are not limited to,
cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopentenyl, 1-cyclopentenyl, 1-cyclopent
enyl, cyclohexyl, 1-cyclohexenyl, 1-cyclohexenyl, 1-cyclohexenyl, cyclohexadienyl,
cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, and the like.
"Aryl" means a monovalent aromatic hydrocarbon radical of 6-18 carbon atoms
derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic
ring system. Some aryl groups are represented in the exemplary structures as "Ar". Aryl
includes bicyclic radicals comprising an aromatic ring fused to a saturated, partially unsaturated
ring, or aromatic carbocyclic or heterocyclic ring. Typical aryl groups include, but are not
limited to, radicals derived from benzene (phenyl), substituted benzenes, naphthalene,
anthracene, indenyl, indanyl, 1,2-dihydronaphthalene, 1,2,3,4-tetrahydronaphthyl, and the like.
The terms "heterocycle," "heterocyclyl" and "heterocyclic ring" are used
interchangeably herein and refer to a saturated or a partially unsaturated (i.e., having one or
more double and/or triple bonds within the ring) carbocyclic radical of 3 to 18 ring atoms in
which at least one ring atom is a heteroatom selected from nitrogen, oxygen and sulfur, the
remaining ring atoms being C, where one or more ring atoms is optionally substituted
independently with one or more substituents described below. A heterocycle may be a
monocycle having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 4 heteroatoms selected
from N, O, P, and S) or a bicycle having 7 to 10 ring members (4 to 9 carbon atoms and 1 to 6
heteroatoms selected from N, O, P, and S), for example: a bicyclo [4,5], [5,5], [5,6], or [6,6]
system. Heterocycles are described in Paquette, Leo A.; "Principles of Modern Heterocyclic
Chemistry" (W.A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; "The
Chemistry of Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New
York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc.
(1960) 82:5566. "Heterocyclyl" also includes radicals where heterocycle radicals are fused with
a saturated, partially unsaturated ring, or aromatic carbocyclic or heterocyclic ring. Examples of
heterocyclic rings include, but are not limited to, pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl,
tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidinyl,
morpholinyl, thiomorpholinyl, thioxanyl, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl,
thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 2-
pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl,
pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl,
pyrazolidinylimidazolinyl, imidazolidinyl, 3-azabicyco[3.1.0]hexanyl, 3-
azabicyclo[4.1.0]heptanyl, and azabicyclo[2.2.2]hexanyl. Spiro moieties are also included
within the scope of this definition. Examples of a heterocyclic group wherein ring atoms are
substituted with oxo (=O) moieties are pyrimidinonyl and 1,1-dioxo-thiomorpholinyl.
The term "heteroaryl" refers to a monovalent aromatic radical of 5- or 6-membered
rings, and includes fused ring systems (at least one of which is aromatic) of 5-18 atoms,
containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur.
Examples of heteroaryl groups are pyridinyl (including, for example, 2-hydroxypyridinyl),
imidazolyl, imidazopyridinyl, pyrimidinyl (including, for example, 4-hydroxypyrimidinyl),
pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl,
isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl,
cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl,
purinyl, oxadiazolyl, triazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl,
benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl.
The heterocycle or heteroaryl groups may be carbon (carbon-linked) or nitrogen
(nitrogen-linked) attached where such is possible. By way of example and not limitation, carbon
bonded heterocycles or heteroaryls are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position
3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a
pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or
tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of
an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an
azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an
isoquinoline.
By way of example and not limitation, nitrogen bonded heterocycles or heteroaryls are
bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline,
imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-
pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 2 of a isoindole, or
isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or β-carboline.
The heteroatoms present in heteroaryl or heterocyclcyl include the oxidized forms such
as N →O , S(O) and S(O) .
The term “halo” refers to F, Cl, Br or I.
The phrase "pharmaceutically acceptable salt" as used herein, refers to
pharmaceutically acceptable organic or inorganic salts of a compound as described. Exemplary
salts include, but are not limited, to sulfate, citrate, acetate, oxalate, chloride, bromide, iodide,
nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate,
tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate,
fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate
“mesylate”, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, pamoate (i.e., 1,1'-
methylene-bis -(2-hydroxynaphthoate)) salts, alkali metal (e.g., sodium and potassium) salts,
alkaline earth metal (e.g., magnesium) salts, and ammonium salts. A pharmaceutically
acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate
ion or other counter ion. The counter ion may be any organic or inorganic moiety that stabilizes
the charge on the parent compound. Furthermore, a pharmaceutically acceptable salt may have
more than one charged atom in its structure. Instances where multiple charged atoms are part of
the pharmaceutically acceptable salt can have multiple counter ions. Hence, a pharmaceutically
acceptable salt can have one or more charged atoms and/or one or more counter ion.
If the compound is a base, the desired pharmaceutically acceptable salt may be
prepared by any suitable method available in the art, for example, treatment of the free base with
an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,
methanesulfonic acid, phosphoric acid and the like, or with an organic acid, such as acetic acid,
maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid,
glycolic acid, salicylic acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an
alpha hydroxy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or
glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as
p-toluenesulfonic acid or ethanesulfonic acid, or the like.
If the compound is an acid, the desired pharmaceutically acceptable salt may be
prepared by any suitable method, for example, treatment of the free acid with an inorganic or
organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide or
alkaline earth metal hydroxide, or the like. Illustrative examples of suitable salts include, but are
not limited to, organic salts derived from amino acids, such as glycine and arginine, ammonia,
primary, secondary, and tertiary amines, and cyclic amines, such as piperidine, morpholine and
piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium,
manganese, iron, copper, zinc, aluminum and lithium.
The phrase "pharmaceutically acceptable" indicates that the substance or composition
must be compatible chemically and/or toxicologically, with the other ingredients comprising a
formulation, and/or the mammal being treated therewith.
A "solvate" refers to an association or complex of one or more solvent molecules and a
compound as described. Examples of solvents that form solvates include, but are not limited to,
water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine. The
term "hydrate" refers to the complex where the solvent molecule is water.
It is understood that aspects and variations of the invention described herein include
“consisting of” and/or “consisting essentially of” aspects and variations.
III Methods
In one embodiment, described herein is a method for treating or delaying progression
of cancer in an individual comprising administering to the individual an effective amount of a
PD-1 axis binding antagonist and a MEK inhibitor. In some embodiments, the treatment results
in sustained response in the individual after cessation of the treatment.
The methods described may find use in treating conditions where enhanced
immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
A variety of cancers may be treated, or their progression may be delayed, including but are not
limited to a cancer that may contain a BRAF V600E mutation, a cancer that may contain a
BRAF wildtype, a cancer that may contain a KRAS wildtype, or a cancer that may contain an
activating KRAS mutation.
In some embodiments, the individual has melanoma. The melanoma may be at early
stage or at late stage. In some embodiments, the individual has colorectal cancer. The colorectal
cancer may be at early stage or at late stage. In some embodiments, the individual has non-small
cell lung cancer. The non-small cell lung cancer may be at early stage or at late stage. In some
emodiements, the individual has pancreatic cancer. The pancreatice cancer may be at early stage
or late state. In some embodiments, the individual has a hematological malignancy. The
hematological malignancy may be early stage or late stage. In some embodiments, the
individual has ovarian cancer. The ovarian cancer may be at early stage or at late stage. In some
embodiments, the individual has breast cancer. The breast cancer may be at early stage or at late
stage. In some embodiments, the individual has renal cell carcinoma. The renal cell carcinoma
may be at early stage or at late stage.
In some embodiments, the individual is a mammal, such as domesticated animals (e.g.,
cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as
monkeys), rabbits, and rodents (e.g., mice and rats). In some embodiments, the individual treated
is a human.
In another embodiment, described herein is a method of enhancing immune function in
an individual having cancer comprising administering an effective amount of a PD-1 axis
binding antagonist and a MEK inhibitor.
In some embodiments, the CD8 T cells in the individual have enhanced priming,
activation, proliferation and/or cytolytic activity relative to prior to the administration of the PD-
1 pathway antagonist and the MEK inhibitor. In some embodiments, the CD8 T cell priming is
characterized by elevated CD44 expression and/or enhanced cytolytic activity in CD8 T cells. In
some embodiments, the CD8 T cell activation is characterized by an elevated frequency of γ-
IFN CD8 T cells. In some embodiments, the CD8 T cell is an antigen-specific T-cell. In some
embodiments, the immune evasion by signaling through PD-L1 surface expression is inhibited.
In some embodiments, the cancer cells in the individual have elevated expression of
MHC class I antigen expression relative to prior to the administration of the PD-1 pathway
antagonist and the MEK inhibitor.
In some embodiments, the antigen presenting cells in the individual have enhanced
maturation and activation relative prior to the administration of the PD-1 pathway antagonist and
the MEK inhibitor. In some embodiments, wherein the antigen presenting cells are dendritic
cells. In some embodiments, the maturation of the antigen presenting cells is characterized by
increased frequency of CD83 dendritic cells. In some embodiments, the activation of the
antigen presenting cells is characterized by elevated expression of CD80 and CD86 on dendritic
cells.
In some embodiments, the serum levels of cytokine IL-10 and/or chemokine IL-8, a
human homolog of murine KC, in the individual are reduced relative prior to the administration
of the anti-PD-L1 antibody and the MEK inhibitor.
In some embodiments, the cancer has elevated levels of T-cell infiltration.
In some embodiments, the combination therapy comprises administration of a PD-1
axis binding antagonist and a MEK inhibitor. The PD-1 axis binding antagonist and the MEK
inhibitor may be administered in any suitable manner known in the art. For example, The PD-1
axis binding antagonist and the MEK inhibitor may be administered sequentially (at different
times) or concurrently (at the same time).
In some embodiments, the MEK inhibitor is administered continuously. In some
embodiments, the MEK inhibitor is administered intermittently. In some embodiments, the
MEK inhibitor is administered before administration of the PD-1 axis binding antagonist. In
some embodiments, the MEK inhibitor is administered simultaneously with administration of
the PD-1 axis binding antagonist. In some embodiments, the MEK inhibitor is administered
after administration of the PD-1 axis binding antagonist.
In some embodiments, described is a method for treating or delaying progression of
cancer in an individual comprising administering to the individual an effective amount of a PD-1
axis binding antagonist and a MEK inhibitor, further comprising administering an additional
therapy. The additional therapy may be radiation therapy, surgery (e.g., lumpectomy and a
mastectomy), chemotherapy, gene therapy, DNA therapy, viral therapy, RNA therapy,
immunotherapy, bone marrow transplantation, nanotherapy, monoclonal antibody therapy, or a
combination of the foregoing. The additional therapy may be in the form of adjuvant or
neoadjuvant therapy. In some embodiments, the additional therapy is the administration of small
molecule enzymatic inhibitor or anti-metastatic agent. In some embodiments, the additional
therapy is the administration of side-effect limiting agents (e.g., agents intended to lessen the
occurrence and/or severity of side effects of treatment, such as anti-nausea agents, etc.). In some
embodiments, the additional therapy is radiation therapy. In some embodiments, the additional
therapy is surgery. In some embodiments, the additional therapy is a combination of radiation
therapy and surgery. In some embodiments, the additional therapy is gamma irradiation. In
some embodiments, the additional therapy is therapy targeting PI3K/AKT/mTOR pathway,
HSP90 inhibitor, tubulin inhibitor, apoptosis inhibitor, and/or chemopreventative agent. The
additional therapy may be one or more of the chemotherapeutic agents described hereabove.
The PD-1 axis binding antagonist and the MEK inhibitor may be administered by the
same route of administration or by different routes of administration. In some embodiments, the
PD-1 axis binding antagonist is administered intravenously, intramuscularly, subcutaneously,
topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation,
intrathecally, intraventricularly, or intranasally. In some embodiments, the MEK inhibitor is
administered intravenously, intramuscularly, subcutaneously, topically, orally, transdermally,
intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly,
or intranasally. An effective amount of the PD-1 axis binding antagonist and the MEK inhibitor
may be administered for prevention or treatment of disease. The appropriate dosage of the PD-1
axis binding antagonist and/or the MEK inhibitor may be deterimined based on the type of
disease to be treated, the type of the PD-1 axis binding antagonist and the MEK inhibitor, the
severity and course of the disease, the clinical condition of the individual, the individual’s
clinical history and response to the treatment, and the discretion of the attending physician.
Any of the PD-1 axis binding antagonists and the MEK inhibitors known in the art or
described below may be used in the methods.
PD-1 axis binding antagonists
Described herein is a method for treating or delaying progression of cancer in an
individual comprising administering to the individual an effective amount of a PD-1 axis binding
antagonist and a MEK inhibitor. For example, a PD-1 axis binding antagonist includes a PD-1
binding antagonist, a PD-L1 binding antagonist and a PD-L2 binding antagonist. Alternative
names for “PD-1” include CD279 and SLEB2. Alternative names for “PD-L1” include B7-H1,
B7-4, CD274, and B7-H. Alternative names for “PD-L2” include B7-DC, Btdc, and CD273. In
some embodiments, PD-1, PD-L1, and PD-L2 are human PD-1, PD-L1 and PD-L2.
In some embodiments, the PD-1 binding antagonist is a molecule that inhibits the
binding of PD-1 to its ligand binding partners. In a specific embodiment the PD-1 ligand
binding partners are PD-L1 and/or PD-L2. In another embodiment, a PD-L1 binding antagonist
is a molecule that inhibits the binding of PD-L1 to its binding partners. In a specific
embodiment, PD-L1 binding partners are PD-1 and/or B7-1. In another embodiment, the PD-L2
binding antagonist is a molecule that inhibits the binding of PD-L2 to its binding partners. In a
specific embodiment, a PD-L2 binding partner is PD-1. The antagonist may be an antibody, an
antigen binding fragment thereof, an immunoadhesin, a fusion protein, or oligopeptide.
In some embodiment, the PD-1 binding antagonist is an anti-PD-1 antibody (e.g., a
human antibody, a humanized antibody, or a chimeric antibody). In some embodiments, the
anti-PD-1 antibody is selected from the group consisting of MDX-1106, Merck 3475 and CT-
011. In some embodiments, the PD-1 binding antagonist is an immunoadhesin (e.g., an
immunoadhesin comprising an extracellular or PD-1 binding portion of PD-L1 or PD-L2 fused
to a constant region (e.g., an Fc region of an immunoglobulin sequence). In some embodiments,
the PD-1 binding antagonist is AMP-224. In some embodiments, the PD-L1 binding antagonist
is anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 binding antagonist is selected
from the group consisting of YW243.55.S70, MPDL3280A and MDX-1105. MDX-1105, also
known as BMS-936559, is an anti-PD-L1 antibody described in WO2007/005874. Antibody
YW243.55.S70 (heavy and light chain variable region sequences shown in SEQ ID Nos. 20 and
21, respectively) is an anti-PD-L1 described in A1. MDX-1106, also known
as MDX04, ONO-4538 or BMS-936558, is an anti-PD-1 antibody described in
WO2006/121168. Merck 3745, also known as MK-3475 or SCH-900475, is an anti-PD-1
antibody described in WO2009/114335. CT-011, also known as hBAT or hBAT-1, is an anti-
PD-1 antibody described in WO2009/101611. AMP-224, also known as B7-DCIg, is a PD-L2-
Fc fusion soluble receptor described in WO2010/027827 and WO2011/066342.
In some embodiments, the anti-PD-1 antibody is MDX-1106. Alternative names for
“MDX-1106” include MDX04, ONO-4538, BMS-936558 or Nivolumab. In some
embodiments, the anti-PD-1 antibody is Nivolumab (CAS Registry Number: 9464144). In a
still further embodiment, described is an isolated anti-PD-1 antibody comprising a heavy chain
variable region comprising the heavy chain variable region amino acid sequence from SEQ ID
NO:22 and/or a light chain variable region comprising the light chain variable region amino acid
sequence from SEQ ID NO:23. In a still further embodiment, described is an isolated anti-PD-1
antibody comprising a heavy chain and/or a light chain sequence, wherein:
(a) the heavy chain sequence has at least 85%, at least 90%, at least 91%, at least
92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least
99% or 100% sequence identity to the heavy chain sequence:
QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWY
DGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVT
VSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQF
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQ
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDK
SRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO:22), or
(b) the light chain sequences has at least 85%, at least 90%, at least 91%, at least
92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least
99% or 100% sequence identity to the light chain sequence:
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRAT
GIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFI
FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL
SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:23).
Examples of anti-PD-L1 antibodies useful for the methods described, and methods for
making thereof are described in PCT patent application A1, which is
incorporated herein by reference.
In some embodiments, the PD-1 axis binding antagonist is an anti-PD-L1 antibody. In
some embodiments, the anti-PD-L1 antibody is capable of inhibiting binding between PD-L1
and PD-1 and/or between PD-L1 and B7-1. In some embodiments, the anti-PD-L1 antibody is a
monoclonal antibody. In some embodiments, the anti-PD-L1 antibody is an antibody fragment
selected from the group consisting of Fab, Fab’-SH, Fv, scFv, and (Fab’) fragments. In some
embodiments, the anti-PD-L1 antibody is a humanized antibody. In some embodiments, the
anti-PD-L1 antibody is a human antibody.
The anti-PD-L1 antibodies useful in this invention, including compositions containing
such antibodies, such as those described in A1, may be used in combination
with a MEK inhibitor to treat cancer. In some embodiments, the anti-PD-L1 antibody comprises
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:20 and a light
chain variable region comprising the amino acid sequence of SEQ ID NO:21.
In one embodiment, the anti-PD-L1 antibody contains a heavy chain variable region
polypeptide comprising an HVR-H1, HVR-H2 and HVR-H3 sequence, wherein:
(a) the HVR-H1 sequence is GFTFSX SWIH (SEQ ID NO:1);
(b) the HVR-H2 sequence is AWIX2PYGGSX3YYADSVKG (SEQ ID NO:2);
(c) the HVR-H3 sequence is RHWPGGFDY (SEQ ID NO:3);
further wherein: X is D or G; X is S or L; X is T or S.
1 2 3
In one specific embodiment, X is D; X is S and X is T. In another embodiment, the
1 2 3
polypeptide further comprises variable region heavy chain framework sequences juxtaposed
between the HVRs according to the formula: (HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-
FR3)-(HVR-H3)-(HC-FR4). In yet another embodiment, the framework sequences are derived
from human consensus framework sequences. In a further embodiment, the framework
sequences are VH subgroup III consensus framework. In a still further embodiment, at least one
of the framework sequences is the following:
HC-FR1 is EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO:4)
HC-FR2 is WVRQAPGKGLEWV (SEQ ID NO:5)
HC-FR3 is RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR (SEQ ID NO:6)
HC-FR4 is WGQGTLVTVSA (SEQ ID NO:7).
In a still further embodiment, the heavy chain polypeptide is further combined with a
variable region light chain comprising an HVR-L1, HVR-L2 and HVR-L3, wherein:
(a) the HVR-L1 sequence is RASQX X X TX XA (SEQ ID NO:8);
4 5 6 7 8
(b) the HVR-L2 sequence is SASX LXS, (SEQ ID NO:9);
9 10
(c) the HVR-L3 sequence is QQX X X X PXT (SEQ ID NO:10);
11 12 13 14 15
further wherein: X is D or V; X is V or I; X is S or N; X is A or F; X is V or L; X is
4 5 6 7 8 9
F or T; X is Y or A; X is Y, G, F, or S; X is L, Y, F or W; X is Y, N, A, T, G, F or
11 12 13
I; X is H, V, P, T or I; X is A, W, R, P or T.
14 15
In a still further embodiment, X is D; X is V; X is S; X is A; X is V; X is F; X is
4 5 6 7 8 9 10
Y; X is Y; X is L; X is Y; X is H; X is A. In a still further embodiment, the light chain
11 12 13 14 15
further comprises variable region light chain framework sequences juxtaposed between the
HVRs according to the formula: (LC-FR1)-(HVR-L1)-(LC-FR2)-(HVR-L2)-(LC-FR3)-(HVR-
L3)-(LC-FR4). In a still further embodiment, the framework sequences are derived from human
consensus framework sequences. In a still further embodiment, the framework sequences are
VL kappa I consensus framework. In a still further embodiment, at least one of the framework
sequence is the following:
LC-FR1 is DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO:11)
LC-FR2 is WYQQKPGKAPKLLIY (SEQ ID NO:12)
LC-FR3 is GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO:13)
LC-FR4 is FGQGTKVEIKR (SEQ ID NO:14).
In another embodiment, described is an isolated anti-PD-L1 antibody or antigen
binding fragment comprising a heavy chain and a light chain variable region sequence, wherein:
(a) the heavy chain comprises and HVR-H1, HVR-H2 and HVR-H3, wherein further:
(i) the HVR-H1 sequence is GFTFSX SWIH; (SEQ ID NO:1)
(ii) the HVR-H2 sequence is AWIX PYGGSX YYADSVKG (SEQ ID NO:2)
(iii) the HVR-H3 sequence is RHWPGGFDY, and (SEQ ID NO:3)
(b) the light chain comprises and HVR-L1, HVR-L2 and HVR-L3, wherein further:
(i) the HVR-L1 sequence is RASQX4X5X6TX7X8A (SEQ ID NO:8)
(ii) the HVR-L2 sequence is SASX LX S; and (SEQ ID NO:9)
9 10
(iii) the HVR-L3 sequence is QQX X X X PX T; (SEQ ID NO:10)
11 12 13 14 15
Further wherein: X is D or G; X is S or L; X is T or S; X is D or V; X is V or I; X is
1 2 3 4 5 6
S or N; X is A or F; X is V or L; X is F or T; X is Y or A; X is Y, G, F, or S; X is
7 8 9 10 11 12
L, Y, F or W; X is Y, N, A, T, G, F or I; X is H, V, P, T or I; X is A, W, R, P or T.
13 14 15
In a specific embodiment, X is D; X is S and X is T. In another embodiment, X is
1 2 3 4
D; X is V; X is S; X is A; X is V; X is F; X is Y; X is Y; X is L; X is Y; X is H; X is
6 7 8 9 10 11 12 13 14 15
A. In yet another embodiment, X is D; X is S and X is T, X is D; X is V; X is S; X is A; X
1 2 3 4 5 6 7 8
is V; X is F; X is Y; X is Y; X is L; X is Y; X is H and X is A.
9 10 11 12 13 14 15
In a further embodiment, the heavy chain variable region comprises one or more
framework sequences juxtaposed between the HVRs as: (HC-FR1)-(HVR-H1)-(HC-FR2)-
(HVR-H2)-(HC-FR3)-(HVR-H3)-(HC-FR4), and the light chain variable regions comprises one
or more framework sequences juxtaposed between the HVRs as: (LC-FR1)-(HVR-L1)-(LC-
FR2)-(HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4). In a still further embodiment, the framework
sequences are derived from human consensus framework sequences. In a still further
embodiment, the heavy chain framework sequences are derived from a Kabat subgroup I, II, or
III sequence. In a still further embodiment, the heavy chain framework sequence is a VH
subgroup III consensus framework. In a still further embodiment, one or more of the heavy
chain framework sequences is the following:
HC-FR1 EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO:4)
HC-FR2 WVRQAPGKGLEWV (SEQ ID NO:5)
HC-FR3 RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR (SEQ ID NO:6)
HC-FR4 WGQGTLVTVSA (SEQ ID NO:7).
In a still further embodiment, the light chain framework sequences are derived from a
Kabat kappa I, II, II or IV subgroup sequence. In a still further embodiment, the light chain
framework sequences are VL kappa I consensus framework. In a still further embodiment, one
or more of the light chain framework sequences is the following:
LC-FR1 DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO:11)
LC-FR2 WYQQKPGKAPKLLIY (SEQ ID NO:12)
LC-FR3 GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO:13)
LC-FR4 FGQGTKVEIKR (SEQ ID NO:14).
In a still further specific embodiment, the antibody further comprises a human or
murine constant region. In a still further embodiment, the human constant region is selected
from the group consisting of IgG1, IgG2, IgG2, IgG3, IgG4. In a still further specific
embodiment, the human constant region is IgG1. In a still further embodiment, the murine
constant region is selected from the group consisting of IgG1, IgG2A, IgG2B, IgG3. In a still
further embodiment, the murine constant region if IgG2A. In a still further specific
embodiment, the antibody has reduced or minimal effector function. In a still further specific
embodiment the minimal effector function results from an “effector-less Fc mutation” or
aglycosylation. In still a further embodiment, the effector-less Fc mutation is an N297A or
D265A/N297A substitution in the constant region.
In yet another embodiment, described is an anti-PD-L1 antibody comprising a heavy
chain and a light chain variable region sequence, wherein:
(a) the heavy chain further comprises and HVR-H1, HVR-H2 and an HVR-H3
sequence having at least 85% sequence identity to GFTFSDSWIH (SEQ ID
NO:15), AWISPYGGSTYYADSVKG (SEQ ID NO:16) and RHWPGGFDY
(SEQ ID NO:3), respectively, or
(b) the light chain further comprises an HVR-L1, HVR-L2 and an HVR-L3 sequence
having at least 85% sequence identity to RASQDVSTAVA (SEQ ID NO:17),
SASFLYS (SEQ ID NO:18) and QQYLYHPAT (SEQ ID NO:19), respectively.
In a specific embodiment, the sequence identity is 86%, 87%, 88%, 89%, 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. In another embodiment, the heavy chain
variable region comprises one or more framework sequences juxtaposed between the HVRs as:
(HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-FR3)-(HVR-H3)-(HC-FR4), and the light
chain variable regions comprises one or more framework sequences juxtaposed between the
HVRs as: (LC-FR1)-(HVR-L1)-(LC-FR2)-(HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4). In yet
another embodiment, the framework sequences are derived from human consensus framework
sequences. In a still further embodiment, the heavy chain framework sequences are derived
from a Kabat subgroup I, II, or III sequence. In a still further embodiment, the heavy chain
framework sequence is a VH subgroup III consensus framework. In a still further embodiment,
one or more of the heavy chain framework sequences is the following:
HC-FR1 EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO:4)
HC-FR2 WVRQAPGKGLEWV (SEQ ID NO:5)
HC-FR3 RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR (SEQ ID NO:6)
HC-FR4 WGQGTLVTVSA (SEQ ID NO:7).
In a still further embodiment, the light chain framework sequences are derived from a
Kabat kappa I, II, II or IV subgroup sequence. In a still further embodiment, the light chain
framework sequences are VL kappa I consensus framework. In a still further embodiment, one
or more of the light chain framework sequences is the following:
LC-FR1 DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO:11)
LC-FR2 WYQQKPGKAPKLLIY (SEQ ID NO:12)
LC-FR3 GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO:13)
LC-FR4 FGQGTKVEIKR (SEQ ID NO:14).
In a still further specific asp embodiment ect, the antibody further comprises a human
or murine constant region. In a still further embodiment, the human constant region is selected
from the group consisting of IgG1, IgG2, IgG2, IgG3, IgG4. In a still further specific
embodiment, the human constant region is IgG1. In a still further embodiment, the murine
constant region is selected from the group consisting of IgG1, IgG2A, IgG2B, IgG3. In a still
further embodiment, the murine constant region if IgG2A. In a still further specific
embodiment, the antibody has reduced or minimal effector function. In a still further specific
embodimentthe minimal effector function results from an “effector-less Fc mutation” or
aglycosylation. In still a further embodiment, the effector-less Fc mutation is an N297A or
D265A/N297A substitution in the constant region.
In a still further embodiment, described is an isolated anti-PD-L1 antibody comprising
a heavy chain and a light chain variable region sequence, wherein:
(a) the heavy chain sequence has at least 85% sequence identity to the heavy chain
sequence: EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWIS
PYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWG
QGTLVTVSA (SEQ ID NO:20), or
(b) the light chain sequences has at least 85% sequence identity to the light chain
sequence: DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIY SASF
LYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKR (SEQ
ID NO:21).
In a specific embodiment, the sequence identity is 86%, 87%, 88%, 89%, 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. In another embodiment, the heavy chain
variable region comprises one or more framework sequences juxtaposed between the HVRs as:
(HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-FR3)-(HVR-H3)-(HC-FR4), and the light
chain variable regions comprises one or more framework sequences juxtaposed between the
HVRs as: (LC-FR1)-(HVR-L1)-(LC-FR2)-(HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4). In yet
another embodiment, the framework sequences are derived from human consensus framework
sequences. In a further embodiment, the heavy chain framework sequences are derived from a
Kabat subgroup I, II, or III sequence. In a still further embodiment, the heavy chain framework
sequence is a VH subgroup III consensus framework. In a still further embodiment, one or more
of the heavy chain framework sequences is the following:
HC-FR1 EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO:4)
HC-FR2 WVRQAPGKGLEWV (SEQ ID NO:5)
HC-FR3 RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR (SEQ ID NO:6)
HC-FR4 WGQGTLVTVSA (SEQ ID NO:7).
In a still further embodiment, the light chain framework sequences are derived from a
Kabat kappa I, II, II or IV subgroup sequence. In a still further embodiment, the light chain
framework sequences are VL kappa I consensus framework. In a still further embodiment, one
or more of the light chain framework sequences is the following:
LC-FR1 DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO:11)
LC-FR2 WYQQKPGKAPKLLIY (SEQ ID NO:12)
LC-FR3 GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO:13)
LC-FR4 FGQGTKVEIKR (SEQ ID NO:14).
In a still further specific embodiment, the antibody further comprises a human or
murine constant region. In a still further embodiment, the human constant region is selected
from the group consisting of IgG1, IgG2, IgG2, IgG3, IgG4. In a still further specific
embodiment, the human constant region is IgG1. In a still further embodiment, the murine
constant region is selected from the group consisting of IgG1, IgG2A, IgG2B, IgG3. In a still
further embodiment, the murine constant region if IgG2A. In a still further specific
embodiment, the antibody has reduced or minimal effector function. In a still further specific
embodiment, the minimal effector function results from production in prokaryotic cells. In a
still further specific embodiment the minimal effector function results from an “effector-less Fc
mutation” or aglycosylation. In still a further embodiment, the effector-less Fc mutation is an
N297A or D265A/N297A substitution in the constant region.
In another further embodiment, described is an isolated anti-PD-L1 antibody
comprising a heavy chain and a light chain variable region sequence, wherein:
(a) the heavy chain sequence has at least 85% sequence identity to the heavy chain
sequence:EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWIS
PYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWG
QGTLVTVSS (SEQ ID NO:24), or
(b) the light chain sequences has at least 85% sequence identity to the light chain
sequence: DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIY SASF
LYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKR (SEQ
ID NO:21).
In a specific embodiment, the sequence identity is 86%, 87%, 88%, 89%, 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. In another embodiment, the heavy chain
variable region comprises one or more framework sequences juxtaposed between the HVRs as:
(HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-FR3)-(HVR-H3)-(HC-FR4), and the light
chain variable regions comprises one or more framework sequences juxtaposed between the
HVRs as: (LC-FR1)-(HVR-L1)-(LC-FR2)-(HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4). In yet
another embodiment, the framework sequences are derived from human consensus framework
sequences. In a further embodiment, the heavy chain framework sequences are derived from a
Kabat subgroup I, II, or III sequence. In a still further embodiment, the heavy chain framework
sequence is a VH subgroup III consensus framework. In a still further embodiment, one or more
of the heavy chain framework sequences is the following:
HC-FR1 EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO:4)
HC-FR2 WVRQAPGKGLEWV (SEQ ID NO:5)
HC-FR3 RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR (SEQ ID NO:6)
HC-FR4 WGQGTLVTVSS (SEQ ID NO:25).
In a still further embodiment, the light chain framework sequences are derived from a
Kabat kappa I, II, II or IV subgroup sequence. In a still further embodiment, the light chain
framework sequences are VL kappa I consensus framework. In a still further embodiment, one
or more of the light chain framework sequences is the following:
LC-FR1 DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO:11)
LC-FR2 WYQQKPGKAPKLLIY (SEQ ID NO:12)
LC-FR3 GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO:13)
LC-FR4 FGQGTKVEIKR (SEQ ID NO:14).
In a still further specific embodiment, the antibody further comprises a human or
murine constant region. In a still further embodiment, the human constant region is selected
from the group consisting of IgG1, IgG2, IgG2, IgG3, IgG4. In a still further specific
embodiment, the human constant region is IgG1. In a still further embodiment, the murine
constant region is selected from the group consisting of IgG1, IgG2A, IgG2B, IgG3. In a still
further embodiment, the murine constant region if IgG2A. In a still further specific
embodiment, the antibody has reduced or minimal effector function. In a still further specific
embodiment, the minimal effector function results from production in prokaryotic cells. In a
still further specific embodiment the minimal effector function results from an “effector-less Fc
mutation” or aglycosylation. In still a further embodiment, the effector-less Fc mutation is an
N297A or D265A/N297A substitution in the constant region.
In yet another embodiment, the anti-PD-1 antibody is MPDL3280A. In a still further
embodiment, described is an isolated anti-PD-1 antibody comprising a heavy chain variable
region comprising the heavy chain variable region amino acid sequence from SEQ ID NO:24
and/or a light chain variable region comprising the light chain variable region amino acid
sequence from SEQ ID NO:25. In a still further embodiment, described is an isolated anti-PD-1
antibody comprising a heavy chain and/or a light chain sequence, wherein:
(a) the heavy chain sequence has at least 85%, at least 90%, at least 91%, at least
92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least
99% or 100% sequence identity to the heavy chain sequence:
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGST
YYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVT
VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL
QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL
LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR
EEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT
LPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSK
LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:26), or
(b) the light chain sequences has at least 85%, at least 90%, at least 91%, at least
92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least
99% or 100% sequence identity to the light chain sequence:
DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRTVAAPSVFIFPPS
DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTL
TLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:27).
In a still further embodiment, described are compositions comprising any of the above
described anti-PD-L1 antibodies in combination with at least one pharmaceutically-acceptable
carrier.
In a still further embodiment, described is an isolated nucleic acid encoding a light
chain or a heavy chain variable region sequence of an anti-PD-L1 antibody, wherein:
(a) the heavy chain further comprises and HVR-H1, HVR-H2 and an HVR-H3
sequence having at least 85% sequence identity to GFTFSDSWIH (SEQ ID
NO:15), AWISPYGGSTYYADSVKG (SEQ ID NO:16) and RHWPGGFDY
(SEQ ID NO:3), respectively, and
(b) the light chain further comprises an HVR-L1, HVR-L2 and an HVR-L3 sequence
having at least 85% sequence identity to RASQDVSTAVA (SEQ ID NO:17),
SASFLYS (SEQ ID NO:18) and QQYLYHPAT (SEQ ID NO:19), respectively.
In a specific embodiment, the sequence identity is 86%, 87%, 88%, 89%, 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. In embodiment, the heavy chain
variable region comprises one or more framework sequences juxtaposed between the HVRs as:
(HC-FR1)-(HVR-H1)-(HC-FR2)-(HVR-H2)-(HC-FR3)-(HVR-H3)-(HC-FR4), and the light
chain variable regions comprises one or more framework sequences juxtaposed between the
HVRs as: (LC-FR1)-(HVR-L1)-(LC-FR2)-(HVR-L2)-(LC-FR3)-(HVR-L3)-(LC-FR4). In yet
another embodiment, the framework sequences are derived from human consensus framework
sequences. In a further embodiment, the heavy chain framework sequences are derived from a
Kabat subgroup I, II, or III sequence. In a still further embodiment, the heavy chain framework
sequence is a VH subgroup III consensus framework. In a still further embodiment, one or more
of the heavy chain framework sequences is the following:
HC-FR1 EVQLVESGGGLVQPGGSLRLSCAAS (SEQ ID NO:4)
HC-FR2 WVRQAPGKGLEWV (SEQ ID NO:5)
HC-FR3 RFTISADTSKNTAYLQMNSLRAEDTAVYYCAR (SEQ ID NO:6)
HC-FR4 WGQGTLVTVSA (SEQ ID NO:7).
In a still further embodiment, the light chain framework sequences are derived from a
Kabat kappa I, II, II or IV subgroup sequence. In a still further embodiment, the light chain
framework sequences are VL kappa I consensus framework. In a still further embodiment, one
or more of the light chain framework sequences is the following:
LC-FR1 DIQMTQSPSSLSASVGDRVTITC (SEQ ID NO:11)
LC-FR2 WYQQKPGKAPKLLIY (SEQ ID NO:12)
LC-FR3 GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC (SEQ ID NO:13)
LC-FR4 FGQGTKVEIKR (SEQ ID NO:14).
In a still further specific embodiment, the antibody described herein (such as an anti-
PD-1 antibody, an anti-PD-L1 antibody, or an anti-PD-L2 antibody) further comprises a human
or murine constant region. In a still further embodiment, the human constant region is selected
from the group consisting of IgG1, IgG2, IgG2, IgG3, IgG4. In a still further specific
embodiment, the human constant region is IgG1. In a still further embodiment, the murine
constant region is selected from the group consisting of IgG1, IgG2A, IgG2B, IgG3. In a still
further embodiment, the murine constant region if IgG2A. In a still further specific
embodiment, the antibody has reduced or minimal effector function. In a still further specific
embodiment, the minimal effector function results from production in prokaryotic cells. In a
still further specific embodiment the minimal effector function results from an “effector-less Fc
mutation” or aglycosylation. In still a further embodiment, the effector-less Fc mutation is an
N297A or D265A/N297A substitution in the constant region.
In a still further embodiment, described herein are nucleic acids encoding any of the
antibodies described herein. In some embodiments, the nucleic acid further comprises a vector
suitable for expression of the nucleic acid encoding any of the previously described anti-PD-L1,
anti-PD-1, or anti-PD-L2 antibodies. In a still further specific embodiment, the vector further
comprises a host cell suitable for expression of the nucleic acid. In a still further specific
embodiment, the host cell is a eukaryotic cell or a prokaryotic cell. In a still further specific
embodiment, the eukaryotic cell is a mammalian cell, such as Chinese Hamster Ovary (CHO).
The antibody or antigen binding fragment thereof, may be made using methods known
in the art, for example, by a process comprising culturing a host cell containing nucleic acid
encoding any of the previously described anti-PD-L1, anti-PD-1, or anti-PD-L2 antibodies or
antigen-binding fragment in a form suitable for expression, under conditions suitable to produce
such antibody or fragment, and recovering the antibody or fragment.
In a still further embodiment, described is a composition comprising an anti-PD-L1, an
anti-PD-1, or an anti-PD-L2 antibody or antigen binding fragment thereof as described herein
and at least one pharmaceutically acceptable carrier. In some embodiments, the anti-PD-L1,
anti-PD-1, or anti-PD-L2 antibody or antigen binding fragment thereof administered to the
individual is a composition comprising one or more pharmaceutically acceptable carrier. Any of
the pharmaceutically acceptable carrier described herein or known in the art may be used.
MEK inhibitors
Also described are methods for treating cancer or slowing progression of cancer in an
individual comprising administering an effective amount of a PD-1 pathway antagonist and a
MEK inhibitor. Any known MEK inhibitors are intended, such as the MEK inhibitor
compounds described in PCT patent applications WO 03/077914 A1, A1, WO
2007/044515 A1, A1 and A1, the content of which are
incorporated herein by reference. The MEK inhibitor administered may be in a pharmaceutical
composition or formulation. In some embodiments, the pharmaceutical composition or
formulation comprises one or more MEK inhibitors described herein and a pharmaceutically
acceptable carrier or excipient.
In some embodiments, the MEK inhibitor is a competitive inhibitor of MEK. In some
embodiments, the MEK inhibitor is more selective against an activating KRAS mutation. In
some embodiments, the MEK inhibitor is an allosteric inhibitor of MEK. In some embodiments,
the MEK inhibitor is more selective against an activating BRAF mutation (e.g., BRAF V600E
mutation). In some embodiments, the MEK inhibitor binds and inhibits the activity of MEK1
and/or MEK2 (such as human MEK1 and/or human MEK2).
In some embodiments, the MEK inhibitor is a compound selected from the group
consisting of GDC-0973, G-38963, G02443714 (also known as “AS703206”), G02442104 (also
known as “GSK-1120212”), and G00039805 (also known as “AZD-6244”), or a
pharmaceutically acceptable salt or solvate thereof.
In some embodiments, the MEK inhibitor is a compound of formula (I),
1 2 3 4 5 6
or a pharmaceutically acceptable salt or solvate thereof, wherein A, X, R , R , R , R , R , R ,
and R are as defined in Group A, Group B, Group C, or Group D:
Group A:
12 14
A is arylene optionally substituted with one, two, three or four groups selected from R , R , R ,
16 19 10 12 14 16
R , and R where R , R , R and R are independently hydrogen, alkyl, alkenyl,
alkynyl, halo, haloalkoxy, hydroxy, alkoxy, amino, alkylamino, dialkylamino, haloalkyl,
8 8 8 8 8’ 8 8’ 19
-NHS(O) R , -CN, -C(O)R , -C(O)OR , -C(O)NR R and -NR C(O)R and where R is
hydrogen, alkyl, or alkenyl;
X is alkyl, halo, haloalkyl, or haloalkoxy;
1 2 3 4 5 6 8 8’ 8 8
R , R , R , R , R and R are independently hydrogen, halo, nitro, -NR R , -OR , -NHS(O) R ,
8 8 8’ 8 8 8 8’ 8 8’
-CN, -S(O) R , -S(O) NR R , -C(O)R , -C(O)OR , -C(O)NR R , -NR C(O)OR ,
8 8’ 8” 8 8’ 8 8’ 25 25a 25b
-NR C(O)NR R , -NR C(O)OR , -NR C(O)R , -CH N(R )(NR R ),
25a 25b 25 25a
-CH NR C(=NH)(NR R ), -CH NR C(=NH)(N(R )(NO )),
2 2 2
25a 25 25
-CH2NR C(=NH)(N(R )(CN)), -CH2NR C(=NH)(R ),
25a 25b
-CH NR C(NR R )=CH(NO ), alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, or
heterocycloalkyl; where the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, and
heterocycloalkyl are independently optionally substituted with one, two, three, four, five,
six or seven groups independently selected from halo, alkyl, haloalkyl, nitro, optionally
substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl,
optionally substituted arylalkyl, optionally substituted heteroaryl, -OR ,
8 8’ 8 9 9 8 8
-NR R , -NR S(O) R , -CN, -S(O) R , -C(O)R , -C(O)OR ,
8 8’ 8 8’ 8” 8 8’ 8 8’ 1 2
-C(O)NR R , -NR C(O)NR R , -NR C(O)OR and -NR C(O)R ; or one of R and R
together with the carbon to which they are attached, R and R together with the carbon
to which they are attached, and R and R together with the carbon to which they are
attached form C(O) or C(=NOH);
m is 0, 1, or 2;
R is hydrogen, halo or alkyl;
8 8’ 8”
each R , R and R is independently selected from hydrogen, hydroxy, optionally substituted
alkoxy, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl; where
the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are
independently optionally substituted with one, two three, four, or five groups
independently selected from alkyl, halo, hydroxy, hydroxyalkyl, optionally substituted
alkoxy, alkoxyalkyl, haloalkyl, carboxy, alkoxycarbonyl, alkenyloxycarbonyl, optionally
substituted cycloalkyl, optionally substituted cycloalkyloxycarbonyl, optionally
substituted aryl, optionally substituted aryloxy, optionally substituted aryloxycarbonyl,
optionally substituted arylalkyl, optionally substituted arylalkyloxy, optionally
substituted arylalkyloxycarbonyl, nitro, cyano, optionally substituted heterocycloalkyl,
31 31
optionally substituted heteroaryl, -S(O)R (where n is 0, 1, or 2 and R is optionally
substituted alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, or
34 34a 34 34a
optionally substituted heteroaryl), -NR SO R (where R is hydrogen or alkyl and R
35a
is alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl), -SO NR R (where
35a
R is hydrogen or alkyl and R is alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, or
32 32a 32 32a
heterocycloalkyl), -NR C(O)R (where R is hydrogen or alkyl and R is alkyl,
30’ 30 30’
alkenyl, alkoxy, or cycloalkyl), -NR R (where R and R are independently
33 33a 33
hydrogen, alkyl, or hydroxyalkyl), and -C(O)NR R (where R is hydrogen or alkyl
and R is alkyl, alkenyl, alkynyl, or cycloalkyl); and
each R is independently selected from alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and
heterocycloalkyl; where the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and
heterocycloalkyl are independently optionally susbstituted with one, two, three, four, or
five groups selected from halo, hydroxy, alkyl, haloalkyl, haloalkoxy, amino, alkylamino,
and dialkylamino;
Group B:
A is heteroarylene optionally substituted with one, two, three, or four groups selected from R ,
12 14 16 19 10 12 14 16
R , R , R and R where R , R , R and R are independently hydrogen, alkyl,
alkenyl, alkynyl, halo, haloalkoxy, hydroxy, alkoxy, cyano, amino, alkylamino,
dialkylamino, haloalkyl, alkylsulfonylamino, alkylcarbonyl, alkenylcarbonyl,
alkoxycarbonyl, alkenyloxycarbonyl, aminocarbonyl, alkylaminocarbonyl,
dialkylaminocarbonyl, or alkylcarbonylamino; where R is hydrogen, alkyl, or alkenyl;
12
and where each alkyl and alkenyl, either alone or as part of another group within R , R ,
14 16 19
R , R , and R , is independently optionally substituted with halo, hydroxy, or alkoxy;
X is alkyl, halo, haloalkyl, or haloalkoxy;
1 2 3 4 3 6 8 8’ 8 8
R , R , R , R , R and R are independently hydrogen, halo, nitro, -NR R , -OR , -NHS(O) R ,
8 8 8’ 8 8 8 8’ 8 8’
-CN, -S(O) R , -S(O) NR R , -C(O)R , -C(O)OR , -C(O)NR R , -NR C(O)OR ,
8 8’ 8” 8 8’ 8 8’ 25 25a 25b
-NR C(O)NR R , -NR C(O)OR , -NR C(O)R , -CH N(R )(NR R ),
25a 25b 25 25a
-CH2NR C(=NH)(NR R ), -CH2NR C(=NH)(N(R )(NO2)),
25a 25 25
-CH NR C(NH)(N(R )(CN)), -CH NR C(=NH)(R ),
25a 25b
-CH NR C(NR R )=CH(NO ), alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, or
heterocycloalkyl, where the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, and
heterocycloalkyl are independently optionally substituted with one, two, three, four, five,
six or seven groups independently selected from halo, alkyl, haloalkyl, nitro, optionally
substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl,
optionally substituted arylalkyl, optionally substituted heteroaryl, -OR ,
8 8’ 8 9 9 8 8
-NR R , -NR S(O) R , -CN, -S(O) R , -C(O)R , -C(O)OR ,
8 8’ 8 8’ 8” 8 8’ 8 8’ 1 2
-C(O)NR R , -NR C(O)NR R , -NR C(O)OR and -NR C(O)R ; or one of R and R
together with the carbon to which they are attached, R and R together with the carbon
to which they are attached, and R and R together with the carbon to which they are
attached form C(O) or C(=NOH);
m is 1 or 2;
R is hydrogen, halo or alkyl; and
8 8’ 8”
each R , R and R is independently selected from hydrogen, hydroxy, optionally substituted
alkoxy, alkyl, haloalkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and
heterocycloalkyl, where the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and
heterocycloalkyl are independently optionally substituted with one, two three, four, or
five groups independently selected from alkyl, halo, hydroxy, hydroxyalkyl, optionally
substituted alkoxy, alkoxyalkyl, haloalkyl, carboxy, carboxy ester, nitro, cyano, -
31 31
S(O) R (where n is 0, 1, or 2 and R is optionally substituted alkyl, optionally
substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl,
36 36a 36
or optionally substituted heteroaryl), -NR S(O) R (where R is hydrogen, alkyl, or
alkenyl and R is alkyl, alkenyl, optionally substituted aryl, optionally substituted
cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted
37 37a 37 37a
heteroaryl), -S(O) NR R (where R is hydrogen, alkyl, or alkenyl and R is alkyl,
alkenyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally
substituted heterocycloalkyl, or optionally substituted heteroaryl), optionally substituted
cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally
substituted arylalkyl, optionally substituted aryloxy, optionally substituted arylalkyloxy,
32 32
optionally substituted heteroaryl, -NHC(O)R (where R is alkyl, alkenyl, alkoxy, or
30’ 30 30’
cycloalkyl) and -NR R (where R and R are independently hydrogen, alkyl, or
33 33
hydroxyalkyl), and -C(O)NHR (where R is alkyl, alkenyl, alkynyl, or cycloalkyl);
Group C:
A is
where R is hydrogen, alkyl, alkenyl, alkynyl, halo, haloalkoxy, hydroxy, alkoxy, amino,
8 8 8
alkylamino, dialkylamino, haloalkyl, -NHS(O) R , -CN, -C(O)R , -C(O)OR ,
8 8’ 8 8’
-C(O)NR R and -NR C(O)R ;
R is hydrogen, alkyl, or alkenyl;
Y is =CH- or =N-;
X is alkyl, halo, haloalkyl, or haloalkoxy;
1 2 3 4 5 6 8 8’ 8 8
R , R , R , R , R and R are independently hydrogen, halo, nitro, -NR R , -OR , -NHS(O) R ,
8 8 8’ 8 8 8 8’ 8 8’
-CN, -S(O) R , -S(O) NR R , -C(O)R , -C(O)OR , -C(O)NR R , -NR C(O)OR ,
8 8’ 8” 8 8’ 8 8’ 25 25a 25b
-NR C(O)NR R , -NR C(O)OR , -NR C(O)R , -CH N(R )NR R ),
25a 25b 25 25a
-CH NR C(=NH)(NR R ), -CH NR C(=NH)(N(R )(NO )),
2 2 2
25a 25 25
-CH NR C(=NH)(N(R )(CN)), -CH NR C(=NH)(R ),
25a 25b
-CH NR C(NR R )=CH(NO ), alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, or
heterocycloalkyl, where the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, and
heterocycloalkyl are independently optionally substituted with one, two, three, four, five,
six or seven groups independently selected from halo, alkyl, haloalkyl, nitro, optionally
substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl,
8 8 8’
optionally substituted arylalkyl, optionally substituted heteroaryl, -OR , -NR R ,
8 9 9 8 8 8 8’ 8 8’ 8”
-NR S(O) R , -CN, -S(O) R , -C(O)R , -C(O)OR , -C(O)NR R , -NR C(O)NR R ,
8 8’ 8 8’ 1 2
-NR C(O)OR and -NR C(O)R ; or one of R and R together with the carbon to which
3 4 5
they are attached, R and R together with the carbon to which they are attached, and R
and R together with the carbon to which they are attached form C(O) or C(NOH);
m is 1 or 2;
R is hydrogen, halo or alkyl; and
8 8’ 8”
each R , R and R is independently selected from hydrogen, hydroxy, optionally substituted
alkoxy, alkyl, haloalkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and
heterocycloalkyl, where the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and
heterocycloalkyl are independently optionally substituted with one, two three, four, or
five groups independently selected from alkyl, halo, hydroxy, hydroxyalkyl, optionally
substituted alkoxy, alkoxyalkyl, haloalkyl, carboxy, carboxy ester, nitro, cyano, -
31 31
S(O) R (where n is 0, 1, or 2 and R is optionally substituted alkyl, optionally
substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl,
36 36a 36
or optionally substituted heteroaryl), -NR S(O) R (where R is hydrogen, alkyl, or
alkenyl and R is alkyl, alkenyl, optionally substituted aryl, optionally substituted
cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted
37 37a 37 37a
heteroaryl), -S(O)2NR R (where R is hydrogen, alkyl, or alkenyl and R is alkyl,
alkenyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally
substituted heterocycloalkyl, or optionally substituted heteroaryl), optionally substituted
cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally
substituted arylalkyl, optionally substituted aryloxy, optionally substituted arylalkyloxy,
32 32
optionally substituted heteroaryl, -NHC(O)R (where R is alkyl, alkenyl, alkoxy, or
30’ 30 30’
cycloalkyl) and -NR R (where R and R are independently hydrogen, alkyl, or
33 33
hydroxyalkyl), and -C(O)NHR (where R is alkyl, alkenyl, alkynyl, or cycloalkyl); or
Group D:
A is
(b) or
40 40a
R and R are independently hydrogen or alkyl;
X is alkyl, halo, haloalkyl, or haloalkoxy;
1 2 3 4 5 6 8 8’ 8 8
R , R , R , R , R and R are independently hydrogen, halo, nitro, -NR R , -OR , -NHS(O) R ,
8 8 8’ 8 8 8 8’ 8 8’
-CN, -S(O) R , -S(O) NR R , -C(O)R , -C(O)OR , -C(O)NR R , -NR C(O)OR ,
8 8’ 8” 8 8’ 8 8’ 25 25a 25b
-NR C(O)NR R , -NR C(O)OR , -NR C(O)R , -CH N(R )(NR R ),
25a 25b 25 25a
-CH NR C(=NH)(NR R ), -CH NR C(=NH)(N(R )(NO )),
2 2 2
25a 25 25
-CH NR C(=NH)(N(R )(CN)), -CH NR C(=NH)(R ),
25a 25b
-CH NR C(NR R )=CH(NO ), alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, or
heterocycloalkyl, where the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, and
heterocycloalkyl are independently optionally substituted with one, two, three, four, five,
six or seven groups independently selected from halo, alkyl, haloalkyl, nitro, optionally
substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl,
optionally substituted arylalkyl, optionally substituted heteroaryl, -OR , -
8 8’ 8 9 9 8 8
NR R , -NR S(O) R , -CN, -S(O) R , -C(O)R , -C(O)OR , -
8 8’ 8 8’ 8” 8 8’ 8 8’ 1 2
C(O)NR R , -NR C(O)NR R , -NR C(O)OR and -NR C(O)R ; or one of R and R
together with the carbon to which they are attached, R and R together with the carbon
to which they are attached, and R and R together with the carbon to which they are
attached form C(O) or C(NOH);
m is 1 or 2;
R is hydrogen, halo or alkyl; and
8 8’ 8”
R , R and R are independently selected from hydrogen, hydroxy, optionally substituted
alkoxy, alkyl, haloalkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and
heterocycloalkyl, where the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and
heterocycloalkyl are independently optionally substituted with one, two three, four, or
five groups independently selected from alkyl, halo, hydroxy, hydroxyalkyl, optionally
substituted alkoxy, alkoxyalkyl, haloalkyl, carboxy, carboxy ester, nitro, cyano, -
31 31
S(O) R (where n is 0, 1, or 2 and R is optionally substituted alkyl, optionally
substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl,
36 36a 36
or optionally substituted heteroaryl), -NR S(O) R (where R is hydrogen, alkyl, or
alkenyl and R is alkyl, alkenyl, optionally substituted aryl, optionally substituted
cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted
37 37a 37 37a
heteroaryl), -S(O) NR R (where R is hydrogen, alkyl, or alkenyl and R is alkyl,
alkenyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally
substituted heterocycloalkyl, or optionally substituted heteroaryl), optionally substituted
cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally
substituted arylalkyl, optionally substituted aryloxy, optionally substituted arylalkyloxy,
32 32
optionally substituted heteroaryl, -NHC(O)R (where R is alkyl, alkenyl, alkoxy, or
30’ 30 30’
cycloalkyl) and -NR R (where R and R are independently hydrogen, alkyl, or
33 33
hydroxyalkyl), and -C(O)NHR (where R is alkyl, alkenyl, alkynyl, or cycloalkyl).
In some variations, the MEK inhibitor compound of the formula (I) is a compound of
the Group A, having the formula I(a) or I(b):
or a pharmaceutically acceptable salt or solvate thereof, wherein the variables are as defined for
the formula (I), Group A, or as defined in A1, incorporated herein by
reference.
In some variations, the MEK inhibitor compound of the formula (I) is a compound of
the Group B, having the formula I(c), I(d), I(e), I(f), I(g), I(h), I(i), I(j), I(k), I(m), I(n), I(o), I(p),
I(q), I(r), I(s), I(u), I(v), I(w), I(x), I(cc) or I(dd):
; ;
or ;
or a pharmaceutically acceptable salt or solvate thereof, wherein the variables are as defined for
the formula (I), Group B, or as defined in A1, incorporated herein by
reference.
In some variations, the MEK inhibitor compound of the formula (I) is a compound of
the Group C, having the formula I(y) or I(z):
or a pharmaceutically acceptable salt or solvate thereof, wherein the variables are as defined for
the formula (I), Group C, or as defined in A1, incorporated herein by
reference.
In some variations, the MEK inhibitor compound of the formula (I) is a compound of
the Group D, having the formula I(aa) or I(bb):
or a pharmaceutically acceptable salt or solvate thereof, wherein the variables are as defined for
the formula (I), Group D, or as defined in A1, incorporated herein by
reference.
In some embodiments, the MEK inhibitor compound of the formula (I) is a compound
selected from the compound Nos. 1-362 as listed in A1, Table 1 on pages 71-
144 (herein collectively referred to as the Formula I Species), or a pharmaceutically acceptable
salt or solvate thereof.
Also embraced are any variations of formula (I) as described in A1,
which is incorporated herein by reference. Compounds of the formula (I) or any variations
thereof can be synthesized using methods known in the art, for example, the synthetic methods
described in A1, incorporated herein by reference.
Unless defined otherwise herein, the terms used in describing compounds of the
formula (I) should be understood to have the same meaning as defined in A1.
In some embodiments, the MEK inhibitor is a compound of formula (II):
(II)
or a pharmaceutically acceptable salt or solvate thereof, wherein:
Z is CR or N;
Z is CR or N;
Z is CR or N;
Z is CR or N;
1 2 3 4
where one or two of Z , Z , Z , and Z are N;
1 2 3 4
R , R , R and R are independently selected from H, halo, CN, CF , -OCF , -NO ,
3 3 2
14 15 11 14 15 11 14 15 11 12
-(CR R ) C(=Y)R , -(CR R ) C(=Y)OR , -(CR R ) C(=Y)NR R ,
n n n
14 15 11 12 14 15 11 14 15 11 14 15 12 11
-(CR R ) NR R , -(CR R ) OR , -(CR R ) SR , -(CR R ) NR C(=Y)R ,
n n n n
14 15 12 11 14 15 13 11 12 14 15 12 11
-(CR R ) NR C(=Y)OR , -(CR R ) NR C(=Y)NR R , -(CR R ) NR SO R ,
n n n 2
14 15 11 14 15 11 14 15 11 12
-(CR R ) OC(=Y)R , -(CR R ) OC(=Y)OR , -(CR R ) OC(=Y)NR R ,
n n n
14 15 11 14 15 11 12 14 15 11 12
-(CR R ) OS(O) (OR ), -(CR R ) OP(=Y)(OR )(OR ), -(CR R ) OP(OR )(OR ),
n 2 n n
14 15 11 14 15 11 14 15 11 12 14 15 11
-(CR R ) S(O)R , -(CR R ) S(O) R , -(CR R ) S(O) NR R , -(CR R ) S(O)(OR ),
n n 2 n 2 n
14 15 11 14 15 11 14 15 11
-(CR R )nS(O)2(OR ), -(CR R )n SC(=Y)R , -(CR R )nSC(=Y)OR ,
14 15 11 12
-(CR R ) SC(=Y)NR R , C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl,
n 1 12 2 8 2 8
heterocyclyl, aryl, and heteroaryl;
1 11
W is or ;
R and R are independently selected from H or C -C alkyl;
1 12
1 11 11 11 12 11 11 1 11
X is selected from R , -OR , -NR R , -S(O)R , and -S(O) R ; when X is R or
11 11 11 1 5
-OR , R or -OR of X and -R are optionally taken together with the nitrogen atom to which
they are attached to form a 4-7 membered saturated or unsaturated ring having 0-2 additional
heteroatoms selected from O, S and N, wherein said ring is optionally substituted with one or
more groups selected from halo, CN, CF , -OCF , -NO , oxo, -Si(C -C alkyl),
3 3 2 1 6
19 20 16 19 20 16 19 20 16 17
-(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR , -(CR R ) C(=Y’)NR R ,
n n n
19 20 16 17 19 20 16 19 20 16 19 20 16 17
-(CR R ) NR R , -(CR R ) OR , -(CR R ) -SR , -(CR R ) NR C(=Y’)R ,
n n n n
19 20 16 17 19 20 18 16 17 19 20 17 16
-(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R , -(CR R ) NR SO R ,
n n n 2
19 20 16 19 20 16 19 20 16 17
-(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR , -(CR R ) OC(=Y’)NR R ,
n n n
19 20 16 19 20 16 17 19 20 16 17
-(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ), -(CR R ) OP(OR )(OR ),
n 2 n n
19 20 16 19 20 16 19 20 16 17 19 20 16
-(CR R ) S(O)R , -(CR R ) S(O) R , -(CR R ) S(O) NR R , -(CR R ) S(O)(OR ),
n n 2 n 2 n
19 20 16 19 20 16 19 20 16 19 20
-(CR R ) S(O) (OR ), -(CR R ) SC(=Y’)R , -(CR R ) SC(=Y’)OR , -(CR R )
n 2 n n n
16 17 21
SC(=Y’)NR R , and R ;
X is selected from carbocyclyl, heterocyclyl, aryl, and heteroaryl;
11 12 13
R , R and R are independently H, C -C alkyl, C -C alkenyl, C -C alkynyl,
1 12 2 8 2 8
carbocyclyl, heterocyclyl, aryl, or heteroaryl,
11 12
or R and R together with the nitrogen to which they are attached form a 3-8
membered saturated, unsaturated or aromatic ring having 0-2 heteroatoms selected from O, S
and N, wherein said ring is optionally substituted with one or more groups selected from halo,
CN, CF3, -OCF3, -NO2, C1-C6 alkyl, -OH, -SH, -O(C1-C6 alkyl), -S(C1-C6 alkyl), -NH2,
-NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C alkyl),
1 6 1 6 2 2 1 6 2 2 1 6
-C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C alkyl),
2 1 6 1 6 2 1 6 1 6
-NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), -SO NH ,
1 6 2 1 6 1 6 2 1 6 2 2
-SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl),
2 1 6 2 1 6 2 2 1 6
-OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C
1 6 2 1 6 1 6 1 6
alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) ,
2 1 6 1 6 1 6 1 6 2
-NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C
1 6 1 6 2 1 6 1 6
alkyl)C(O)O(C -C alkyl);
14 15
R and R are independently selected from H, C -C alkyl, aryl, carbocyclyl,
1 12
heterocyclyl, and heteroaryl;
m and n are independently selected from 0, 1, 2, 3, 4, 5, or 6;
Y is independently O, NR , or S;
wherein each said alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl
1 2 3 4 5 6 1 2 11 12 13 14 15
of R , R , R , R , R , R , X , X , R , R , R , R , and R is independently optionally
substituted with one or more groups independently selected from halo, CN, CF , -OCF , -NO ,
3 3 2
19 20 16 19 20 16
oxo, -Si(C -C alkyl), -(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR ,
1 6 n n
19 20 16 17 19 20 16 17 19 20 16 19 20 16
-(CR R ) C(=Y’)NR R , -(CR R ) NR R , -(CR R ) OR , -(CR R ) -SR ,
n n n n
19 20 16 17 19 20 16 17 19 20 18 16 17
-(CR R ) NR C(=Y’)R , -(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R ,
n n n
19 20 17 16 19 20 16 19 20 16
-(CR R ) NR SO R , -(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR ,
n 2 n n
19 20 16 17 19 20 16 19 20 16 17
-(CR R ) OC(=Y’)NR R , -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ),
n n 2 n
19 20 16 17 19 20 16 19 20 16
-(CR R ) OP(OR )(OR ), -(CR R ) S(O)R , -(CR R ) S(O) R ,
n n n 2
19 20 16 17 19 20 16 19 20 16 19 20
-(CR R ) S(O) NR R , -(CR R ) S(O)(OR ), -(CR R ) S(O) (OR ), -(CR R )
n 2 n n 2 n
16 19 20 16 19 20 16 17 21
SC(=Y’)R , -(CR R ) SC(=Y’)OR , -(CR R ) SC(=Y’)NR R , and R ;
16 17 18
each R , R and R is independently H, C -C alkyl, C -C alkenyl, C -C alkynyl,
1 12 2 8 2 8
carbocyclyl, heterocyclyl, aryl, or heteroaryl, wherein said alkyl, alkenyl, alkynyl,carbocyclyl,
heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more groups selected from
halo, oxo, CN, -OCF , CF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), -S(C -C alkyl),
3 3 2 1 6 1 6 1 6
-NH , -NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C alkyl),
2 1 6 1 6 2 2 1 6 2 2 1 6
-C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C alkyl),
2 1 6 1 6 2 1 6 1 6
-NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), -SO NH ,
1 6 2 1 6 1 6 2 1 6 2 2
-SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl),
2 1 6 2 1 6 2 2 1 6
-OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C
1 6 2 1 6 1 6 1 6
alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) ,
2 1 6 1 6 1 6 1 6 2
-NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C
1 6 1 6 2 1 6 1 6
alkyl)C(O)O(C -C alkyl);
16 17
or R and R together with the nitrogen to which they are attached form a 3-8
membered saturated, unsaturated or aromatic ring having 0-2 heteroatoms selected from O, S
and N, wherein said ring is optionally substituted with one or more groups selected from halo,
CN, -OCF , CF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), -S(C -C alkyl), -NH ,
3 3 2 1 6 1 6 1 6 2
-NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C alkyl),
1 6 1 6 2 2 1 6 2 2 1 6
-C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C alkyl),
2 1 6 1 6 2 1 6 1 6
-NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), -SO NH ,
1 6 2 1 6 1 6 2 1 6 2 2
-SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl),
2 1 6 2 1 6 2 2 1 6
-OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C
1 6 2 1 6 1 6 1 6
alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) ,
2 1 6 1 6 1 6 1 6 2
-NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C
1 6 1 6 2 1 6 1 6
alkyl)C(O)O(C -C alkyl);
19 20
R and R are independently selected from H, C -C alkyl, -(CH ) -aryl, -(CH ) -
1 12 2 n 2 n
carbocyclyl, -(CH ) -heterocyclyl, and -(CH ) -heteroaryl;
2 n 2 n
R is C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, heterocyclyl, aryl, or
1 12 2 8 2 8
heteroaryl, wherein each member of R is optionally substituted with one or more groups
selected from halo, CN, -OCF , CF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), -S(C -C
3 3 2 1 6 1 6 1 6
alkyl), -NH , -NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C
2 1 6 1 6 2 2 1 6 2 2 1 6
alkyl), -C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C
2 1 6 1 6 2 1 6 1 6
alkyl), -NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl),
1 6 2 1 6 1 6 2 1 6
-SO NH , -SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl),
2 2 2 1 6 2 1 6 2 2 1 6
-OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C
1 6 2 1 6 1 6 1 6
alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) ,
2 1 6 1 6 1 6 1 6 2
-NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C
1 6 1 6 2 1 6 1 6
alkyl)C(O)O(C -C alkyl);
each Y’ is independently O, NR , or S; and
R is H or C -C alkyl.
1 12
In some variations, the MEK inhibitor compound of the formula (II) is a compound of
the formula (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (II
a), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (IIi), (IIa), (IIb), (II
c), (IId), (IIe), (IIf), (IIg), (IIh), or (IIi):
6 N 6
2 N 2
1 1 2
R R R R
IIa IIb IIc IId
R O R
O R O
6 1 6
R X N
N 4 R
2 1 1
R R R N
IIe IIf IIg IIh
O R N O
11 11
N R 6 R N
N X N
R R R
IIi IIa IIb IIc
R 11 O 11 O
11 O
N O R R
R 11
O N N
1 1 1
R R R R
IId IIe IIf IIg
O O
6 11
11 11
11 O
R R N
N 2 O
N R R
IIh IIi IIa IIb
O 11
O 11
2 1 1
R R R R
IIc IId IIe IIf
IIg IIh IIi
or a pharmaceutically acceptable salt or solvate thereof, wherein the variables are as defined for
the formula (II) or as defined in A1, incorporated herein by reference.
In some embodiments, the MEK inhibitor compound of the formula (II) is a compound
selected from the compounds of Examples 5-18, 20-102, 105-109, 111-118, 120-133, 136-149
and 151-160 in A1 (herein collectively referred to as the Formula II Species),
or a pharmaceutically acceptable salt or solvate thereof. These compounds exhibited an IC of
less than 10 µM in the assay described either in Example 8a or 8b (MEK activity assays). Most
of these compounds exhibited an IC of less than 5 µM. See page 62 in A1.
Also embraced are MEK inhibitor compounds (and/or solvates and salts thereof)
described in A1, which is incorporated herein by reference, for example, aza-
benzofuran compounds of the formula (II) (designated as formula I in A1,
e.g., on page 3) and variations thereof as described in A1. Compounds of
formula (II) can be synthesized using methods known in the art, for example, the synthetic
methods described in A1, incorporated herein by reference.
In some embodiments, the MEK inhibitor is a compound of formula (III):
(III)
or a pharmaceutically acceptable salt or solvate thereof, wherein:
Z is CR or N;
1 A A A
R is H, C -C alkyl, halo, CF , CHF , CN, OR or NR R ;
1 3 3 2
1’ A A A
R is H, C -C alkyl, halo, CF , CHF , CN, OR , or NR R ;
1 3 3 2
wherein each R is independently H or C -C alkyl;
Z is CR or N;
3 3 1 2 3
Z is CR or N; provided that only one of Z , Z and Z can be N at the same time;
R and R are independently selected from H, halo, CN, CF , -OCF , -NO ,
3 3 2
14 15 11 14 15 11 14 15 11 12
-(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR , -(CR R ) C(=Y’)NR R ,
n n n
14 15 11 12 14 15 11 14 15 11 14 15 12 11
-(CR R ) NR R , -(CR R ) OR , -(CR R ) SR , -(CR R ) NR C(=Y’)R ,
n n n n
14 15 12 11 14 15 13 11 12 14 15 12 11
-(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R , -(CR R ) NR SO R ,
n n n 2
14 15 11 14 15 11 14 15 11 12
-(CR R )nOC(=Y’)R , -(CR R )nOC(=Y’)OR , -(CR R )nOC(=Y’)NR R ,
14 15 11 14 15 11 12 14 15 11 12
-(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ), -(CR R ) OP(OR )(OR ),
n 2 n n
14 15 11 14 15 11 14 15 11 12 14 15 11
-(CR R ) S(O)R , -(CR R ) S(O) R , -(CR R ) S(O) NR R , -(CR R ) S(O)(OR ),
n n 2 n 2 n
14 15 11 14 15 11 14 15 11
-(CR R ) S(O) (OR ), -(CR R ) SC(=Y’)R , -(CR R ) SC(=Y’)OR ,
n 2 n n
14 15 11 12
-(CR R ) SC(=Y’)NR R , C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl,
n 1 12 2 8 2 8
heterocyclyl, aryl, and heteroaryl;
R is H, C -C alkyl or C -C carbocyclyl;
1 6 3 4
Y is W-C(O)- or W’;
1 11'
W is or ;
R is H or C -C alkyl;
1 12
1 11’ 11’ 1 11’ 1
X is selected from R and -OR ; when X is R , X is optionally taken together with
R and the nitrogen atom to which they are bound to form a 4-7 membered saturated or
unsaturated ring having 0-2 additional heteroatoms selected from O, S and N, wherein said ring
is optionally substituted with one or more groups selected from halo, CN, CF , -OCF , -NO ,
3 3 2
19 20 16 19 20 16 19 20 16 17
oxo, -(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR , -(CR R ) C(=Y’)NR R ,
n n n
19 20 16 17 19 20 16 19 20 16 19 20 16 17
-(CR R ) NR R , -(CR R ) OR , -(CR R ) -SR , -(CR R ) NR C(=Y’)R ,
n n n n
19 20 16 17 19 20 18 16 17 19 20 17 16
-(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R , -(CR R ) NR SO R ,
n n n 2
19 20 16 19 20 16 19 20 16 17
-(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR , -(CR R ) OC(=Y’)NR R ,
n n n
19 20 16 19 20 16 17 19 20 16 17
-(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ), -(CR R ) OP(OR )(OR ),
n 2 n n
19 20 16 19 20 16 19 20 16 17 19 20 16
-(CR R ) S(O)R , -(CR R ) S(O) R , -(CR R ) S(O) NR R , -(CR R ) S(O)(OR ),
n n 2 n 2 n
19 20 16 19 20 16 19 20 16 19 20
-(CR R ) S(O) (OR ), -(CR R ) SC(=Y’)R , -(CR R ) SC(=Y’)OR , -(CR R )
n 2 n n n
16 17 21
SC(=Y’)NR R , and R ;
each R is independently H, C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl,
1 12 2 8 2 8
heterocyclyl, aryl, or heteroaryl;
11 12 13
R , R and R are independently H, C -C alkyl, C -C alkenyl, C -C alkynyl,
1 12 2 8 2 8
carbocyclyl, heterocyclyl, aryl, or heteroaryl,
11 12
or R and R together with the nitrogen to which they are attached form a 3-8
membered saturated, unsaturated or aromatic ring having 0-2 heteroatoms selected from O, S
and N, wherein said ring is optionally substituted with one or more groups selected from halo,
CN, CF3, -OCF3, -NO2, C1-C6 alkyl, -OH, -SH, -O(C1-C6 alkyl), -S(C1-C6 alkyl), -NH2,
-NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C alkyl),
1 6 1 6 2 2 1 6 2 2 1 6
-C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C alkyl),
2 1 6 1 6 2 1 6 1 6
-NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), -SO NH ,
1 6 2 1 6 1 6 2 1 6 2 2
-SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl),
2 1 6 2 1 6 2 2 1 6
-OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C
1 6 2 1 6 1 6 1 6
alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) ,
2 1 6 1 6 1 6 1 6 2
-NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C
1 6 1 6 2 1 6 1 6
alkyl)C(O)O(C -C alkyl);
14 15
R and R are independently selected from H, C -C alkyl, aryl, carbocyclyl,
1 12
heterocyclyl, and heteroaryl;
R O N O
NH NH
W’ is ;
wherein is
7 7 7
2 2 2
R R R
N 7 N N
X 7 N X 7 X 7 N 7 N N
R R R R
X N N
N N N N N N N
R N N N N HN O
N N R O
N NH N
N 7 O 7
N N NN
each X is independently O, S, or NR ;
each R is independently selected from H, halo, CN, CF , -OCF , -NO ,
3 3 2
14 15 11 14 15 11 14 15 11 12
-(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR , -(CR R ) C(=Y’)NR R ,
n n n
14 15 11 12 14 15 11 14 15 11 14 15 12 11
-(CR R ) NR R , -(CR R ) OR , -(CR R ) SR , -(CR R ) NR C(=Y’)R ,
n n n n
14 15 12 11 14 15 13 11 12 14 15 12 11
-(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R , -(CR R ) NR SO R ,
n n n 2
14 15 11 14 15 11 14 15 11 12
-(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR , -(CR R ) OC(=Y’)NR R ,
n n n
14 15 11 14 15 11 12 14 15 11 12
-(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ), -(CR R ) OP(OR )(OR ),
n 2 n n
14 15 11 14 15 11 14 15 11 12 14 15 11
-(CR R ) S(O)R , -(CR R ) S(O) R , -(CR R ) S(O) NR R , -(CR R ) S(O)(OR ),
n n 2 n 2 n
14 15 11 14 15 11 14 15 11
-(CR R ) S(O) (OR ), -(CR R ) SC(=Y’)R , -(CR R ) SC(=Y’)OR ,
n 2 n n
14 15 11 12
-(CR R ) SC(=Y’)NR R , C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl,
n 1 12 2 8 2 8
heterocyclyl, aryl, and heteroaryl;
each R is independently selected from C -C alkyl, aryl, carbocyclyl, heterocyclyl, and
1 12
heteroaryl;
9 14 15 11 14 15 11
R is selected from H, -(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR ,
14 15 11 12 14 15 11 12 14 15 11 14 15 11
-(CR R ) C(=Y’)NR R , -(CR R ) NR R , -(CR R ) OR , -(CR R ) SR ,
n q q q
14 15 12 11 14 15 12 11 14 15 13 11 12
-(CR R ) NR C(=Y’)R , -(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R ,
q q q
14 15 12 11 14 15 11 14 15 11
-(CR R ) NR SO R , -(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR ,
q 2 q q
14 15 11 12 14 15 11 14 15 11 12
-(CR R ) OC(=Y’)NR R , -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ),
q q 2 q
14 15 11 12 14 15 11 14 15 11 14 15
-(CR R ) OP(OR )(OR ), -(CR R ) S(O)R , -(CR R ) S(O) R , -(CR R )
q n n 2 n
11 12
S(O) NR R , C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, heterocyclyl, aryl, and
2 1 12 2 8 2 8
heteroaryl;
R is H, C -C alkyl or C -C carbocyclyl;
1 6 3 4
(R )
X is ;
R is H, halo, C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, heteroaryl,
1 6 2 8 2 8
19 20 16 17 19 20 16
heterocyclyl, -OCF , -NO , -Si(C -C alkyl), -(CR R ) NR R , -(CR R ) OR , or
3 2 1 6 n n
19 20 16
-(CR R ) -SR ;
R is H, halo, C -C alkyl, carbocyclyl, CF , -OCF , -NO , -Si(C -C alkyl),
1 6 3 3 2 1 6
19 20 16 17 19 20 16 19 20 16
-(CR R ) NR R , -(CR R ) OR , -(CR R ) -SR , C -C alkenyl, C -C alkynyl,
n n n 2 8 2 8
heterocyclyl, aryl, or heteroaryl;
p is 0, 1, 2 or 3;
n is 0,1, 2 or 3;
q is 2 or 3;
wherein each said alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl
1 2 3 4 5 6 6’ 7 8 9 10 11 11’ 12 13 14 15 A
of R , R , R , R , R , R , R , R , R , R , R , R , R , R , R , R , R and R is independently
optionally substituted with one or more groups independently selected from halo, CN, CF ,
19 20 16 19 20 16
-OCF , -NO , oxo, -Si(C -C alkyl), -(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR ,
3 2 1 6 n n
19 20 16 17 19 20 16 17 19 20 16 19 20 16
-(CR R ) C(=Y’)NR R , -(CR R ) NR R , -(CR R ) OR , -(CR R ) SR ,
n n n n
19 20 16 17 19 20 16 17 19 20 18 16 17
-(CR R )nNR C(=Y’)R , -(CR R )nNR C(=Y’)OR , -(CR R )nNR C(=Y’)NR R ,
19 20 17 16 19 20 16 19 20 16
-(CR R ) NR SO R , -(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR ,
n 2 n n
19 20 16 17 19 20 16 19 20 16 17
-(CR R ) OC(=Y’)NR R , -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ),
n n 2 n
19 20 16 17 19 20 16 19 20 16
-(CR R ) OP(OR )(OR ), -(CR R ) S(O)R , -(CR R ) S(O) R ,
n n n 2
19 20 16 17 19 20 16 19 20 16
-(CR R ) S(O) NR R , -(CR R ) S(O)(OR ), -(CR R ) S(O) (OR ),
n 2 n n 2
19 20 16 19 20 16 19 20 16 17 21
-(CR R ) SC(=Y’)R , -(CR R ) SC(=Y’)OR , -(CR R ) SC(=Y’)NR R , and R ;
n n n
16 17 18
each R , R and R is independently H, C -C alkyl, C -C alkenyl, C -C alkynyl,
1 12 2 8 2 8
carbocyclyl, heterocyclyl, aryl, or heteroaryl, wherein said alkyl, alkenyl, alkynyl,carbocyclyl,
heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more groups selected from
halo, CN, -OCF , CF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), -S(C -C alkyl), -NH ,
3 3 2 1 6 1 6 1 6 2
-NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C alkyl),
1 6 1 6 2 2 1 6 2 2 1 6
-C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C alkyl),
2 1 6 1 6 2 1 6 1 6
-NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), -SO NH ,
1 6 2 1 6 1 6 2 1 6 2 2
-SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl),
2 1 6 2 1 6 2 2 1 6
-OC(O)N(C1-C6 alkyl)2, -OC(O)O(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -NHC(O)N(C1-C6
alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) ,
2 1 6 1 6 1 6 1 6 2
-NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C
1 6 1 6 2 1 6 1 6
alkyl)C(O)O(C -C alkyl);
16 17
or R and R together with the nitrogen to which they are attached form a 3-8
membered saturated, unsaturated or aromatic ring having 0-2 heteroatoms selected from O, S
and N, wherein said ring is optionally substituted with one or more groups selected from halo,
CN, -OCF , CF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), -S(C -C alkyl), -NH ,
3 3 2 1 6 1 6 1 6 2
-NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -SO2(C1-C6 alkyl), -CO2H, -CO2(C1-C6 alkyl),
-C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C alkyl),
2 1 6 1 6 2 1 6 1 6
-NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), -SO NH ,
1 6 2 1 6 1 6 2 1 6 2 2
-SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl),
2 1 6 2 1 6 2 2 1 6
-OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C
1 6 2 1 6 1 6 1 6
alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) ,
2 1 6 1 6 1 6 1 6 2
-NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C
1 6 1 6 2 1 6 1 6
alkyl)C(O)O(C -C alkyl);
19 20
R and R are independently selected from H, C -C alkyl, -(CH ) -aryl, -(CH ) -
1 12 2 n 2 n
carbocyclyl, -(CH ) -heterocyclyl, and -(CH ) -heteroaryl;
2 n 2 n
R is C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, heterocyclyl, aryl, or
1 12 2 8 2 8
heteroaryl, wherein each member of R is optionally substituted with one or more groups
selected from halo, oxo, CN, -OCF , CF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl),
3 3 2 1 6 1 6
-S(C -C alkyl), -NH , -NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H,
1 6 2 1 6 1 6 2 2 1 6 2
-CO (C -C alkyl), -C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C
2 1 6 2 1 6 1 6 2 1 6
alkyl)C(O)(C -C alkyl), -NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C
1 6 1 6 2 1 6 1 6
alkyl)SO (C -C alkyl), -SO NH , -SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH ,
2 1 6 2 2 2 1 6 2 1 6 2 2
-OC(O)NH(C -C alkyl), -OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C
1 6 1 6 2 1 6 1 6
alkyl), -NHC(O)N(C -C alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C
1 6 2 1 6 1 6 1 6
alkyl)C(O)N(C -C alkyl) , -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) ,
1 6 2 1 6 1 6 2
-NHC(O)O(C -C alkyl), and -N(C -C alkyl)C(O)O(C -C alkyl);
1 6 1 6 1 6
each Y’ is independently O, NR , or S; and
R is H or C -C alkyl.
1 12
In some variations, the MEK inhibitor compound of the formula (III) has the formula
(III-a) or (III-b):
1' N
III-a III-b
or a pharmaceutically acceptable salt or solvate thereof, wherein the variables are as defined for
the formula (III) or as defined in A1, incorporated herein by reference.
In some embodiments, the MEK inhibitor compound of the formula (III) is a
compound selected from the compounds listed in Table 1, or a pharmaceutically acceptable salt
or solvate thereof.
Table 1
Compound No. Chemical Name Structure
-(2-Fluoro
iodophenylamino)-imidazo[1,5-
(III)-5
a]pyridinecarboxylic acid (2-
hydroxyethoxy)-amide
HO O F
-(2-Fluoroiodo-
OH N
phenylamino)-imidazo[1,5-
(III)-6 a]pyridinecarboxylic acid
((R)-2,3-dihydroxy-propoxy)-
amide
HO N O
-(2-Fluoroiodo-
phenylamino)-imidazo[1,5-
(III)-7
a]pyridinecarboxylic acid
((S)hydroxy-propoxy)-amide
-(4-Bromo HO
fluorophenylamino)-
(III)-8 imidazo[1,5-a]pyridine
carboxylic acid (2-
hydroxyethoxy)-amide
HO N O
-(4-Bromofluoro-
phenylamino)-imidazo[1,5-
(III)-9
a]pyridinecarboxylic acid
((S)hydroxy-propoxy)-amide
-(4-Bromofluoro-
phenylamino)fluoro-
(III)-10 imidazo[1,5-a]pyridine
carboxylic acid ((S)hydroxy-
propoxy)-amide
Compound No. Chemical Name Structure
HO O
8-Fluoro(2-fluoroiodo-
phenylamino)-imidazo[1,5-
(III)-11
a]pyridinecarboxylic acid (2-
hydroxy-ethoxy)-amide
HO F
8-Fluoro(2-fluoroiodo-
OH N
phenylamino)-imidazo[1,5-
(III)-12 a]pyridinecarboxylic acid
((R)-2,3-dihydroxy-propoxy)-
amide
8-Fluoro(2-fluoroiodo-
phenylamino)-imidazo[1,5-
(III)-13
a]pyridinecarboxylic acid
((S)hydroxy-propoxy)-amide
HO N O
-(2-Fluoro-methanesulfanyl-
phenylamino)-imidazo[1,5-
(III)-14
a]pyridinecarboxylic acid (2-
hydroxy-ethoxy)-amide
HO N O
-(2-Fluoroiodo-
phenylamino)-imidazo[1,5-
(III)-15
a]pyrazinecarboxylic acid (2-
hydroxy-ethoxy)-amide
HO N O
-(2-Fluoroiodo-
phenylamino)-imidazo[1,5-
(III)-16
a]pyrazinecarboxylic acid
((S)hydroxy-propoxy)-amide
HO N O
-(4-Cyclopropylfluoro-
phenylamino)-imidazo[1,5-
(III)-17
a]pyridinecarboxylic acid (2-
hydroxy-ethoxy)-amide
Compound No. Chemical Name Structure
HO O F
(R)-N-(2,3-Dihydroxypropoxy)-
HO N
-(2-fluoro
(III)-18
iodophenylamino)imidazo[1,5-
a]pyrazinecarboxamide
N-Ethoxy(2-fluoro
(III)-19 iodophenylamino)imidazo[1,5-
a]pyrazinecarboxamide
N-(Cyclopropylmethoxy)(2-
fluoro
(III)-20
iodophenylamino)imidazo[1,5-
a]pyrazinecarboxamide
HN O
-(2-Fluoro
iodophenylamino)-N-
(III)-21
methylimidazo[1,5-a]pyrazine-
6-carboxamide I
HO N O
-(4-Bromo
fluorophenylamino)-N-(2-
(III)-22
hydroxy-ethoxy)imidazo[1,5-
a]pyrazinecarboxamide
(S)(4-Bromo
fluorophenylamino)-N-(2-
(III)-23
hydroxy-propoxy)imidazo[1,5-
a]pyrazinecarboxamide
(R)(4-Bromo
HO H
fluorophenylamino)-N-(2,3-
(III)-24
dihydroxy-propoxy)imidazo[1,5-
a]pyrazinecarboxamide
Compound No. Chemical Name Structure
-(4-Bromo
fluorophenylamino)-N-
(III)-25 (cyclopropyl-
methoxy)imidazo[1,5-
a]pyrazinecarboxamide
Compounds in Table 1 correspond to Examples 5-25 in A1.
Compounds (III)-5 – (III)-20 and (III)-22 – (III)-24 exhibited an IC of less than 0.5 µM in the
assay described in Example 8b (MEK activity assay). Some of these compounds exhibited an
IC of less than 0.1 µM. Compounds (III)-21 and (III)-25 exhibited an IC of less than 10 µM.
50 50
See page 49 in A1.
Also embraced are MEK inhibitor compounds (and/or solvates and salts thereof)
described in A1, which is incorporated herein by reference, for example,
imidazopyridine compounds of the formula (III) (designated as formula I in
A1, e.g., on page 3) and variations thereof as described in A1. Compounds of
formula (III) can be synthesized using methods known in the art, for example, the synthetic
methods described in A1, incorporated herein by reference.
In some embodiments, the MEK inhibitor is a compound of formula (IV),
or a pharmaceutically acceptable salt or solvate thereof, wherein the variables are as defined in
WO 03/077914 A1 for the formula I on pages 4-9 or any applicable variations described in WO
03/077914 A1, incorporated herein by reference.
In some variations, the MEK inhibitor compound of the formula (IV) is a compound of
the formula (IV-a), (IV-b), (IV-c), or (IV-d):
IV-a IV-b
IV-c IV-d
or a pharmaceutically acceptable salt or solvate thereof, wherein the variables are as defined in
WO 03/077914 A1 for the formulae II, III, IIIa and IIIb, respectively on pages 10-13 or any
applicable variations described in WO 03/077914 A1, incorporated herein by reference.
In some embodiments, the MEK inhibitor compound of the formula (IV) is a
compound selected from the group consisting of:
7-Fluoro(4-bromomethyl-phenylamino)-3H-benzoimidazolecarboxylic acid
cyclopropylmethoxy-amide;
6-(4-Bromochloro-phenylamino)fluoro-3H-benzoimidazolecarboxylic acid
cyclopropylmethoxy-amide;
6-(4-Bromochloro-phenylamino)fluoromethyl-3H-benzoimidazole
carboxylic acid (2-hydroxy-ethoxy)-amide;
6-(4-Bromochloro-phenylamino)fluoromethyl-3H-benzoimidazole
carboxylic acid (2,3-dihydroxy-propoxy)-amide;
6-(4-Bromochloro-phenylamino)fluoro(tetrahydro-pyranylmethyl)-3H-
benzoimidazolecarboxylic acid (2-hydroxy-ethoxy)-amide;
[6-(5-Amino-[1,3,4]oxadiazolyl)fluoro-lH-benzoimidazolyl]-(4-bromo
methyl-phenyl)-amine;
1-[6-(4-Bromochloro-phenylamino)fluoromethyl-3H-benzoimidazolyl]
hydroxy-ethanone;
1-[6-(4-Bromochloro-phenylamino)fluoro-3H-benzoimidazolyl]methoxy
ethanone;
6-(4-Bromochloro-phenylamino)fluoromethyl-3H-benzoimidazole
carboxylic acid (2-hydroxy-1,1-dimethyl-ethoxy)-amide;
6-(4-Bromochloro-phenylamino)fluoro(tetrahydro-furanylmethyl)-3H-
benzoimidazolecarboxylic acid (2-hydroxy-ethoxy)-amide;
6-(4-Bromochloro-phenylamino)fluoro-3H-benzoimidazolecarboxylic acid (2-
hydroxy-ethoxy)-amide;
6-(-Bromofluoro-phenylamino)fluoromethyl-3H-benzoimidazolecarboxylic
acid (2-hydroxy-ethoxy)-amide; and
6-(2,4-Dichloro-phenylamino)fluoromethyl-3H-benzoimidazolecarboxylic
acid (2-hydroxy-ethoxy)-amide;
or a pharmaceutically acceptable salt or solvate thereof.
Also embraced are any variations of formula (IV) as described in WO 03/077914 A1,
which is incorporated herein by reference. Compounds of the formula (IV) or any variations
thereof can be synthesized using methods known in the art, for example, the synthetic methods
described in WO 03/077914 A1, incorporated herein by reference.
In some embodiments, the MEK inhibitor is a compound of formula (V),
or a pharmaceutically acceptable salt or solvate thereof, wherein the variables are as defined in
A1 for the formula [I] on pages 6-10 or any applicable variations described in
A1, incorporated herein by reference.
Also embraced are any variations of formula (V) as described in A1,
such as the individual MEK inhibitor compounds described in A1, e.g.,
Examples 1-1 to 1-343 in Table 1, Examples 2-1 and 2-2 in Table 2, Examples 3-1 to 3-9 in
Table 3, Examples 4-1 to 4-148 in Table 4. Compounds of the formula (V) or any variations
thereof can be synthesized using methods known in the art, for example, the synthetic methods
described in A1, incorporated herein by reference.
In some embodiments, the MEK inhibitor is a compound of formula (VI),
or a pharmaceutically acceptable salt or ester thereof, wherein:
R1 is selected from the group consisting of bromo, iodo, ethynyl, cycloalkyl, alkoxy,
azetidinyl, acetyl, heterocycyl, cyano, straight-chained alkyl and branched-chain alkyl;
R2 is selected from the group consisting of hydrogen, chlorine, fluorine, and alkyI;
R3 is selected from the group consisting of hydrogen, chlorine, and fluorine;
R4 is selected from the group consisting of hydrogen, optionally substituted aryl, alkyl,
and cycloalkyl;
R5 is selected from the group consisting of hydrogen and ;
wherein R6 is selected from the group consisting of hydroxyl, alkoxy, cycloalkyl,
optionally substituted alkyl, optionally substituted aryl, and optionally substituted heteroaryl;
R7 and R8 are independently selected from the group consisting of hydrogen and
optionally substituted alkyl;
or R6 and R7 can together form a cycloalkyl group and R8 is hydrogen.
In some variations, the MEK inhibitor compound is of the formula (VI), or a
pharmaceutically acceptable salt or ester thereof, wherein the variables are as defined in WO
2007/096259 A1 for the formula I or any applicable variations described on pages 4-10 in WO
2007/096259 A1, incorporated herein by reference. Further embraced MEK inhibitors are
compounds described in Examples 1-182 in A1, incorporated herein by
reference.
In some embodiments, the MEK inhibitor compound of the formula (VI) is a
compound selected from the group consisting of:
(2S,3S)-N-(4-Bromo-phenyl)[(R)(4-methoxy-phenyl)-2,5-dioxo-imidazolidin
yl]phenyl-butyramide;
(2S,3S)-N-(4-lodo-phenyl)[(R)(4-methoxy-phenyl)-2,5-dioxo-imidazolidinyl]-
3-phenyl-butyramide;
(2S,3S)-N-(2-Fluoroiodo-phenyl){(R)[4-(2-hydroxy-ethoxy)-phenyl]-2,5-
dioxo-imidazolidinyl}phenyl-butyramide;
(2S,3S)-N-(4-Ethynylfluoro-phenyl){(R)[4-(2-hydroxy-ethoxy)-phenyl]-2,5-
dioxo-imidazolidinyl}phenyl-butyramide;
(2R,3S)-N-(4-Ethynylfluoro-phenyl){(R)[4-(2-hydroxy-ethoxy)-phenyl]-2,5-
dioxo-imidazolidinyl}phenyl-butyramide;
(2S,3S)-N-(2-Chloroiodo-phenyl){(R)[4-(2-hydroxy-ethoxy)-phenyl]-2,5-
dioxo-imidazolidinyl}phenyl-butyramide;
(2S,3S){(R)[4-(2-Hydroxy-ethoxy)-phenyl]-2,5-dioxo-imidazolidinyl}-N-(4-
iodomethyl-phenyl)phenyl-butyramide;
(2S,3S)-N-(2-Chloroiodo-phenyl){(R)[4-((R)-2,3-dihydroxy-propoxy)-
phenyl]-2,5-dioxo-imidazolidinyl}phenyl-butyramide;
(2S,3S)-N-(2-Chloroiodo-phenyl){(R)[4-((S)-2,3-di hydroxy-propoxy)-
phenyl]-2,5-dioxo-imidazolidinyl}phenyl-butyramide;
(2S,3S){(R)-2,5-Dioxo[4-(2-oxopyrrolidinyl-ethoxy)-phenyl]-imidazolidin-
1-yl}-N-(2-fluoroiodo-phenyl)phenyl-butyramide;
(2S,3S)((R)-2,5-Dioxothiophenyl-imidazolidinyl)-N-(4-iodo-phenyl)
phenyl-butyramide;
(S)[(R)(2,3-Dihydro-benzo[1,4]dioxinyl)-2,5-dioxo-imidazolidinyl]-N-(2-
fluoroiodo-phenyl)phenyl-propionamide;
(S)[(R)(4-Acetylamino-phenyl)-2,5-dioxo-imidazolidinyl]-N-(2-fluoroiodo-
phenyl)phenyl-propionamide;
(4-{(R)[(1S,2S)(2-Fluoroiodo-phenylcarbamoyl)phenyl-propyl]-2,5-dioxo-
imidazolidinyl}-phenoxymethyl)-phosphonic acid dimethyl ester;
(2S,3S)-N-(2-Fluoroiodo-phenyl)((R)isopropyl-2,5-dioxo-imidazolidinyl)-
3-phenyl-butyramide;
(S)-N-(2-Fluoroiodo-phenyl){(R)[4-(2-hydroxy-ethoxy)-phenyl]-2,5-dioxo-
imidazolidinyl}methyl-butyramide;
(S)-N-(2-Fluoroiodo-phenyl)[(R)(4-methoxy-phenyl)-2,5-dioxo-imidazolidin-
1-yl]o-tolyl-propionamide;
(S)-N-(2-Fluoroiodo-phenyl)[(R)(4-methoxy-phenyl)-2,5-dioxo-imidazolidin-
1-yl]m-tolyl-propionamide;
(S)-N-(2-Fluoroiodo-phenyl)[(R)(4-methoxy-phenyl)-2,5-dioxo-imidazolidin-
1-yl]p-tolyl-propionamide; and
(S)-N-(4-Cyclopropylfluoro-phenyl)(4-fluoro-phenyl){(R)[4-(2-hydroxy
hydroxymethyl-ethoxy)-phenyl]-2,5-dioxo-imidazolidinyl}-propionamide ;
or a pharmaceutically acceptable salt or ester thereof.
In some embodiments, the MEK inhibitor is a compound of formula (VII),
or a pharmaceutically acceptable salt or ester thereof, wherein:
R1 is selected from the group consisting of halogen, ethynyl, and cycloalkyl;
R2 is selected from the group consisting of hydrogen and CH(R3)(R4);
R3 is selected from the group consisting of lower alkyl, lower alkoxy, optionally
substituted aryl, and optionally substituted heteroaryl;
R4 is selected from the group consisting of hydrogen and lower alkyl;
R5 is hydrogen or, taken together with R2 and the carbon to which R2 and R5 are
attached, forms lower cycloalkyl; and
R6 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl,
optionally substituted aryl, and optionally substituted heteroaryl.
In some variations, the MEK inhibitor compound is of the formula (VI), or a
pharmaceutically acceptable salt or ester thereof, wherein the variables are as defined in WO
2009/021887 A1 for the formula I or any applicable variations described on pages 4-5 in WO
2009/021887 A1, incorporated herein by reference. Further embraced MEK inhibitors are
compounds described in Examples 1-21 in 2009/021887 A1, incorporated herein by reference.
In some embodiments, the MEK inhibitor compound of the formula (VI) is a
compound selected from the group consisting of:
(R)[4-(2-Hydroxy-ethoxy)-phenyl][(S)(6-iodo-1H-benzoimidazolyl)
phenyl-ethyl]-imidazolidine-2,4-dione;
(R)[4-(2-Hydroxy-ethoxy)-phenyl](5-iodo-1H-benzoimidazolylmethyl)-
imidazolidine-2,4-dione;
(R)[4-(2-Hydroxy-ethoxy)-phenyl][(S)(5-iodo-1H-benzoimidazolyl)
methyl-propyl]-imidazolidine-2,4-dione;
(R)[4-(2-Hydroxy-ethoxy)-phenyl][(1R,2R)(5-iodo-1H-benzoimidazolyl)-
2-methoxy-propyl]-imidazolidine-2,4-dione;
3-[(S)(5-lodo-1H-benzoimidazolyl)phenyl-ethyl]-imidazolidine-2,4-dione;
compound with trifluoro-acetic acid;
(R)[(S)(4-Fluoro-phenyl)(5-iodo-1H-benzoimidazolyl)-ethyl][4-(2-
hydroxy-ethoxy)-phenyl]-imidazolidine-2,4-dione;
(R)[4-(2-Hydroxy-ethoxy)-phenyl][(S)(5-iodo-1H-benzoimidazolyl)(4-
methoxy-phenyl)-ethyl]-imidazolidine-2,4-dione;
(R)[4-(2-Hydroxy-ethoxy)-phenyl][(S)(5-iodo-1H-benzoimidazolyl)
thiophenyl-ethyl]-imidazolidine-2,4-dione;
(R)[(1S,2S)(6-lodo-1H-benzoimidazolyl)phenyl-propyl]phenyl-
imidazolidine-2,4-dione;
(R)[(1S,2S)(6-lodo-1H-benzoimidazolyl)phenyl-propyl](4-methoxy-
phenyl)-imidazolidine-2,4-dione;
(R)[4-(2-Hydroxy-ethoxy)-phenyl][(1S,2S)(6-iodo-1H-benzoimidazolyl)
phenyl-propyl]-imidazolidine-2,4-dione;
(R)[(1S,2S)(6-lodo-1H-benzoimidazolyl)phenyl-propyl][4-(2-methoxy-
ethoxy)-phenyl]-imidazolidine-2,4-dione;
2-(4-{(R)[(1S,2S)(6-lodo-1H-benzoimidazolyl)phenyl-propyl]-2,5-dioxo-
imidazolidinyl}-phenoxy)-N,N-dimethyl-acetamide;
N,N-Bis-(2-hydroxy-ethyl)(4-{(R)[(1S,2S)(6-iodo-1H-benzoimidazolyl)
phenyl-propyl]-2,5-dioxo-imidazolidinyl}-phenoxy)-acetamide;
(R)[(1S,2S)(5-lodo-1H-benzoimidazolyl)phenyl-propyl]isopropyl-
imidazolidine-2,4-dione;
(R)Cyclohexyl[(1S,2S)(5-iodo-1H-benzoimidazolyl)phenyl-propyl]-
imidazolidine-2,4-dione;
(R)[4-(2-Hydroxy-ethoxy)-phenyl][1-(5-iodo-1H-benzoimidazolyl)-
cyclopropyl]-imidazolidine-2,4-dione;
(R)[(1S,2S)(6-Bromo-1H-benzoimidazolyl)phenyl-propyl][4-(2-
hydroxy-ethoxy)-phenyl]-imidazolidine-2,4-dione;
(R)[(S)(5-Cyclopropyl-1H-benzoimidazolyl)phenyl-ethyl][4-(2-
hydroxy-ethoxy)-phenyl]-imidazolidine-2,4-dione;
(R)[(S)(5-Ethynyl-1H-benzoimidazolyl)phenyl-ethyl][4-(2-hydroxy-
ethoxy)-phenyl]-imidazolidine-2,4-dione; and
(R)[(1S,2S)(5-Ethynyl-1H-benzoimidazolyl)phenyl-propyl][4-(2-
hydroxy-ethoxy)-phenyl]-imidazolidine-2,4-dione;
or a pharmaceutically acceptable salt or solvate thereof.
In some embodiments, the MEK inhibitor is a compound selected from the group
consisting of GDC-0973 (Methanone, [3,4-difluoro[(2-fluoroiodophenyl)amino]phenyl][3-
hydroxy(2S)piperidinylazetidinyl]-), G-38963, G02443714, G02442104, and
G00039805, or a pharmaceutically acceptable salt or solvate thereof.
HN O
GDC-0973 G-38963 G02443714
G02442104 G00039805
IV Kits
In another embodiment, described is a kit comprising a PD-L1 axis binding antagonist
and/or a MEK inhibitor for treating or delaying progression of a cancer in an individual or for
enhancing immune function of an individual having cancer. In some embodiments, the kit
comprises a PD-1 axis binding antagonist and a package insert comprising instructions for using
the PD-1 axis binding antagonist in combination with a MEK inhibitor to treat or delay
progression of cancer in an individual or to enhance immune function of an individual having
cancer. In some embodiments, the kit comprises a MEK inhibitor and a package insert
comprising instructions for using the MEK inhibitor in combination with a PD-1 axis binding
antagonist to treat or delay progression of cancer in an individual or to enhance immune function
of an individual having cancer. In some embodiments, the kit comprises a PD-1axis binding
antagonist and a MEK inhibitor, and a package insert comprising instructions for using the PD-1
axis binding antagonist and the MEK inhibitor to treat or delay progression of cancer in an
individual or to enhance immune function of an individual having cancer. Any of the PD-1 axis
binding antagonists and/or MEK inhibitors described herein may be included in the kits.
In some embodiments, the kit comprises a container containing one or more of the PD-
1 axis binding antagonists and MEK inhibitors described herein. Suitable containers include, for
example, bottles, vials (e.g., dual chamber vials), syringes (such as single or dual chamber
syringes) and test tubes. The container may be formed from a variety of materials such as glass
or plastic. In some embodiments, the kit may comprise a label (e.g., on or associated with the
container) or a package insert. The label or the package insert may indicate that the compound
contained therein may be useful or intended for treating or delaying progression of cancer in an
individual or for enhancing immune function of an individual having cancer. The kit may
further comprise other materials desirable from a commercial and user standpoint, including
other buffers, diluents, filters, needles, and syringes.
EXAMPLES
The invention can be further understood by reference to the following examples, which
are provided by way of illustration and are not meant to be limiting.
Example 1: MEK inhibitor enhanced MHC I expression on tumor cell lines
To determine if treatment with MEK inhibitor (MEKi) enhanced immunogenicity of
tumor cells, surface expression of MHC-I on tumor cell lines treated with MEK inhibitors GDC-
0973 and G-38963 was assayed. Briefly, human melanoma cell lines (Malme-3M, A2058,
A375, HS294T, SK23, SKMEL-28, 537 Mel, RPMI-795) and human colorectal cell lines (Colo
320 DM, Colo 205, WiDr, Colo 741, RKO, DLD-1, HM7, HCT-15) were treated with 1
micromolar MEKi GDC-0973 or G-38963, BRAF inhibitor (BRAFi) GDC-0879, or DMSO
vehicle for 24 hours. Following treatment, cells were stained for surface MHC Class I
expression with an antibody against HLA-A,B,C for subsequent FACS analysis. Data shown is
for treatment with MEKi GDC-0973. Labeled isotype-matched antibodies were used to
determine the level of non-specific staining. Data analysis and construction of histograms
demonstrated that cell surface expression of MHC-I was upregulated in MEKi treated cells as
compared to vehicle treated cells (Figure 1A). In contrast, cell surface expression of MHC-I in
BRAFi treated cells was not upregulated as compared to vehicle treated cells (Figure 2). These
results demonstrate that enhanced cell surface expression of MHC-I in both melanoma and
colorectal tumor cells is specific to MEK inhibition and not due to general inhibition of the
RAS/RAF/MEK signaling pathway.
To determine if treatment with MEK inhibitor (MEKi) enhanced immunogenicity of
mouse tumor cells similarly to human tumor cells, surface expression of MHC-I on mouse tumor
cell lines treated with MEKi GDC-0973 was assayed. Briefly, mouse melanoma cell lines
(MC38 and B16.F10) and a mouse colorectal cell line (CT26) were treated with MEKi GDC-
0973, G-38963 or vehicle. Briefly, cells were stimulated for 24 hours with 1 micromolar MEK
inhibitor or DMSO vehicle control. Following treatment, cells were surfaced stained with an
antibody against MHC-I (H-2D) and expression was assayed by subsequent FACS analysis.
Labeled isotype-matched antibodies were used to determine the level of non-specific staining.
Data analysis and construction of histograms demonstrated that cell surface expression of MHC-
I was upregulated in MEKi treated cells (data shown is for MEKi GDC-0973) as compared to
vehicle treated cells (Figure 1B). These results demonstrate that enhanced cell surface
expression of MHC-I occurred across several melanoma and colorectal tumor cell lines
regardless of mouse or human origin.
To determine if enhanced cell surface expression of MHC-I is specific to tumor cells,
the effect of MEKi treatment on MHC-I expression on human peripheral blood mononuclear
cells (PMBCs) was assayed. Briefly, PMBCS were isolated from whole blood by first diluting it
with an equal volume of room temperature PBS and subsequent overlay onto Ficoll-filled
Leucosep tubes (Greiner Bio-One). Post-centrifugation, the PBMC interface was then washed
twice and resuspended in culture media (RPMI-1640 with 10% fetal bovine serum, 20µM
HEPES, 55µM 2-mercaptoethanol, 50µg/ml gentamicin, and 1:100 dilutions of the following
supplements from Gibco: Gluta-MAX, sodium pyruvate, penicillin/streptomycin, and non-
essential amino acids). Cells were plated in 6 well plates at 4x10 per well with a total of 4 ml
per well. MEK inhibitor GDC-0973 was added at either 1µM or 3µM. Cells were harvested 24
hours later and distributed to a 96-well V-bottom plate for FACS staining. Cells were stained
with the following antibodies (all from BD Biosciences, at 1:10 for 30 minutes on ice): CD3-
FITC, HLA-ABC-PE, CD4-APC, CD19-FITC, and CD14-FITC. Propidium iodide was
included to exclude dead cells. Samples were run on a BD FACSCaliber flow cytometer and
data was analyzed using FlowJo software (Tree Star, Inc.). Data analysis and construction of
histograms demonstrated that cell surface expression of MHC-I was not upregulated in CD4+ T
cells (Figure 3A), CD8+ T cells (Figure 3B), B cells (Figure 3C), or monocytes (Figure 3D)
treated with 1µM MEKi GDC-0973 or 3µM MEKi GDC-0973 as compared to vehicle treated
cells. These results demonstrate that enhanced cell surface expression of MHC-I by MEK
inhibitor treatment is specific to tumor cells.
Example 2: Co-stimulatory signals made T cells resistant to TCR signaling inactivation by
MEK inhibitor
Recent studies have shown that MEK inhibitor treatment impairs T lymphocyte
function (Boni et al., Cancer Res., 70(13), 2010). To confirm that MEK inhibitor treatment
impaired CD8+ T cells, T cells were treated with MEKi in combination with T cell stimulation
signals and assayed for T cell proliferation. Briefly, human CD8+ T cells were purified from
whole blood using StemCell Technologies human CD8 RosetteSep as per manufacturer’s
instructions. Purified cells were plated at 200,000 per well in triplicate in 96-well U-bottom
plates with 200,000 per well of either anti-CD3 or anti-CD3/anti-CD28 Dynabeads (Invitrogen).
MEK inhibitors GDC-0973 and G-38963 were titrated 10-fold from 10µM to 0.001µM such that
the final culture concentration was 0.5% DMSO in a total volume of 200µl per well. Culture
medium was RPMI-1640 with 10% fetal bovine serum, 20µM HEPES, 55µM 2-
mercaptoethanol, 50µg/ml gentamicin, and 1:100 dilutions of the following supplements from
Gibco: Gluta-MAX, sodium pyruvate, penicillin/streptomycin, and non-essential amino acids.
At 48 hours, wells were pulsed with 1µCi/well of 3H-thymidine and cultured an additional 16
hours prior to freezing and harvest. Data analysis demonstrated that treatment of CD8+ T cells
with anti-CD3 stimulated T cell activation (closed triangle) as compared to unstimulated T cells
(open circle). Treatment of T cells with two different MEK inhibitors reduced the stimulatory
effect of anti-CD3 (closed circle, closed square) at all MEKi concentrations tested, with nearly
complete inhibition of T cell receptor induced proliferation occurring at 0.01 mM MEKi
treatment (Figure 4A). In contrast, co-stimulation with anti-CD3 and anti-CD28 in MEKi
treated T cells (closed circle, closed square) was sufficient to overcome the inhibitory effect of
MEKi on T cell activation (Figure 4B). These unexpected results demonstrate the novel finding
that inhibition of TCR signaling by MEKi treatment can be overcome by providing sufficient T
cell co-stimulation which is provided to T cells by antigen presenting cells such as B cells,
macrophages, and dendritic cells.
Without being bound to theory, a key component of co-stimulation is thought to be the
activation of PI3 kinase and is provided by CD28 via association of PI3K p85 subunit with its
cytoplsmic YMNM motif. PD-1, through its interaction with SHP2, impedes the activity of
PI3K. Therefore, blockade of the PD1 axis may disinhibit PI3kinase, resulting in enhanced T
cell costimulation and provides a means to overcome the inhibitory effect of MEKi on T cell
activation. PD-1/-L1 blockade is to enhance co-stimulation under conditions when expression of
co-stimulatory ligands such as B7.1 and B7.2 is often limiting such as in most tumors or the
tumor microenvironment. Combining MEKi with blockade of the PD1 axis should enhance
tumor specific T cell immunity by enhancing Ag recognition by the TCR through upregulation
of tumor MHC I (enhancing Signal I) by MEKi and by relieving inhibition of PI3K (enhancing
Signal 2) through PD1/PDL1 blockade.
Example 3: MEK inhibitor specifically enhanced maturation and activation of dendritic
cells
To determine if MEK inhibitor treatment specifically enhanced tumor immunogenicity
by stimulating dendritic cells (DCs), monocyte-derived dendritic cells were treated with
increasing concentration of MEKi GDC-0973, MEKi GDC-38963 or BRAFi GDC-0879 in
combination with antibodies to the DC co-stimulatory molecule CD40. Briefly, human
monocytes were purified from whole blood using StemCell Technologies human monocyte
RosetteSep as per manufacturer’s instructions. Monocytes were seeded in T175 flasks at
approximately 0.5-1.0x10 per ml in 50ng/ml human GM-CSF and 100ng/ml human IL-4 for 7
days total, with half-media exchanges every 2 days. Cells were then harvested and plated at
100,000 cells/well in 96-well flat bottom plates with or without Pfizer anti-CD40 at 1µg/ml.
MEK inhibitors and BRAF inhibitor were titrated 10-fold from 10µM to 0.001µM such that the
final culture concentration was 0.5% DMSO in a total volume of 200µl per well. Forty-eight
hours later, cells were harvested and transferred to a 96-well V-bottom plate. Cells were first
Fc-receptor blocked (Miltenyi) and then stained using the following antibodies (from BD
Biosciences at 1:10, 30 minutes on ice): HLA-DR,-DP,-DQ-FITC, HLA-ABC-PE, CD83-APC,
CD14-FITC, CD80-PE, and CD86-APC. Propidium iodide was included to exclude dead cells.
Samples were run on a BD FACSCaliber flow cytometer and data was analyzed using FlowJo
software (Tree Star, Inc.). Data analysis and construction of histograms demonstrated that the
frequency of cells expressing the maturation marker CD83 (Figure 5A), MHC-II (Figure 5B),
and co-stimulatory molecule CD86 (Figure 5C) was increased in cells treated with 1µM MEKi
GDC-0973 as compared to vehicle treated cells. In contrast, cell surface expression of these DC
surface activation markers in DCs treated with 1µM BRAFi was not upregulated and was similar
to vehicle treated cells. Furthermore, increasing concentrations of either MEKi G-38963 (closed
square) or MEKi GDC-0973 (closed circle) enhanced the frequency of DCs expressing these
surface markers of DC maturation and activation in concentration dependent manner (Figure
5D-5F). In contrast BRAFi (closed triangle) treatment did not enhance the anti-CD40 co-
stimulatory effect. These novel results demonstrate that enhanced maturation and activation of
DCs is specific to MEK inhibitor treatment and not due to general inhibition of the
RAS/RAF/MEK signaling pathway. Furthermore, MEKi enhanced activation of human
monocyte-derived DCs co-stimulated with anti-CD40 in a concentration dependent manner
indicating that MEKi may have an immunomodulatory effect on DCs.
Example 4: Co-treatment with MEK inhibitor and anti-PD-L1 antibodies reduced serum
levels of cytokines that promote tumor growth
Due to the novel observation that MEKi treatment enhanced T cell and DC activation
in the presence of a co-stimulator, MEKi G-38963 was used in combination with anti-PD-L1
antibodies to determine if MEKi could enhance the anti-tumor effects of anti-PD-L1 antibody
treatment and modulate cytokine levels in tumor bearing animals. The anti-PD-L1 antibody
employed in these experiments was PRO314483, LOT#59554.96, raised against human PD-L1
and recognizes both human and murine PD-L1. Briefly, 7 days after treatment, mice were
anaesthetized and bled retro-orbitally for serum. Analysis for serum levels of cytokines was
conducted using the BioRad Bio-Plex assay and it was determined that the immunosuppressive
cytokine IL-10 was significantly reduced in in vivo models for both melanoma (Figure 6A) and
colorectal (Figure 6C) tumors. IL-10 levels were decreased with anti-PD-L1 antibody or MEKi
treatment alone but were significantly reduced by co-treatment with MEKi and anti-PD-L1
antibodies. Furthermore, serum levels of the murine chemokine KC, homolog of the human
chemokine IL-8 that is known to play a role in tumor progression, was also significantly reduced
in in vivo models for both melanoma (Figure 6B) and colorectal (Figure 6D) tumors with the
most significant reduction induced by co-treatment with MEKi and anti-PD-LI antibodies.
These results indicate that combination treatment of anti-PD-L1 antibodies and MEKi inhibits
release of cytokines that promote tumor growth.
Example 5: MEK inhibition enhanced anti-tumor activity of anti-PD-L1 antibodies in
colorectal tumors in vivo
To determine if MEKi enhanced the anti-tumor effect of anti-PD-L1 antibodies, mouse
models for colorectal tumors were treated with the combination treatment. Briefly, mice were
inoculated subcutaneously with tumor cells and allowed to grow tumors. When tumor bearing
mice achieved a mean tumor volume of 200 mm3 (Figure 7A) or 450 mm3 (Figure 7B), mice
were randomly assigned to 1 of 4 treatment groups. Group 1: received 10 mg/kg of an isotype
control antibody (anti-gp120, PRO67181, PUR#20455) intraperitoneally three times a week for
3 weeks plus MCT control vehicle, orally, daily for 21 days; Group 2: received 10 mg/kg anti-
PD-L1 antibody PRO314483, LOT#59554.96 intraperitoneally three times a week for three
weeks; Group 3: received 10 mg/kg of an isotype control antibody (anti-gp120, PRO67181,
PUR#20455) intraperitoneally 3x/week x 3 plus 75 mg/kg MEKi G-38963, orally, daily for 21
days; Group 4: received 10 mg/kg of an anti-PD-L1 antibody PRO314483, LOT#59554.96
intraperitoneally three times a week for three weeks plus 75 mg/kg MEKi G-38963, orally, daily
for 21 days. Mice were monitored for tumor growth and body weight changes. Blockade of PD-
Ll with anti-PD-L1 antibody PRO314483, LOT#5944.96 either in early (Figure 7A) or in late
(Figure 7B) intervention was highly effective as a single agent therapy at preventing tumor
growth. Treatment with MEKi G-38963 was also highly effective as a single agent therapy at
preventing tumor growth either in early or in late intervention and was comparable to anti-PD-
L1 antibody treatment. Combination treatment with anti-PD-L1 antibodies and MEKi
significantly inhibited tumor growth both in early and late intervention and was significantly
more effective than anti-PD-L1 antibodies or MEKi treatment alone. Furthermore, co-treatment
at an early stage of tumor growth resulted not only in significant reduction of tumor volume but
also demonstrated a sustained response. Early intervention resulted in about a 60% complete
response that was maintained for at least 92 days. These results indicate that MEKi enhanced
the anti-tumor activity of PD-L1 blockade and therefore worked synergistically with anti-PD-LI
antibodies to inhibit tumor growth.
To further determine if MEKi enhanced the anti-tumor effect of anti-PD-L1 antibodies,
mouse models for colorectal tumors were treated with the combination treatment using a
different MEK inhibitor, MEKi GDC-0973, in two different studies.
For the first study, female BALB/c mice were inoculated subcutaneously in the
unilateral thoracic region with 100,000 CT26 murine colorectal cells in 100 µL of
HBSS:matrigel. When mice achieved a mean tumor volume of approximately 200 mm3, they
were randomly assigned to one of nine different treatment groups on experimental day 0 and
treatment was initiated on experimental day 1. Groups of 10 mice were orally given the
following in a volume of 200 µl daily for 21 days: Group 1 received MCT vehicle; Group 2
received 0.5 mg/kg GDC-0973; Group 3 received 1.0 mg/kg GDC-0973; Group 4 received 2.0
mg/kg GDC-0973; Group 5 received 3.0 mg/kg GDC-0973; Group 6 received 4.0 mg/kg GDC-
0973; Group 7 received 5.0 mg/kg GDC-0973; Group 8 received 6.0 mg/kg GDC-0973; and
Group 9 received 7.5 mg/kg GDC-0973.
For the second study, female BALB/c mice were inoculated subcutaneously in the
unilateral thoracic region with 100,000 CT26 murine colorectal cells in 100 µL of
HBSS:matrigel. When mice achieved a mean tumor volume of approximately 200 mm3, they
were randomly assigned to one of six different treatment groups on experimental day 0 and
treatment was initiated on experimental day 1. Groups of 10 mice were given the following:
Group 1 received MCT vehicle orally in 200 uL volume daily for 21 days and 10 mg/kg of an
isotype control antibody (anti-gp120, PRO67181, PUR#20455) intraperitoneally 3 times per
week; Group 2 received 7.5 mg/kg GDC-0973 orally daily for 21 days; Group 3 received 10
mg/kg anti-PD-L1 antibody PRO314483, LOT#5944.96 intraperitoneally 3 times per week;
Group 4 received 10 mg/kg anti-PD-L1 antibody PRO314483, LOT#5944.96 intraperitoneally 3
times per week and 1.0 mg/kg GDC-0973 orally daily for 21 days; Group 5 received 10 mg/kg
anti-PD-L1 antibody PRO314483, LOT#5944.96 intraperitoneally 3 times per week and 3.0
mg/kg GDC-0973 orally daily for 21 days; and Group 6 received 10 mg/kg anti-PD-L1 antibody
PRO314483, LOT#5944.96 intraperitoneally 3 times per week and 6.0 mg/kg GDC-0973 orally
daily for 21 days. The anti-PD-L1 antibody PRO314483, LOT#5944.96 was a reverse chimera,
containing the human variable region of MPDL3280A and the murine constant region of IgG2A,
with an effector-less Fc D265A/N297A substitution in the constant region.
For both studies, mice were monitored for tumor growth and body weight changes two
to three times per week for the duration of the study. For measurement of tumor growth, tumor
volume was measured using UltraCal-IV calipers (Model 54111; Fred V. Fowler Company;
Newton, MA) with length and width measurements perpendicular to one another, and tumor
volume was calculated using the equation:
Tumor Volume (mm ) = (Length x Width ) x 0.5
For measurement of body weights, mice were weighed using an Adventura Pro AV812
scale (Ohaus Corporation; Pine Brook, NJ). Percent body weight change was calculated using
the equation:
Body weight change (%) = [(Weight – Weight )/Weight ] x 100
Day new Day 0 Day 0
Data was analyzed using R, version 2.9.2 (R Development Core Team 2008; R
Foundation for Statistical Computing; Vienna, Austria), and the mixed models were fit within R
using the nlme package, version 3.1-96 (Pinheiro J et al., R package version 3. 2009, 1-96).
Plotting was performed in Prism, version 5.0b for Mac (GraphPad Software, Inc.; La Jolla, CA).
A mixed modeling approach was used to analyze the repeated measurement of tumor volumes
from the same animals over time (Pinheiro J et al., Statistics and Computing, Springer. 2010).
This approach addressed both repeated measurements and modest dropouts before study end for
reasons classifiable statistically as missing at random (MAR). The fixed effect changes in log
(volume) by time and dose are modeled as the sum of the main effects and interaction of a
natural cubic regression spline basis in time with an auto-determined natural spline basis in dose.
Intercepts and growth rates (slopes) were assumed to vary randomly by animal. Tumor growth
inhibition as a percentage of the control-treated group (%TGI) was calculated as the percentage
of the area under the fitted curve (AUC) for the respective treatment group per day in relation to
the control while the control treated mice were still on study, using the equation:
%TGI = 100 x (1 – AUC /AUC )
dose vehicles
Complete Response (CR) was defined as an individual animal whose tumor volume
fell below the Limit of Detection (LOD), at any time during the study. Partial Response (PR)
was defined as an individual animal whose tumor volume decreased by 50% of its initial tumor
volume at any time during the study. Overall Response Rate (ORR) was defined as the sum of
the complete and partial responses.
Time To Progression 5X (TTP5X) was defined as the time in days for a group’s fitted
tumor volume (based upon the mixed modeling analysis described above) to exceed 5 times the
starting volume, rounded to the nearest half day and reported as the TTP5X for that group.
Linear mixed-effects analysis was also employed to analyze the repeated measurement of body
weight changes from the same animals over time.
Treatment with increasing concentrations of MEKi GDC-0973 suppressed tumor
growth with maximal inhibition demonstrated by the 7.5 mg/kg GDC-0973 treatment group at
days post-treatment (Figure 8A, Table 2).
Table 2. Increased TGI due to increasing doses of MEKi GDC-0973
Treatment % TGI
Vehicle 0
GDC-0973, 0.5 mg/kg -8
GDC-0973, 1.0 mg/kg -16
GDC-0973, 2.0 mg/kg -21
GDC-0973, 3.0 mg/kg -4
GDC-0973, 4.0 mg/kg 27
GDC-0973, 5.0 mg/kg 55
GDC-0973, 6.0 mg/kg 72
GDC-0973, 7.5 mg/kg 87
Combination treatment with the anti-PD-L1 antibody and MEKi GDC-0973
demonstrated enhanced reduction of tumor growth for a longer period of time as compared to
treatment with anti-PD-L1 antibodies or MEKi GDC-0973 alone (Figure 8B, Table 3).
Furthermore, lower dosage concentrations of MEKi GDC-0973 (1 mg/kg, 3 mg/kg, and 6
mg/kg) were more effective at suppressing tumor growth when used in combination with the
anti-PD-L1 antibody as compared to when a higher dosage concentration of MEKi GDC-0973
was used alone (7.5 mg/kg) (Figure 8A and B, Table 3).
Table 3. Effectiveness of anti-PD-L1 antibody and MEKi GDC-0973 combination treatment
TTP5X
Treatment %TGI (days) %PR %CR
Control 0 12 0 0
anti-PD-L1 antibody 78 24 20 0
GDC-0973, 7.5 mg/kg 71 21.5 10 0
anti-PD-L1 antibody
+ GDC-0973, 1.0 mg/kg 78 30 20 10
anti-PD-L1 antibody
+ GDC-0973, 3.0 mg/kg 98 43 30 20
anti-PD-L1 antibody
+ GDC-0973, 6.0 mg/kg 106 44.5 40 20
Further studies were conducted to determine if additional MEK inhibitors (G02443714,
G02442104, and G00039805) also enhanced the anti-tumor effect of anti-PD-L1 antibodies
when used for combination treatment in a mouse model for colorectal tumors.
For combination treatment with the MEK inhibitor G02443714, female BALB/c mice
were inoculated subcutaneously in the unilateral thoracic region with 100,000 CT26 murine
colorectal cells in 100 µL of HBSS:matrigel. When mice achieved a mean tumor volume of
approximately 200 mm , they were randomly assigned to one of four different treatment groups
on experimental day 0 and treatment was initiated on experimental day 1. Groups of 10 mice
were given the following: Group 1 received MCT vehicle orally in 200 uL volume daily for 21
days and 10 mg/kg of an isotype control antibody (anti-gp120, PRO67181, PUR#20455)
intraperitoneally 3 times per week; Group 2 received 25 mg/kg G02443714 orally daily for 21
days; Group 3 received 10 mg/kg anti-PD-L1 antibody PRO314483, LOT#5944.96
intraperitoneally 3 times per week; and Group 4 received 10 mg/kg anti-PD-L1 antibody
PRO314483, LOT#5944.96 intraperitoneally 3 times per week and 25 mg/kg G02443714 orally
daily for 21 days. G02443714 as well as oral vehicle (MCT) were dosed orally by gavage four
hours prior to administration of anti-PD-L1 and/or isotype control antibody.
For combination treatment with the MEK inhibitor G02442104, female BALB/c mice
were inoculated subcutaneously in the unilateral thoracic region with 100,000 CT26 murine
colorectal cells in 100 µL of HBSS:matrigel. When mice achieved a mean tumor volume of
approximately 200 mm , they were randomly assigned to one of four different treatment groups
on experimental day 0 and treatment was initiated on experimental day 1. Groups of 10 mice
were given the following: Group 1 received MCT vehicle orally in 200 uL volume daily for 21
days and 10 mg/kg of an isotype control antibody (anti-gp120, PRO67181, PUR#20455)
intraperitoneally 3 times per week; Group 2 received 25 mg/kg G02442104 orally daily for 21
days; Group 3 received 10 mg/kg anti-PD-L1 antibody PRO314483, LOT#5944.96
intraperitoneally 3 times per week; and Group 4 received 10 mg/kg anti-PD-L1 antibody
PRO314483, LOT#5944.96 intraperitoneally 3 times per week and 25 mg/kg G02442104 orally
daily for 21 days. G02442104 as well as oral vehicle (MCT) were dosed orally by gavage four
hours prior to administration of anti-PD-L1 and/or isotype control antibody.
For combination treatment with the MEK inhibitor G00039805, female BALB/c mice
were inoculated subcutaneously in the unilateral thoracic region with 100,000 CT26 murine
colorectal cells in 100 µL of HBSS:matrigel. When mice achieved a mean tumor volume of
approximately 200 mm3, they were randomly assigned to one of four different treatment groups
on experimental day 0 and treatment was initiated on experimental day 1. Groups of 10 mice
were given the following: Group 1 received MCT vehicle orally in 200 uL volume daily for 21
days and 10 mg/kg of an isotype control antibody (anti-gp120, PRO67181, PUR#20455)
intraperitoneally 3 times per week; Group 2 received 100 mg/kg G00039805 orally daily for 21
days; Group 3 received 10 mg/kg anti-PD-L1 antibody PRO314483, LOT#5944.96
intraperitoneally 3 times per week; and Group 4 received 10 mg/kg anti-PD-L1 antibody
PRO314483, LOT#5944.96 intraperitoneally 3 times per week and 100 mg/kg G00039805 orally
daily for 21 days. G00039805 as well as oral vehicle (MCT) were dosed orally by gavage four
hours prior to administration of anti-PD-L1 and/or isotype control antibody.
For all three combination studies with G02443714, G02442104, or G00039805, mice
were monitored for tumor growth and body weight changes two to three times per week for the
duration of the study. For measurement of tumor growth, tumor volume was measured using
UltraCal-IV calipers (Model 54111; Fred V. Fowler Company; Newton, MA) with length
and width measurements perpendicular to one another, and tumor volume was calculated using
the equation:
Tumor Volume (mm ) = (Length x Width ) x 0.5
For measurement of body weights, mice were weighed using an Adventura Pro AV812
scale (Ohaus Corporation; Pine Brook, NJ). Percent body weight change was calculated using
the equation:
Body weight change (%) = [(Weight – Weight )/Weight ] x 100
Day new Day 0 Day 0
Data was analyzed using R, version 2.9.2 (R Development Core Team 2008; R
Foundation for Statistical Computing; Vienna, Austria), and the mixed models were fit within R
using the nlme package, version 3.1-96 (Pinheiro J et al., R package version 3. 2009, 1-96).
Plotting was performed in Prism, version 5.0b for Mac (GraphPad Software, Inc.; La Jolla, CA).
A mixed modeling approach was used to analyze the repeated measurement of tumor volumes
from the same animals over time (Pinheiro J et al., Statistics and Computing, Springer. 2010).
This approach addressed both repeated measurements and modest dropouts before study end for
reasons classifiable statistically as missing at random (MAR). The fixed effect changes in log
(volume) by time and dose are modeled as the sum of the main effects and interaction of a
natural cubic regression spline basis in time with an auto-determined natural spline basis in dose.
Intercepts and growth rates (slopes) were assumed to vary randomly by animal. Tumor growth
inhibition as a percentage of the control-treated group (%TGI) was calculated as the percentage
of the area under the fitted curve (AUC) for the respective treatment group per day in relation to
the control while the control treated mice were still on study, using the equation:
%TGI = 100 x (1 – AUCdose/AUCvehicles)
Complete Response (CR) was defined as an individual animal whose tumor volume
fell below the Limit of Detection (LOD), at any time during the study. Partial Response (PR)
was defined as an individual animal whose tumor volume decreased by 50% of its initial tumor
volume at any time during the study. Overall Response Rate (ORR) was defined as the sum of
the complete and partial responses.
Time To Progression 5X (TTP5X) was defined as the time in days for a group’s fitted
tumor volume (based upon the mixed modeling analysis described above) to exceed 5 times the
starting volume, rounded to the nearest half day and reported as the TTP5X for that group.
Linear mixed-effects analysis was also employed to analyze the repeated measurement of body
weight changes from the same animals over time.
Combination treatment with the anti-PD-L1 antibody and G02443714 resulted in
enhanced reduction of tumor growth for a longer period of time as compared to treatment with
anti-PD-L1 antibodies or G02443714 alone with a 20% partial response observed at 18 days
(Figure 9). Combination treatment with the anti-PD-L1 antibody and G02442104 also resulted in
enhanced reduction of tumor growth for a longer period of time as compared to treatment with
anti-PD-L1 antibodies or MEKi G02442104 alone with a 40% partial response and 10%
complete response observed at 37.5 days (Figure 10). In addition, combination treatment with
the anti-PD-L1 antibody and G00039805 resulted in enhanced reduction of tumor growth for a
longer period of time as compared to treatment with anti-PD-L1 antibodies or MEKi G00039805
alone with a 30% partial response observed at 22 days (Figure 11). Altogether these results
demonstrate that a variety of MEK inhibitors can enhance the anti-tumor activity of anti-PD-LI
antibodies to inhibit tumor growth.
Example 6: MEK inhibition enhanced anti-tumor activity of anti-PD-L1 antibodies in
melanoma tumors in vivo
To determine if MEKi enhanced the anti-tumor effect of anti-PD-L1 antibodies, mouse
models for melanoma tumors were treated with the combination treatment. Briefly, mice were
inoculated subcutaneously with tumor cells and allowed to grow tumors. When tumor bearing
mice achieved a mean tumor volume of 100-200 mm3, mice were randomly assigned to 1 of 4
treatment groups. Group 1: received 10 mg/kg of an isotype control antibody (anti-gp120,
PRO67181, PUR#20455) intraperitoneally three times a week for three weeks plus MCT control
vehicle, orally, daily for 21 days; Group 2: received 10 mg/kg anti-PD-L1 antibody PRO314483,
LOT#59554.96 intraperitoneally three times a week for three weeks; Group 3: received 10
mg/kg of an isotype control antibody (anti-gp120, PRO67181, PUR#20455) intraperitoneally
three times a week for three weeks plus 75 mg/kg MEKi G-38963, orally, daily for 21 days;
Group 4: received 10 mg/kg of an anti-PD-L1 antibody PRO314483, LOT#59554.96
intraperitoneally three times a week for three weeks plus 75 mg/kg MEKi G-38963, orally, daily
for 21 days. Mice were monitored for tumor growth and body weight changes. Blockade of PD-
Ll with anti-PD-L1 antibody PRO314483, LOT#59554.96 in Cloudman S91 (Figure 12)
melanoma tumors was effective as a single agent therapy at preventing tumor growth.
Treatment with MEKi G-38963 was also highly effective as a single agent therapy at preventing
tumor growth (Figure 12) and was comparable to anti-PD-L1 antibody treatment. Combination
treatment with anti-PD-L1 antibodies and MEKi significantly inhibited tumor growth in both
melanoma cell lines. In contrast, Temodar, a chemotherapeutic agent, when used in combination
with anti-PD-L1 antibodies inhibited the anti-tumor activity of anti-PD-L1 antibodies (Figure
13). Similar results were obtained when an antibody that blocks the T cell OX40 co-stimulatory
molecule was used in combination with the MEK inhibitor G-38963 (Figure 14). These results
indicate that MEKi specifically enhanced the anti-tumor activity of PD-L1 blockade and
therefore worked synergistically with anti-PD-LI antibodies to inhibit melanoma tumor growth.
Example 7: MEK inhibitor increased activation of dendritic cells independently of PDL1
antibody activity
Previous studies have indicated that MEK inhibition can augment immune function by
downregulation of surface PD-L1 suggesting that the effects of MEKi were mediated via
alterations in PD-L1 expression. To determine if enhanced tumor immunogenicity is due to
dependency of PD-L1 expression upon MEK activation, activation of dendritic cells was
compared when treated with MEKi GDC-0973 alone, anti-PD-L1 antibodies (a chimeric
antibody composed of variable regions of MPDL3280A fused to mouse IgG2a constant
sequences that contain an Fc mutation to prevent effective binding to Fcgamma receptors) alone
or MEKi in combination with anti-PD-L1 antibodies. Briefly, mouse bone marrow cells were
isolated and seeded at 2x10 per 10ml total volume per 10cm non-tissue culture treated dishes
with 40ng/ml mouse GM-CSF for 7 days. Fresh media was half-exchanged every 2-3 days.
Culture medium was RPMI-1640 with 10% fetal bovine serum, 20µM HEPES, 55µM 2-
mercaptoethanol, 50µg/ml gentamicin, and 1:100 dilutions of the following supplements from
Gibco: Gluta-MAX, sodium pyruvate, penicillin/streptomycin, and non-essential amino acids.
On day 7 all cells were harvested and washed, then seeded at 100,000 cells/well in a 96-well
flat-bottom plate. MEK inhibitor GDC-0973 was added at a final concentration of 1µM, anti-
PDL1 human/mouse reverse chimera or anti-Ragweed mouse IgG2a isotype control (Genentech
PUR 22251) were added at 10µg/ml. Prior to adding to cells for a final concentration of 1µg/ml
each, anti-CD40 clone FGK-45 (Genentech lot 68020-62) was crossed-linked with goat anti-Rat
IgG Fc-gamma-receptor (Jackson ImmunoResearch) at room temperature for one hour. After 48
hours of stimulation, cells were harvested and transferred to a 96-well V-bottom plate. Samples
were first Fc receptor blocked (purified anti-CD16/CD32 from BD Biosciences, 5µg/ml) and
then stained with I-A/I-E-FITC, H-2Db/H-2Kb-biotin (followed by streptavidin-PE), CD11c-
APC, CD86-FITC, and CD80-PE (all from BD Biosciences). Propidium iodide was included to
exclude dead cells. Samples were run on a BD FACSCaliber flow cytometer and data was
analyzed using FlowJo software (Tree Star, Inc.). Treatment with functionally blocking anti-
PD-L1 antibodies alone modestly increased DC surface expression of MHC-I (Figure 15A)
however it did not induce expression of DC surface activation markers MHC-II (Figure 15B),
CD80 (Figure 15C), or CD86 (Figure 15D). In contrast MEKi treatment enhanced MHC-II,
CD80, and CD86 as well as MHC-I expression. Interestingly, combination treatment of MEKi
and anti-PD-LI antibodies did not alter DC surface activation markers as compared to MEKi
alone. Similar results were obtained with the addition of the co-stimulatory anti-CD40
antibodies (Figure 15E-H). These novel findings indicate that MEKi induced activation of DCs
independently of its effect on PD-L1 expression. Altogether these results demonstrate that
MEKi increased tumor immunogenicity by mechanisms unique from anti-PDL and provide
support for combining MEKi and PD-L1 blockade for optimal enhancement of anti-tumor
immunity.
Example 8a: MEK Assay (MEK activity assay)
Constitutively activated human mutant MEK1 expressed in insect cells is used as
source of enzymatic activity at a final concentration in the kinase assay of 62.5nM.
The assay is carried out for 30 minutes in the presence of 50µM ATP using
recombinant GST-ERK1 produced in E.Coli as substrate. Phosphorylation of the substrate is
detected and quantified using HTRF reagents supplied by Cisbio. These consist of an anti-GST
antibody conjugated to allophycocyanin (XL665) and an anti-phospho (Thr202/Tyr204) ERK
antibody conjugated to europium-cryptate. The anti-phospho antibody recognises ERK1 dually
phosphorylated on Thr202 and Tyr204. When both antibodies are bound to ERK1 (i.e. when the
substrate is phosphorylated), energy transfer from the cryptate to the allophycocyanin occurs
following excitation at 340nm, resulting in fluorescence being emitted that is proportional to the
amount of phosphorylated substrate produced. Fluorescence is detected using a multiwell
fluorimeter.
Compounds are diluted in DMSO prior to addition to assay buffer and the final DMSO
concentration in the assay is 1%.
The IC is defined as the concentration at which a given compound achieves 50%
inhibition of control. IC values are calculated using the XLfit software package (version
2.0.5).
Example 8b: MEK Assay (MEK activity assay)
Constitutively activated human mutant MEK1 expressed in insect cells is used as
source of enzymatic activity at a final concentration in the kinase assay of 15nM.
The assay is carried out for 30 minutes in the presence of 50µM ATP using
recombinant GST-ERK1 produced in E.Coli as substrate. Phosphorylation of the substrate is
detected and quantified using HTRF reagents supplied by Cisbio. These consist of an anti-GST
antibody conjugated to allophycocyanin (XL665) and an anti-phospho (Thr202/Tyr204) ERK
antibody conjugated to europium-cryptate. These are used at a final concentration of 4mg/ml and
0.84mg/ml respectively. The anti-phospho antibody recognises ERK1 dually phosphorylated on
Thr202 and Tyr204. When both antibodies are bound to ERK1 (i.e. when the substrate is
phosphorylated), energy transfer from the cryptate to the allophycocyanin occurs following
excitation at 340nm, resulting in fluorescence being emitted that is proportional to the amount of
phosphorylated substrate produced. Fluorescence is detected using a multiwell fluorimeter.
Compounds are diluted in DMSO prior to addition to assay buffer and the final DMSO
concentration in the assay is 1%.
The IC is defined as the concentration at which a given compound achieves 50%
inhibition of control. IC values are calculated using the XLfit software package (version 2.0.5).
All patents, patent applications, documents, and articles cited herein are herein
incorporated by reference in their entireties.
In this specification where reference has been made to patent specifications, other
external documents, or other sources of information, this is generally for the purpose of
providing a context for discussing the features of the invention. Unless specifically stated
otherwise, reference to such external documents is not to be construed as an admission that such
documents, or such sources of information, in any jurisdiction, are prior art, or form part of the
common general knowledge in the art.
Claims (103)
1. Use of a PD-1 axis binding antagonist and a MEK inhibitor in the manufacture of a medicament for treating or delaying progression of cancer in an individual.
2. The use of claim 1, wherein the medicament is for simultaneous, separate or sequential use.
3. The use of claim 1 or claim 2, wherein the medicament comprises a first medicament comprising the PD-1 axis binding antagonist and a second medicament comprising the MEK inhibitor.
4. Use of a PD-1 axis binding antagonist in the manufacture of a medicament for treating or delaying progression of cancer in an individual, wherein the PD-1 axis binding agent is for use in combination with a MEK inhibitor.
5. Use of a MEK inhibitor in the manufacture of a medicament for treating or delaying progression of cancer in an individual, wherein the MEK inhibitor is for use in combination with a PD-1 axis binding antagonist.
6. The use of any one of claims 1-5, wherein the PD-1 axis binding antagonist is selected from the group consisting of a PD-1 binding antagonist, a PD-L1 binding antagonist and a PD- L2 binding antagonist.
7. The use of claim 6, wherein the PD-1 axis binding antagonist is a PD-1 binding antagonist.
8. The use of claim 7, wherein the PD-1 binding antagonist inhibits the binding of PD-1 to its ligand binding partners.
9. The use of claim 8, wherein the PD-1 binding antagonist inhibits the binding of PD-1 to PD-L1.
10. The use of claim 8, wherein the PD-1 binding antagonist inhibits the binding of PD-1 to PD-L2.
11. The use of claim 8, wherein the PD-1 binding antagonist inhibits the binding of PD-1 to both PD-L1 and PD-L2.
12. The use of claim 8, wherein the PD-1 binding antagonist is an antibody.
13. The use of claim 12, wherein the PD-1 binding antagonist is MDX-1106.
14. The use of claim 12, wherein the PD-1 binding antagonist is Merck 3745.
15. The use of claim 12, wherein the PD-1 binding antagonist is CT-011.
16. The use of claim 8, wherein the PD-1 binding antagonist is AMP-224.
17. The use of claim 6, wherein the PD-1 axis binding antagonist is a PD-L1 binding antagonist.
18. The use of claim 17, wherein the PD-L1 binding antagonist inhibits the binding of PD-L1 to PD-1.
19. The use of claim 17, wherein the PD-L1 binding antagonist inhibits the binding of PD-L1 to B7-1.
20. The use of claim 17, wherein the PD-L1 binding antagonist inhibits the binding of PD-L1 to both PD-1 and B7-1.
21. The use of claim 17, wherein the PD-L1 binding antagonist is an antibody.
22. The use of claim 21, wherein the PD-L1 binding antagonist is selected from the group consisting of: MPDL3280A, and MDX-1105.
23. The use of claim 21, wherein the PD-L1 binding antagonist is anti-PD-L1 antibody YW243.55.S70, where the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:20 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:21.
24. The use of claim 21, wherein the antibody comprises a heavy chain comprising HVR-H1 sequence of SEQ ID NO:15, HVR-H2 sequence of SEQ ID NO:16, and HVR-H3 sequence of SEQ ID NO:3; and a light chain comprising HVR-L1 sequence of SEQ ID NO:17, HVR-L2 sequence of SEQ ID NO:18, and HVR-L3 sequence of SEQ ID NO:19.
25. The use of claim 21, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:24 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:21.
26. The use of claim 6, wherein the PD-1 axis binding antagonist is a PD-L2 binding antagonist.
27. The use of claim 26, wherein the PD-L2 binding antagonist is an antibody.
28. The use of claim 26, wherein the PD-L2 binding antagonist is an immunoadhesin.
29. The use of any one of claims 1-28, wherein the MEK inhibitor is a competitive inhibitor of MEK.
30. The use of any one of claims 1-28, wherein the MEK inhibitor is more selective against an activating KRAS mutation.
31. The use of any one of claims 1-28, wherein the MEK inhibitor is an allosteric inhibitor of MEK.
32. The use of any one of claims 1-28, wherein the MEK inhibitor is more selective against an activating BRAF mutation.
33. The use of any one of claims 1-28, wherein the MEK inhibitor is a compound of the formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein provisions (i), (ii), (iii) or (iv) applies: (i): A is arylene optionally substituted with one, two, three or four groups selected from R10, R12, R14, R16, and R19, where R10, R12, R14 and R16 are independently hydrogen, alkyl, alkenyl, alkynyl, halo, haloalkoxy, hydroxy, alkoxy, amino, alkylamino, dialkylamino, haloalkyl, -NHS(O)2R8, -CN, -C(O)R8, -C(O)OR8, -C(O)NR8R8’ and -NR8C(O)R8’ and where R19 is hydrogen, alkyl, or alkenyl; X is alkyl, halo, haloalkyl, or haloalkoxy; R1, R2, R3, R4, R5 and R6 are independently hydrogen, halo, nitro, -NR8R8’, - OR8, -NHS(O)2R8, -CN, -S(O)mR8, -S(O)2NR8R8’, -C(O)R8, -C(O)OR8, -C(O)NR8R8’, -NR8C(O)OR8’, -NR8C(O)NR8’R8”, -NR8C(O)OR8’, -NR8C(O)R8’, -CH2N(R25)(NR25aR25b), -CH2NR25C(=NH)(NR25aR25b), -CH2NR25C(=NH)(N(R25a)(NO2)), -CH2NR25C(=NH)(N(R25a)(CN)), -CH2NR25C(=NH)(R25), -CH2NR25C(NR25aR25b)=CH(NO2), alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, or heterocycloalkyl; where the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, and heterocycloalkyl are independently optionally substituted with one, two, three, four, five, six or seven groups independently selected from halo, alkyl, haloalkyl, nitro, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, -OR8, -NR8R8’, -NR8S(O)2R9, -CN, -S(O)mR9, -C(O)R8, -C(O)OR8, -C(O)NR8R8’, -NR8C(O)NR8’R8”, -NR8C(O)OR8’ and -NR8C(O)R8’; or one of R1 and R2 together with the carbon to which they are attached, R3 and R4 together with the carbon to which they are attached, and R5 and R6 together with the carbon to which they are attached form C(O) or C(=NOH); m is 0, 1, or 2; R7 is hydrogen, halo or alkyl; each R8, R8’ and R8” is independently selected from hydrogen, hydroxy, optionally substituted alkoxy, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl; where the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are independently optionally substituted with one, two three, four, or five groups independently selected from alkyl, halo, hydroxy, hydroxyalkyl, optionally substituted alkoxy, alkoxyalkyl, haloalkyl, carboxy, alkoxycarbonyl, alkenyloxycarbonyl, optionally substituted cycloalkyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted aryl, optionally substituted aryloxy, optionally substituted aryloxycarbonyl, optionally substituted arylalkyl, optionally substituted arylalkyloxy, optionally substituted arylalkyloxycarbonyl, nitro, cyano, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, -S(O)R31 (where n is 0, 1, or 2 and R31 is optionally substituted alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl), -NR34SO2R34a (where R34 is hydrogen or alkyl and R34a is alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl), -SO2NR35R35a (where R35 is hydrogen or alkyl and R35a is alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl), - NR32C(O)R32a (where R32 is hydrogen or alkyl and R32a is alkyl, alkenyl, alkoxy, or cycloalkyl), -NR30R30’ (where R30 and R30’ are independently hydrogen, alkyl, or hydroxyalkyl), and -C(O)NR33R33a (where R33 is hydrogen or alkyl and R33a is alkyl, alkenyl, alkynyl, or cycloalkyl); and each R9 is independently selected from alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl; where the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are independently optionally susbstituted with one, two, three, four, or five groups selected from halo, hydroxy, alkyl, haloalkyl, haloalkoxy, amino, alkylamino, and dialkylamino; (ii): A is heteroarylene optionally substituted with one, two, three, or four groups selected from R10, R12, R14, R16 and R19 where R10, R12, R14 and R16 are independently hydrogen, alkyl, alkenyl, alkynyl, halo, haloalkoxy, hydroxy, alkoxy, cyano, amino, alkylamino, dialkylamino, haloalkyl, alkylsulfonylamino, alkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, alkenyloxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, or alkylcarbonylamino; where R19 is hydrogen, alkyl, or alkenyl; and where each alkyl and alkenyl, either alone or as part of another group within R10, R12, R14, R16, and R19, is independently optionally substituted with halo, hydroxy, or alkoxy; X is alkyl, halo, haloalkyl, or haloalkoxy; R1, R2, R3, R4, R3 and R6 are independently hydrogen, halo, nitro, -NR8R8’, - OR8, -NHS(O)2R8, -CN, -S(O)mR8, -S(O)2NR8R8’, -C(O)R8, -C(O)OR8, -C(O)NR8R8’, -NR8C(O)OR8’, -NR8C(O)NR8’R8”, -NR8C(O)OR8’, -NR8C(O)R8’, -CH2N(R25)(NR25aR25b), -CH2NR25C(=NH)(NR25aR25b), -CH2NR25C(=NH)(N(R25a)(NO2)), -CH2NR25C(NH)(N(R25a)(CN)), -CH2NR25C(=NH)(R25), -CH2NR25C(NR25aR25b)=CH(NO2), alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, or heterocycloalkyl, where the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, and heterocycloalkyl are independently optionally substituted with one, two, three, four, five, six or seven groups independently selected from halo, alkyl, haloalkyl, nitro, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, -OR8, -NR8R8’, -NR8S(O)2R9, -CN, -S(O)mR9, -C(O)R8, -C(O)OR8, -C(O)NR8R8’, -NR8C(O)NR8’R8”, -NR8C(O)OR8’ and -NR8C(O)R8’; or one of R1 and R2 together with the carbon to which they are attached, R3 and R4 together with the carbon to which they are attached, and R5 and R6 together with the carbon to which they are attached form C(O) or C(=NOH); m is 1 or 2; R7 is hydrogen, halo or alkyl; and each R8, R8’ and R8” is independently selected from hydrogen, hydroxy, optionally substituted alkoxy, alkyl, haloalkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, where the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are independently optionally substituted with one, two three, four, or five groups independently selected from alkyl, halo, hydroxy, hydroxyalkyl, optionally substituted alkoxy, alkoxyalkyl, haloalkyl, carboxy, carboxy ester, nitro, cyano, - S(O)nR31 (where n is 0, 1, or 2 and R31 is optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl), -NR36S(O)2R36a (where R36 is hydrogen, alkyl, or alkenyl and R36a is alkyl, alkenyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl), -S(O)2NR37R37a (where R37 is hydrogen, alkyl, or alkenyl and R37a is alkyl, alkenyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl), optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted aryloxy, optionally substituted arylalkyloxy, optionally substituted heteroaryl, -NHC(O)R32 (where R32 is alkyl, alkenyl, alkoxy, or cycloalkyl) and -NR30R30’ (where R30 and R30’ are independently hydrogen, alkyl, or hydroxyalkyl), and -C(O)NHR33 (where R33 is alkyl, alkenyl, alkynyl, or cycloalkyl); (iii): A is , where R10 is hydrogen, alkyl, alkenyl, alkynyl, halo, haloalkoxy, hydroxy, alkoxy, amino, alkylamino, dialkylamino, haloalkyl, -NHS(O)2R8, -CN, -C(O)R8, -C(O)OR8, -C(O)NR8R8’ and -NR8C(O)R8’; R10a is hydrogen, alkyl, or alkenyl; and Y1 is =CH- or =N-; X is alkyl, halo, haloalkyl, or haloalkoxy; R1, R2, R3, R4, R5 and R6 are independently hydrogen, halo, nitro, -NR8R8’, - OR8, -NHS(O)2R8, -CN, -S(O)mR8, -S(O)2NR8R8’, -C(O)R8, -C(O)OR8, -C(O)NR8R8’, -NR8C(O)OR8’, -NR8C(O)NR8’R8”, -NR8C(O)OR8’, -NR8C(O)R8’, -CH2N(R25)NR25aR25b), -CH2NR25C(=NH)(NR25aR25b), -CH2NR25C(=NH)(N(R25a)(NO2)), -CH2NR25C(=NH)(N(R25a)(CN)), -CH2NR25C(=NH)(R25), -CH2NR25C(NR25aR25b)=CH(NO2), alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, or heterocycloalkyl, where the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, and heterocycloalkyl are independently optionally substituted with one, two, three, four, five, six or seven groups independently selected from halo, alkyl, haloalkyl, nitro, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, -OR8, -NR8R8’, -NR8S(O)2R9, -CN, -S(O)mR9, -C(O)R8, -C(O)OR8, - C(O)NR8R8’, -NR8C(O)NR8’R8”, -NR8C(O)OR8’ and -NR8C(O)R8’; or one of R1 and R2 together with the carbon to which they are attached, R3 and R4 together with the carbon to which they are attached, and R5 and R6 together with the carbon to which they are attached form C(O) or C(NOH); m is 1 or 2; R7 is hydrogen, halo or alkyl; and each R8, R8’ and R8” is independently selected from hydrogen, hydroxy, optionally substituted alkoxy, alkyl, haloalkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, where the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are independently optionally substituted with one, two three, four, or five groups independently selected from alkyl, halo, hydroxy, hydroxyalkyl, optionally substituted alkoxy, alkoxyalkyl, haloalkyl, carboxy, carboxy ester, nitro, cyano, - S(O)nR31 (where n is 0, 1, or 2 and R31 is optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl), -NR36S(O)2R36a (where R36 is hydrogen, alkyl, or alkenyl and R36a is alkyl, alkenyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl), -S(O)2NR37R37a (where R37 is hydrogen, alkyl, or alkenyl and R37a is alkyl, alkenyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl), optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted aryloxy, optionally substituted arylalkyloxy, optionally substituted heteroaryl, -NHC(O)R32 (where R32 is alkyl, alkenyl, alkoxy, or cycloalkyl) and -NR30R30’ (where R30 and R30’ are independently hydrogen, alkyl, or hydroxyalkyl), and -C(O)NHR33 (where R33 is alkyl, alkenyl, alkynyl, or cycloalkyl); (iv): A is or , where R40 and R40a are independently hydrogen or alkyl; X is alkyl, halo, haloalkyl, or haloalkoxy; R1, R2, R3, R4, R5 and R6 are independently hydrogen, halo, nitro, -NR8R8’, - OR8, -NHS(O)2R8, -CN, -S(O)mR8, -S(O)2NR8R8’, -C(O)R8, -C(O)OR8, -C(O)NR8R8’, -NR8C(O)OR8’, -NR8C(O)NR8’R8”, -NR8C(O)OR8’, -NR8C(O)R8’, -CH2N(R25)(NR25aR25b), -CH2NR25C(=NH)(NR25aR25b), -CH2NR25C(=NH)(N(R25a)(NO2)), -CH2NR25C(=NH)(N(R25a)(CN)), -CH2NR25C(=NH)(R25), -CH2NR25C(NR25aR25b)=CH(NO2), alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, or heterocycloalkyl, where the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, and heterocycloalkyl are independently optionally substituted with one, two, three, four, five, six or seven groups independently selected from halo, alkyl, haloalkyl, nitro, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, -OR8, - NR8R8’, -NR8S(O)2R9, -CN, -S(O)mR9, -C(O)R8, -C(O)OR8, - C(O)NR8R8’, -NR8C(O)NR8’R8”, -NR8C(O)OR8’ and -NR8C(O)R8’; or one of R1 and R2 together with the carbon to which they are attached, R3 and R4 together with the carbon to which they are attached, and R5 and R6 together with the carbon to which they are attached form C(O) or C(NOH); m is 1 or 2; R7 is hydrogen, halo or alkyl; and R8, R8’ and R8” are independently selected from hydrogen, hydroxy, optionally substituted alkoxy, alkyl, haloalkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, where the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are independently optionally substituted with one, two three, four, or five groups independently selected from alkyl, halo, hydroxy, hydroxyalkyl, optionally substituted alkoxy, alkoxyalkyl, haloalkyl, carboxy, carboxy ester, nitro, cyano, -S(O)nR31 (where n is 0, 1, or 2 and R31 is optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl), -NR36S(O)2R36a (where R36 is hydrogen, alkyl, or alkenyl and R36a is alkyl, alkenyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl), -S(O)2NR37R37a (where R37 is hydrogen, alkyl, or alkenyl and R37a is alkyl, alkenyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl), optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted aryloxy, optionally substituted arylalkyloxy, optionally substituted heteroaryl, -NHC(O)R32 (where R32 is alkyl, alkenyl, alkoxy, or cycloalkyl) and -NR30R30’ (where R30 and R30’ are independently hydrogen, alkyl, or hydroxyalkyl), and -C(O)NHR33 (where R33 is alkyl, alkenyl, alkynyl, or cycloalkyl).
34. The use of any one of claims 1-28, wherein the MEK inhibitor is a compound of the formula (II): (II) or a pharmaceutically acceptable salt or solvate thereof, wherein: Z is CR or N; Z is CR or N; Z is CR or N; Z is CR or N; 1 2 3 4 where one or two of Z , Z , Z , and Z are N; 1 2 3 4 R , R , R and R are independently selected from H, halo, CN, CF , -OCF , -NO , 3 3 2 14 15 11 14 15 11 14 15 11 12 -(CR R ) C(=Y)R , -(CR R ) C(=Y)OR , -(CR R ) C(=Y)NR R , n n n 14 15 11 12 14 15 11 14 15 11 14 15 12 11 -(CR R ) NR R , -(CR R ) OR , -(CR R ) SR , -(CR R ) NR C(=Y)R , n n n n 14 15 12 11 14 15 13 11 12 14 15 12 11 -(CR R ) NR C(=Y)OR , -(CR R ) NR C(=Y)NR R , -(CR R ) NR SO R , n n n 2 14 15 11 14 15 11 14 15 11 12 -(CR R ) OC(=Y)R , -(CR R ) OC(=Y)OR , -(CR R ) OC(=Y)NR R , n n n 14 15 11 14 15 11 12 14 15 11 12 -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y)(OR )(OR ), -(CR R ) OP(OR )(OR ), n 2 n n 14 15 11 14 15 11 14 15 11 12 14 15 11 -(CR R ) S(O)R , -(CR R ) S(O) R , -(CR R ) S(O) NR R , -(CR R ) S(O)(OR ), n n 2 n 2 n 14 15 11 14 15 11 14 15 11 -(CR R ) S(O) (OR ), -(CR R ) SC(=Y)R , -(CR R ) SC(=Y)OR , n 2 n n 14 15 11 12 -(CR R ) SC(=Y)NR R , C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, n 1 12 2 8 2 8 heterocyclyl, aryl, and heteroaryl; 1 11 W is or ; R and R are independently selected from H or C -C alkyl; 1 12 1 11 11 11 12 11 11 1 11 X is selected from R , -OR , -NR R , -S(O)R , and -S(O) R ; when X is R or 11 11 11 1 5 -OR , R or -OR of X and -R are optionally taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated or unsaturated ring having 0-2 additional heteroatoms selected from O, S and N, wherein said ring is optionally substituted with one or more groups selected from halo, CN, CF , -OCF , -NO , oxo, -Si(C -C alkyl), 3 3 2 1 6 19 20 16 19 20 16 19 20 16 17 -(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR , -(CR R ) C(=Y’)NR R , n n n 19 20 16 17 19 20 16 19 20 16 19 20 16 17 -(CR R )nNR R , -(CR R )nOR , -(CR R )n-SR , -(CR R )n NR C(=Y’)R , 19 20 16 17 19 20 18 16 17 19 20 17 16 -(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R , -(CR R ) NR SO R , n n n 2 19 20 16 19 20 16 19 20 16 17 -(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR , -(CR R ) OC(=Y’)NR R , n n n 19 20 16 19 20 16 17 19 20 16 17 -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ), -(CR R ) OP(OR )(OR ), n 2 n n 19 20 16 19 20 16 19 20 16 17 19 20 16 -(CR R ) S(O)R , -(CR R ) S(O) R , -(CR R ) S(O) NR R , -(CR R ) S(O)(OR ), n n 2 n 2 n 19 20 16 19 20 16 19 20 16 19 20 -(CR R ) S(O) (OR ), -(CR R ) SC(=Y’)R , -(CR R ) SC(=Y’)OR , -(CR R ) n 2 n n n 16 17 21 SC(=Y’)NR R , and R ; X is selected from carbocyclyl, heterocyclyl, aryl, and heteroaryl; 11 12 13 R , R and R are independently H, C -C alkyl, C -C alkenyl, C -C alkynyl, 1 12 2 8 2 8 carbocyclyl, heterocyclyl, aryl, or heteroaryl, 11 12 or R and R together with the nitrogen to which they are attached form a 3-8 membered saturated, unsaturated or aromatic ring having 0-2 heteroatoms selected from O, S and N, wherein said ring is optionally substituted with one or more groups selected from halo, CN, CF , -OCF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), -S(C -C alkyl), -NH , 3 3 2 1 6 1 6 1 6 2 -NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C alkyl), 1 6 1 6 2 2 1 6 2 2 1 6 -C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C alkyl), 2 1 6 1 6 2 1 6 1 6 -NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), -SO NH , 1 6 2 1 6 1 6 2 1 6 2 2 -SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl), 2 1 6 2 1 6 2 2 1 6 -OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C 1 6 2 1 6 1 6 1 6 alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) , 2 1 6 1 6 1 6 1 6 2 -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C 1 6 1 6 2 1 6 1 6 alkyl)C(O)O(C -C alkyl); 14 15 R and R are independently selected from H, C -C alkyl, aryl, carbocyclyl, 1 12 heterocyclyl, and heteroaryl; m and n are independently selected from 0, 1, 2, 3, 4, 5, or 6; Y is independently O, NR , or S; wherein each said alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl 1 2 3 4 5 6 1 2 11 12 13 14 15 of R , R , R , R , R , R , X , X , R , R , R , R , and R is independently optionally substituted with one or more groups independently selected from halo, CN, CF , -OCF , -NO , 3 3 2 19 20 16 19 20 16 oxo, -Si(C -C alkyl), -(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR , 1 6 n n 19 20 16 17 19 20 16 17 19 20 16 19 20 16 -(CR R ) C(=Y’)NR R , -(CR R ) NR R , -(CR R ) OR , -(CR R ) -SR , n n n n 19 20 16 17 19 20 16 17 19 20 18 16 17 -(CR R ) NR C(=Y’)R , -(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R , n n n 19 20 17 16 19 20 16 19 20 16 -(CR R ) NR SO R , -(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR , n 2 n n 19 20 16 17 19 20 16 19 20 16 17 -(CR R ) OC(=Y’)NR R , -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ), n n 2 n 19 20 16 17 19 20 16 19 20 16 -(CR R ) OP(OR )(OR ), -(CR R ) S(O)R , -(CR R ) S(O) R , n n n 2 19 20 16 17 19 20 16 19 20 16 19 20 -(CR R ) S(O) NR R , -(CR R ) S(O)(OR ), -(CR R ) S(O) (OR ), -(CR R ) n 2 n n 2 n 16 19 20 16 19 20 16 17 21 SC(=Y’)R , -(CR R ) SC(=Y’)OR , -(CR R ) SC(=Y’)NR R , and R ; 16 17 18 each R , R and R is independently H, C -C alkyl, C -C alkenyl, C -C alkynyl, 1 12 2 8 2 8 carbocyclyl, heterocyclyl, aryl, or heteroaryl, wherein said alkyl, alkenyl, alkynyl,carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more groups selected from halo, oxo, CN, -OCF , CF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), -S(C -C alkyl), 3 3 2 1 6 1 6 1 6 -NH , -NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C alkyl), 2 1 6 1 6 2 2 1 6 2 2 1 6 -C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C alkyl), 2 1 6 1 6 2 1 6 1 6 -NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), -SO NH , 1 6 2 1 6 1 6 2 1 6 2 2 -SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl), 2 1 6 2 1 6 2 2 1 6 -OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C 1 6 2 1 6 1 6 1 6 alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) , 2 1 6 1 6 1 6 1 6 2 -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C 1 6 1 6 2 1 6 1 6 alkyl)C(O)O(C -C alkyl); 16 17 or R and R together with the nitrogen to which they are attached form a 3-8 membered saturated, unsaturated or aromatic ring having 0-2 heteroatoms selected from O, S and N, wherein said ring is optionally substituted with one or more groups selected from halo, CN, -OCF , CF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), -S(C -C alkyl), -NH , 3 3 2 1 6 1 6 1 6 2 -NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C alkyl), 1 6 1 6 2 2 1 6 2 2 1 6 -C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C alkyl), 2 1 6 1 6 2 1 6 1 6 -NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), -SO NH , 1 6 2 1 6 1 6 2 1 6 2 2 -SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl), 2 1 6 2 1 6 2 2 1 6 -OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C 1 6 2 1 6 1 6 1 6 alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) , 2 1 6 1 6 1 6 1 6 2 -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C 1 6 1 6 2 1 6 1 6 alkyl)C(O)O(C -C alkyl); 19 20 R and R are independently selected from H, C -C alkyl, -(CH ) -aryl, -(CH ) - 1 12 2 n 2 n carbocyclyl, -(CH ) -heterocyclyl, and -(CH ) -heteroaryl; 2 n 2 n R is C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, heterocyclyl, aryl, or 1 12 2 8 2 8 heteroaryl, wherein each member of R is optionally substituted with one or more groups selected from halo, CN, -OCF , CF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), -S(C -C 3 3 2 1 6 1 6 1 6 alkyl), -NH , -NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C 2 1 6 1 6 2 2 1 6 2 2 1 6 alkyl), -C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C 2 1 6 1 6 2 1 6 1 6 alkyl), -NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), 1 6 2 1 6 1 6 2 1 6 -SO NH , -SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl), 2 2 2 1 6 2 1 6 2 2 1 6 -OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C 1 6 2 1 6 1 6 1 6 alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) , 2 1 6 1 6 1 6 1 6 2 -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C 1 6 1 6 2 1 6 1 6 alkyl)C(O)O(C -C alkyl); each Y’ is independently O, NR , or S; and R is H or C -C alkyl. 1 12
35. The use of any one of claims 1-28, wherein the MEK inhibitor is a compound of the formula (III): (III) or a pharmaceutically acceptable salt or solvate thereof, wherein: Z is CR or N; 1 A A A R is H, C -C alkyl, halo, CF , CHF , CN, OR or NR R ; 1 3 3 2 1’ A A A R is H, C -C alkyl, halo, CF , CHF , CN, OR , or NR R ; 1 3 3 2 wherein each R is independently H or C -C alkyl; Z is CR or N; 3 3 1 2 3 Z is CR or N; provided that only one of Z , Z and Z can be N at the same time; R and R are independently selected from H, halo, CN, CF , -OCF , -NO , 3 3 2 14 15 11 14 15 11 14 15 11 12 -(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR , -(CR R ) C(=Y’)NR R , n n n 14 15 11 12 14 15 11 14 15 11 14 15 12 11 -(CR R ) NR R , -(CR R ) OR , -(CR R ) SR , -(CR R ) NR C(=Y’)R , n n n n 14 15 12 11 14 15 13 11 12 14 15 12 11 -(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R , -(CR R ) NR SO R , n n n 2 14 15 11 14 15 11 14 15 11 12 -(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR , -(CR R ) OC(=Y’)NR R , n n n 14 15 11 14 15 11 12 14 15 11 12 -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ), -(CR R ) OP(OR )(OR ), n 2 n n 14 15 11 14 15 11 14 15 11 12 14 15 11 -(CR R ) S(O)R , -(CR R ) S(O) R , -(CR R ) S(O) NR R , -(CR R ) S(O)(OR ), n n 2 n 2 n 14 15 11 14 15 11 14 15 11 -(CR R ) S(O) (OR ), -(CR R ) SC(=Y’)R , -(CR R ) SC(=Y’)OR , n 2 n n 14 15 11 12 -(CR R )nSC(=Y’)NR R , C1-C12 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl; R is H, C -C alkyl or C -C carbocyclyl; 1 6 3 4 Y is W-C(O)- or W’; 1 11' W is or ; R is H or C -C alkyl; 1 12 1 11’ 11’ 1 11’ 1 X is selected from R and -OR ; when X is R , X is optionally taken together with R and the nitrogen atom to which they are bound to form a 4-7 membered saturated or unsaturated ring having 0-2 additional heteroatoms selected from O, S and N, wherein said ring is optionally substituted with one or more groups selected from halo, CN, CF , -OCF , -NO , 3 3 2 19 20 16 19 20 16 19 20 16 17 oxo, -(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR , -(CR R ) C(=Y’)NR R , n n n 19 20 16 17 19 20 16 19 20 16 19 20 16 17 -(CR R ) NR R , -(CR R ) OR , -(CR R ) -SR , -(CR R ) NR C(=Y’)R , n n n n 19 20 16 17 19 20 18 16 17 19 20 17 16 -(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R , -(CR R ) NR SO R , n n n 2 19 20 16 19 20 16 19 20 16 17 -(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR , -(CR R ) OC(=Y’)NR R , n n n 19 20 16 19 20 16 17 19 20 16 17 -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ), -(CR R ) OP(OR )(OR ), n 2 n n 19 20 16 19 20 16 19 20 16 17 19 20 16 -(CR R ) S(O)R , -(CR R ) S(O) R , -(CR R ) S(O) NR R , -(CR R ) S(O)(OR ), n n 2 n 2 n 19 20 16 19 20 16 19 20 16 19 20 -(CR R ) S(O) (OR ), -(CR R ) SC(=Y’)R , -(CR R ) SC(=Y’)OR , -(CR R ) n 2 n n n 16 17 21 SC(=Y’)NR R , and R ; each R is independently H, C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, 1 12 2 8 2 8 heterocyclyl, aryl, or heteroaryl; 11 12 13 R , R and R are independently H, C -C alkyl, C -C alkenyl, C -C alkynyl, 1 12 2 8 2 8 carbocyclyl, heterocyclyl, aryl, or heteroaryl, 11 12 or R and R together with the nitrogen to which they are attached form a 3-8 membered saturated, unsaturated or aromatic ring having 0-2 heteroatoms selected from O, S and N, wherein said ring is optionally substituted with one or more groups selected from halo, CN, CF , -OCF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), -S(C -C alkyl), -NH , 3 3 2 1 6 1 6 1 6 2 -NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C alkyl), 1 6 1 6 2 2 1 6 2 2 1 6 -C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C alkyl), 2 1 6 1 6 2 1 6 1 6 -NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), -SO NH , 1 6 2 1 6 1 6 2 1 6 2 2 -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, -OC(O)NH2, -OC(O)NH(C1-C6 alkyl), -OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C 1 6 2 1 6 1 6 1 6 alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) , 2 1 6 1 6 1 6 1 6 2 -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C 1 6 1 6 2 1 6 1 6 alkyl)C(O)O(C -C alkyl); 14 15 R and R are independently selected from H, C -C alkyl, aryl, carbocyclyl, 1 12 heterocyclyl, and heteroaryl; R O N O NH NH W’ is ; wherein is 7 7 7 R R R N 7 N N X 7 N X 7 X 7 N 7 N N R R R R R X N N N N N N N N N R N N N N N R O N HN O N N NH N N 7 O 7 N N NN each X is independently O, S, or NR ; each R is independently selected from H, halo, CN, CF , -OCF , -NO , 3 3 2 14 15 11 14 15 11 14 15 11 12 -(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR , -(CR R ) C(=Y’)NR R , n n n 14 15 11 12 14 15 11 14 15 11 14 15 12 11 -(CR R ) NR R , -(CR R ) OR , -(CR R ) SR , -(CR R ) NR C(=Y’)R , n n n n 14 15 12 11 14 15 13 11 12 14 15 12 11 -(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R , -(CR R ) NR SO R , n n n 2 14 15 11 14 15 11 14 15 11 12 -(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR , -(CR R ) OC(=Y’)NR R , n n n 14 15 11 14 15 11 12 14 15 11 12 -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ), -(CR R ) OP(OR )(OR ), n 2 n n 14 15 11 14 15 11 14 15 11 12 14 15 11 -(CR R ) S(O)R , -(CR R ) S(O) R , -(CR R ) S(O) NR R , -(CR R ) S(O)(OR ), n n 2 n 2 n 14 15 11 14 15 11 14 15 11 -(CR R ) S(O) (OR ), -(CR R ) SC(=Y’)R , -(CR R ) SC(=Y’)OR , n 2 n n 14 15 11 12 -(CR R ) SC(=Y’)NR R , C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, n 1 12 2 8 2 8 heterocyclyl, aryl, and heteroaryl; each R is independently selected from C -C alkyl, aryl, carbocyclyl, heterocyclyl, and 1 12 heteroaryl; 9 14 15 11 14 15 11 R is selected from H, -(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR , 14 15 11 12 14 15 11 12 14 15 11 14 15 11 -(CR R ) C(=Y’)NR R , -(CR R ) NR R , -(CR R ) OR , -(CR R ) SR , n q q q 14 15 12 11 14 15 12 11 14 15 13 11 12 -(CR R ) NR C(=Y’)R , -(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R , q q q 14 15 12 11 14 15 11 14 15 11 -(CR R ) NR SO R , -(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR , q 2 q q 14 15 11 12 14 15 11 14 15 11 12 -(CR R ) OC(=Y’)NR R , -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ), q q 2 q 14 15 11 12 14 15 11 14 15 11 14 15 -(CR R ) OP(OR )(OR ), -(CR R ) S(O)R , -(CR R ) S(O) R , -(CR R ) q n n 2 n 11 12 S(O) NR R , C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, heterocyclyl, aryl, and 2 1 12 2 8 2 8 heteroaryl; R is H, C -C alkyl or C -C carbocyclyl; 1 6 3 4 (R ) X is ; R is H, halo, C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, heteroaryl, 1 6 2 8 2 8 19 20 16 17 19 20 16 heterocyclyl, -OCF , -NO , -Si(C -C alkyl), -(CR R ) NR R , -(CR R ) OR , or 3 2 1 6 n n 19 20 16 -(CR R ) -SR ; R is H, halo, C -C alkyl, carbocyclyl, CF , -OCF , -NO , -Si(C -C alkyl), 1 6 3 3 2 1 6 19 20 16 17 19 20 16 19 20 16 -(CR R ) NR R , -(CR R ) OR , -(CR R ) -SR , C -C alkenyl, C -C alkynyl, n n n 2 8 2 8 heterocyclyl, aryl, or heteroaryl; p is 0, 1, 2 or 3; n is 0,1, 2 or 3; q is 2 or 3; wherein each said alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl 1 2 3 4 5 6 6’ 7 8 9 10 11 11’ 12 13 14 15 A of R , R , R , R , R , R , R , R , R , R , R , R , R , R , R , R , R and R is independently optionally substituted with one or more groups independently selected from halo, CN, CF , 19 20 16 19 20 16 -OCF , -NO , oxo, -Si(C -C alkyl), -(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR , 3 2 1 6 n n 19 20 16 17 19 20 16 17 19 20 16 19 20 16 -(CR R ) C(=Y’)NR R , -(CR R ) NR R , -(CR R ) OR , -(CR R ) SR , n n n n 19 20 16 17 19 20 16 17 19 20 18 16 17 -(CR R ) NR C(=Y’)R , -(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R , n n n 19 20 17 16 19 20 16 19 20 16 -(CR R ) NR SO R , -(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR , n 2 n n 19 20 16 17 19 20 16 19 20 16 17 -(CR R ) OC(=Y’)NR R , -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ), n n 2 n 19 20 16 17 19 20 16 19 20 16 -(CR R ) OP(OR )(OR ), -(CR R ) S(O)R , -(CR R ) S(O) R , n n n 2 19 20 16 17 19 20 16 19 20 16 -(CR R ) S(O) NR R , -(CR R ) S(O)(OR ), -(CR R ) S(O) (OR ), n 2 n n 2 19 20 16 19 20 16 19 20 16 17 21 -(CR R ) SC(=Y’)R , -(CR R ) SC(=Y’)OR , -(CR R ) SC(=Y’)NR R , and R ; n n n 16 17 18 each R , R and R is independently H, C -C alkyl, C -C alkenyl, C -C alkynyl, 1 12 2 8 2 8 carbocyclyl, heterocyclyl, aryl, or heteroaryl, wherein said alkyl, alkenyl, alkynyl,carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more groups selected from halo, CN, -OCF , CF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), -S(C -C alkyl), -NH , 3 3 2 1 6 1 6 1 6 2 -NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C alkyl), 1 6 1 6 2 2 1 6 2 2 1 6 -C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C alkyl), 2 1 6 1 6 2 1 6 1 6 -NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), -SO NH , 1 6 2 1 6 1 6 2 1 6 2 2 -SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl), 2 1 6 2 1 6 2 2 1 6 -OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C 1 6 2 1 6 1 6 1 6 alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) , 2 1 6 1 6 1 6 1 6 2 -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C 1 6 1 6 2 1 6 1 6 alkyl)C(O)O(C -C alkyl); 16 17 or R and R together with the nitrogen to which they are attached form a 3-8 membered saturated, unsaturated or aromatic ring having 0-2 heteroatoms selected from O, S and N, wherein said ring is optionally substituted with one or more groups selected from halo, CN, -OCF , CF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), -S(C -C alkyl), -NH , 3 3 2 1 6 1 6 1 6 2 -NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C alkyl), 1 6 1 6 2 2 1 6 2 2 1 6 -C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C alkyl), 2 1 6 1 6 2 1 6 1 6 -NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), -SO NH , 1 6 2 1 6 1 6 2 1 6 2 2 -SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl), 2 1 6 2 1 6 2 2 1 6 -OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C 1 6 2 1 6 1 6 1 6 alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) , 2 1 6 1 6 1 6 1 6 2 -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C 1 6 1 6 2 1 6 1 6 alkyl)C(O)O(C -C alkyl); 19 20 R and R are independently selected from H, C -C alkyl, -(CH ) -aryl, -(CH ) - 1 12 2 n 2 n carbocyclyl, -(CH ) -heterocyclyl, and -(CH ) -heteroaryl; 2 n 2 n R is C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, heterocyclyl, aryl, or 1 12 2 8 2 8 heteroaryl, wherein each member of R is optionally substituted with one or more groups selected from halo, oxo, CN, -OCF , CF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), 3 3 2 1 6 1 6 -S(C -C alkyl), -NH , -NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, 1 6 2 1 6 1 6 2 2 1 6 2 -CO (C -C alkyl), -C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C 2 1 6 2 1 6 1 6 2 1 6 alkyl)C(O)(C -C alkyl), -NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C 1 6 1 6 2 1 6 1 6 alkyl)SO (C -C alkyl), -SO NH , -SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , 2 1 6 2 2 2 1 6 2 1 6 2 2 -OC(O)NH(C -C alkyl), -OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C 1 6 1 6 2 1 6 1 6 alkyl), -NHC(O)N(C -C alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C 1 6 2 1 6 1 6 1 6 alkyl)C(O)N(C -C alkyl) , -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , 1 6 2 1 6 1 6 2 -NHC(O)O(C -C alkyl), and -N(C -C alkyl)C(O)O(C -C alkyl); 1 6 1 6 1 6 each Y’ is independently O, NR , or S; and R is H or C -C alkyl. 1 12
36. The use of any one of claims 1-28, wherein the MEK inhibitor is a compound of the formula (IV): (IV) or a pharmaceutically acceptable salt or solvate thereof, wherein: each dashed line ( ) represents an optional bond, provided that one and only one nitrogen of the ring is double-bonded; 1 2 9 10 R , R , R and R are independently selected from hydrogen, halogen, cyano, nitro, 3 3 3 trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR , -C(O)R , -C(O)OR , 4 6 3 4 6 3 4 4 3 3 4 -NR C(O)OR , -OC(O)R , -NR SO R , -SO NR R , -NR C(O)R , -C(O)N R R , 5 3 4 5 3 4 3 4 -NR C(O)NR R , -NR C(NCN)NR R , - NR R , C -C alkyl, C -C alkenyl, C -C 1 10 2 10 2 10 alkynyl, C -C cycloalkyl, C -C cycloalkylalkyl, -S(O) (C -C alkyl), 3 10 3 10 j 1 6 -S(O)j(CR R ) -aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, 4 5 4 4 5 4 5 heterocyclylalkyl, -O(CR R ) -aryl, -NR (CR R ) -aryl, -O(CR R ) -heteroaryl, m m m 4 4 5 4 5 4 4 5 -NR (CR R ) -heteroaryl, -O(CR R ) -heterocyclyl and -NR (CR R ) -heterocyclyl; m m m where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, 4 6 3 4 3 3 3 4 6 4 3 -NR SO R , -SO NR R , -C(O)R , -C(O)OR , -OC(O)R , -NR C(O)OR , -NR C(O)R , 3 4 3 4 5 3 4 5 3 4 3 -C(O)NR R , -NR R , -NR C(O)NR R , -NR C(NCN)NR R , -OR , aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R is selected from hydrogen, trifluoromethyl, C -C alkyl, C -C alkenyl, C -C alkynyl, 1 10 2 10 2 10 C -C cycloalkyl, C -C cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, 3 10 3 10 heterocyclyl, and heterocyclylalkyl; where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR’SO R””, -SO NR’R”, -C(O)R’, -C(O)OR’, -OC(O)R’, -NR’C(O)OR””, -NR’C(O)R”, -C(O)NR’R”, -SR’, -S(O)R””, -SO R””, -NR’R”, -NR’C(O)NR”R’”, -NR’C(NCN)NR”R’”, -OR’, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R’, R”, R’” independently are selected from hydrogen, lower alkyl, lower alkenyl, aryl and arylalkyl; R”” is selected from lower alkyl, lower alkenyl, aryl and arylalkyl; or any two of R’, R”, R’” or R”” can be taken together with the atom to which they are attached to form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; or R and R can be taken together with the atom to which they are attached to form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR’SO R””, -SO NR’R”, - C(O)R’, -C(O)OR’, -OC(O)R’, -NR’C(O)OR””, -NR’C(O)R”, -C(O)NR’R”, -SO R””, -NR’R”, -NR’C(O)NR”R’”, -NR’C(NCN)NR”R’”, -OR’, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; or R and R independently represent hydrogen or C1-C6 alkyl; or R and R together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR’SO R””, -SO NR’R”, -C(O)R’, -C(O)OR’, -OC(O)R’, -NR’C(O)OR””, -NR’C(O)R”, -C(O)NR’R”, -SO R””, -NR’R”, -NR’C(O)NR”R’”, -NR’C(NCN)NR”R’”, -OR’, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R is selected from trifluoromethyl, C -C alkyl, C -C cycloalkyl, aryl, arylalkyl, heteroaryl, 1 10 3 10 heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, where each alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR’SO R””, -SO NR’R”, -C(O)R’, -C(O)OR’, -OC(O)R’, -NR’C(O)OR””, -NR’C(O)R”, -C(O)NR’R”, -SO R””, -NR’R”, -NR’C(O)NR”R’”, -NR’C(NCN)NR”R’”, -OR’, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R is selected from hydrogen, C -C alkyl, C -C alkenyl, C -C alkynyl, C -C cycloalkyl, 1 10 2 10 2 10 3 10 C -C cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, 3 10 heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, 4 6 3 4 3 3 3 trifluoromethoxy, azido, -NR SO R , -SO NR R , -C(O)R , -C(O)OR , -OC(O)R , 4 6 4 3 3 4 6 3 4 5 3 4 -NR C(O)OR , -NR C(O)R , -C(O)NR R , -SO R , -NR R , -NR C(O)NR R , 5 3 4 3 -NR C(NCN)NR R , -OR , aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; 3 3 4 4 3 W is selected from heteroaryl, heterocyclyl, -C(O)OR , -C(O)NR R , -C(O)NR OR , -C(O)R OR , -C(O)(C -C cycloalkyl), -C(O)(C -C alkyl), -C(O)(aryl), 3 10 1 10 -C(O)(heteroaryl) and -C(O)(heterocyclyl); each of which is optionally substituted with 3 4 3 2 1-5 groups independently selected from -NR R , -OR , -R , and C -C alkyl, C -C 1 10 2 10 alkenyl, and C -C alkynyl, each of which is optionally substituted with 1 or 2 groups 2 10 3 4 3 independently selected from -NR R and-OR ; R is selected from hydrogen, -SCF , -Cl, -Br, -F, cyano, nitro, trifluoromethyl, difluoromethoxy, 3 3 3 4 6 3 trifluoromethoxy, azido, -OR , -C(O)R , -C(O)OR , -NR C(O)OR , -OC(O)R , 4 6 3 4 4 3 3 4 5 3 4 3 4 -NR SO R , -SO NR R , -NR C(O)R , -C(O)NR R , -NR C(O)NR R , -NR R , and C - 2 2 1 C alkyl, C -C alkenyl, C -C alkynyl, C -C cycloalkyl, C -C cycloalkylalkyl, 10 2 10 2 10 3 10 3 10 -S(O) (C -C alkyl), -S(O) (CR R ) -aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, j 1 6 j m 4 5 4 4 5 heterocyclyl, heterocyclylalkyl, -O(CR R ) -aryl, -NR (CR R ) -aryl, 4 5 4 4 5 4 5 -O(CR R ) -heteroaryl, -NR (CR R ) -heteroaryl, -O(CR R ) -heterocyclyl and m m m 4 4 5 -NR (CR R ) -heterocyclyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, 4 6 3 4 3 3 3 trifluoromethoxy, azido, -NR SO R , -SO NR R , -C(O)R , -C(O)OR , -OC(O)R , 4 6 4 3 3 4 3 4 5 3 4 -NR C(O)OR , -NR C(O)R , -C(O)NR R , -NR R , -NR C(O)NR R , 5 3 4 3 -NR C(NCN)NR R , -OR , aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; m is O, 1, 2, 3, 4 or 5; and j is 1 or 2.
37. The use of any one of claims 1-28, wherein the MEK inhibitor is a compound of the formula (V): or a pharmaceutically acceptable salt or solvate thereof, wherein: X and X are the same or different and each is a carbon atom or a nitrogen atom, a moiety is ; 1 2 6 R , R , and R are the same or different and each is a C alkyl group, a C alkenyl group, 1-6 2-6 wherein the C alkyl group and the C alkenyl group are optionally substituted by 1 to 1-6 2-6 3 substituents selected from the following group A, or , wherein m is 0 or an integer of 1 to 4, ring Cy is a C carbon ring group or a heterocyclic group, wherein the heterocyclic 3-12 group is a saturated or unsaturated ring group having, besides carbon atom, 1 to 4 hetero atoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, the C carbon ring group and the heterocyclic group are optionally substituted 3-12 by 1 to 5 substituents selected from the following group B; 3 4 5 R , R , and R are the same or different and each is a hydrogen atom; a hydroxyl group; a C alkyl group, optionally substituted by 1 to 3 substituents selected from the following group A; a C alkenyl group, optionally substituted by 1 to 3 substituents selected from the following group A; a C carbon ring group, optionally substituted by 1 to 5 3-12 substituents selected from the following group B; or a heterocyclic group, wherein the heterocyclic group is a saturated or unsaturated ring group having, besides carbon atom, 1 to 4 hetero atoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, and is optionally substituted by 1 to 5 substituents selected from the following group B; R and R are optionally linked to form a C alkylene group; or R and R are optionally linked to form a C ι- alkylene group; wherein group A is a group consisting of: 1) a halogen atom, 2) a nitro group, 3) a cyano group, 4) a C alkyl group, A1 A1 5) -OR wherein R is a hydrogen atom or a C alkyl group, A2 A2 6) -SR wherein R is a hydrogen atom or a C alkyl group, A3 A4 A3 A4 7) -NR R wherein R and R are the same or different and each is a hydrogen atom or a C alkyl group, A5 A5 8) -COOR wherein R is a hydrogen atom or a C1-4 alkyl group, A6 A7 A6 A7 9) -NR COR wherein R is a hydrogen atom or a C alkyl group, R is a C alkyl 1-4 1-4 group, a C carbon ring group or a heterocyclic group, 3-12 A8 A9 A8 A9 10) -NR COOR wherein R and R are the same or different and each is a hydrogen atom or a C alkyl group, 11) a C carbon ring group, and 3-12 12) a heterocyclic group, wherein the heterocyclic group is a saturated or unsaturated ring group having, besides carbon atom, 1 to 4 hetero atoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, A1 A2 A3 A5 A6 A7 each of the C alkyl groups of the above-mentioned 4), R , R , R , R , R , R , A8 A9 R and R is optionally substituted by the same or different 1 to 3 substituents selected from the following group C, and each of the C carbon ring groups of the above-mentioned 11) and R , and the 3-12 heterocyclic groups of 12) and R is optionally substituted by the same or different 1 to 5 substituents selected from the following group C; group B is a group consisting of: 1) a halogen atom, 2) a nitro group, 3) a cyano group, 4) a C alkyl group, 5) a C alkenyl group, 6) a C alkynyl group, B1 B1 7) -OR wherein R is a hydrogen atom or a C alkyl group, B2 B2 8) -SR wherein R is a hydrogen atom or a C alkyl group, B3 B4 B3 9) -NR R wherein R is a hydrogen atom, a C alkyl group, a C carbon ring 1-4 3-12 group or a heterocyclic group, and R is a hydrogen atom or a C alkyl group, B5 B6 B5 B6 10) -NR COR wherein R is a hydrogen atom or a C alkyl group, and R is a hydrogen atom, a C alkyl group, a C carbon ring group or a heterocyclic group, 1-4 3-12 B7 B8 B7 B8 11) -NR COOR wherein R and R are the same or different and each is a hydrogen atom or a C alkyl group, B9 B10 B11 B9 B10 B11 12) -NR CONR R wherein R , R and R are the same or different and each is a hydrogen atom or a C alkyl group, B12 B13 B14 B12 B13 B14 13) -NR CONR OR wherein R , R and R are the same or different and each is a hydrogen atom or a C alkyl group, B15 B16 B15 B16 14) -NR SO R wherein R is a hydrogen atom or a C alkyl group, and R is a 2 1-4 C alkyl group, a C carbon ring group or a heterocyclic group, 1-4 3-12 B17 B17 15) -SO -R wherein R is a C alkyl group or a heterocyclic group, 2 1-4 B18 B19 B18 B19 16) -SO NR R wherein R and R are the same or different and each is a hydrogen atom or a C alkyl group , B20 B21 B20 B21 17) -P(=O)(R )(R ) wherein R and R are the same or different and each is a C alkyl group, B22 B22 18) -COOR wherein R is a hydrogen atom or a C alkyl group, B23 B24 B23 B24 19) -CONR R wherein R and R are the same or different and each is a hydrogen atom or a C alkyl group, B25 B26 B27 B25 B26 B27 20) -NR SO NR R wherein R , R and R are the same or different and each is a hydrogen atom or a C alkyl group, B28 B29 B30 B31 B28 B29 B30 B31 21) -NR SO NR CONR R wherein R , R , R and R are the same or different and each is a hydrogen atom or a C alkyl group, 22) a C carbon ring group, and 3-12 23) a heterocyclic group; wherein each of the “C alkyl group” of the above-mentioned 4), and the C alkyl 1-8 1-4 B1 B31 groups for R to R is optionally substituted by the same or different 1 to 3 substituents selected from the above-mentioned group A, each of the C alkenyl group of 5) and the C alkynyl group of 6) is optionally substituted by the same or different 1 to 3 substituents selected from the above-mentioned group A, the heterocyclic group is a saturated or unsaturated ring group having, besides carbon atom, 1 to 4 hetero atoms selected from an oxygen atom, a nitrogen atom and a sulfur B3 B6 atom, and each of the C carbon ring group of the above-mentioned 22), R , R 3-12 B16 B3 B6 B16 and R , and the heterocyclic group of the above- mentioned 23), R , R , R and R is optionally substituted by the same or different 1 to 5 substituents selected from the following group C; group C is a group consisting of: 1) a halogen atom, 2) a cyano group, 3) a C alkyl group, C1 C1 4) -OR wherein R is a hydrogen atom or a C alkyl group, C2 C3 C2 C3 5) -NR R wherein R and R are the same or different and each is a hydrogen atom or a C alkyl group, C4 C4 6) –COOR wherein R is a hydrogen atom or a C alkyl group, and 7) an oxo group.
38. The use of any one of claims 1-28, wherein the MEK inhibitor is a compound of the formula (VI): (VI) or a pharmaceutically acceptable salt or ester thereof, wherein: R1 is selected from the group consisting of bromo, iodo, ethynyl, cycloalkyl, alkoxy, azetidinyl, acetyl, heterocycyl, cyano, straight-chained alkyl and branched-chain alkyl; R2 is selected from the group consisting of hydrogen, chlorine, fluorine, and alkyI; R3 is selected from the group consisting of hydrogen, chlorine, and fluorine; R4 is selected from the group consisting of hydrogen, optionally substituted aryl, alkyl, and cycloalkyl; R5 is selected from the group consisting of hydrogen and ; wherein R6 is selected from the group consisting of hydroxyl, alkoxy, cycloalkyl, optionally substituted alkyl, optionally substituted aryl, and optionally substituted heteroaryl; R7 and R8 are independently selected from the group consisting of hydrogen and optionally substituted alkyl; or R6 and R7 can together form a cycloalkyl group and R8 is hydrogen.
39. The use of any one of claims 1-27, wherein the MEK inhibitor is a compound of the formula (VII): (VII) or a pharmaceutically acceptable salt or ester thereof, wherein: R1 is selected from the group consisting of halogen, ethynyl, and cycloalkyl; R2 is selected from the group consisting of hydrogen and CH(R3)(R4); R3 is selected from the group consisting of lower alkyl, lower alkoxy, optionally substituted aryl, and optionally substituted heteroaryl; R4 is selected from the group consisting of hydrogen and lower alkyl; R5 is hydrogen or, taken together with R2 and the carbon to which R2 and R5 are attached, forms lower cycloalkyl; and R6 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl.
40. The use of any one of claims 1-28, wherein the MEK inhibitor is a compound selected from the group consisting of: , , and or a pharmaceutically acceptable salt or solvate thereof.
41. The use of claim 40, wherein the MEK inhibitor is a compound selected from the group consisting of: , and or a pharmaceutically acceptable salt or solvate thereof.
42.The use of any one of claims 1-41, wherein the cancer contains a BRAF V600E mutation.
43. The use of any one of claims 1-41, wherein the cancer contains a BRAF wildtype.
44. The use of any one of claims 1-41, wherein the cancer contains a KRAS wildtype.
45. The use of any one of claims 1-41, wherein the cancer contains an activating KRAS mutation.
46. The use of any one of claims 1-45, wherein the treatment results in a sustained response in the individual after cessation of the treatment.
47.The use of any one of claims 1-45, wherein the MEK inhibitor is to be used continuously.
48. The use of any one of claims 1-47, wherein the MEK inhibitor is to be used intermittently.
49. The use of any one of claims 1-46, wherein the MEK inhibitor is to be used before the PD-1 axis binding antagonist.
50. The use of any one of claims 1-47, wherein the MEK inhibitor is to be used simultaneously with the PD-1 axis binding antagonist.
51. The use of any one of claims 1-47, wherein the MEK inhibitor is to be used after the PD- 1 axis binding antagonist.
52. The use of any one of claims 1-50, wherein the individual has colorectal cancer.
53. The use of any one of claims 1-50, wherein the individual has melanoma.
54. The use of any one of claims 1-50, wherein the individual has non-small cell lung cancer.
55. The use of any one of claims 1-50, wherein the individual has ovarian cancer.
56. The use of any one of claims 1-50, wherein the individual has breast cancer.
57. The use of any one of claims 1-50, wherein the individual has pancreatic cancer.
58. The use of any one of claims 1-50, wherein the individual has a hematological malignancy.
59. The use of any one of claims 1-50, wherein the individual has renal cell carcinoma.
60. Use of a PD-1 axis binding antagonist and a MEK inhibitor in the manufacture of a medicament for enhancing immune function in an individual having cancer.
61. The use of claim 59, wherein the medicament is for simultaneous, separate or sequential use.
62. The use of claim 59 or claim 60, wherein the medicament comprises a first medicament comprising the PD-1 axis binding antagonist and a second medicament comprising the MEK inhibitor.
63. Use of an effective amount of a PD-1 axis binding antagonist in the manufacture of a medicament for enhancing immune function in an individual having cancer, wherein the PD- 1 axis binding agent is for use in combination with a MEK inhibitor.
64. Use of an effective amount of a MEK inhibitor in the manufacture of a medicament for enhancing immune function in an individual having cancer, wherein the MEK inhibitor is for use in combination with a PD-1 axis binding antagonist.
65. The use of any one of Claims 59-63, wherein CD8 T cells in the individual have enhanced priming, activation, proliferation and/or cytolytic activity relative to prior to the use of the medicament.
66. The use of claim 64, wherein the CD8 T cell activation is characterized by an elevated frequency of γ-IFN CD8 T cells and/or enhanced cytolytic activity relative to prior to the use of the medicament.
67. The use of claim 64, wherein the number of CD8 T cells is elevated relative to prior to the use of the medicament.
68. The use of any one of claims 64-66, wherein the CD8 T cell is an antigen-specific CD8 T cell.
69. The use of claim 64, wherein the cancer cells in the individual selectively have elevated expression of MHC class I antigen expression relative to prior to the use of the PD-1 axis binding antagonist and the MEK inhibitor.
70. The use of claim 68, wherein PBMC cells of the individual do not have elevated expression of MHC class I antigen.
71. The use of any one of claims 64-69, wherein antigen presenting cells in the individual have enhanced maturation and activation relative prior to the use of the PD-1 axis binding antagonist and the MEK inhibitor.
72. The use of claim 70, wherein the antigen presenting cells are dendritic cells.
73. The use of claim 71, wherein the maturation of the antigen presenting cells is characterized by increased frequency of CD83 dendritic cells.
74. The use of claim 71, wherein the activation of the antigen presenting cells is characterized by elevated expression of CD80 and CD86 on dendritic cells.
75. The use of claim 64, wherein serum levels of IL-10 and/or IL-8 in the individual are reduced relative to prior to the use of the medicament.
76. The use of claim 64, wherein the cancer has elevated levels of T-cell infiltration.
77. The use of any one of Claims 64-75, wherein the MEK inhibitor is a compound of the formula (I), , or a pharmaceutically acceptable salt or solvate thereof, wherein provisions (i), (ii), (iii) or (iv) applies: (i): 10 12 14 A is arylene optionally substituted with one, two, three or four groups selected from R , R , R , 16 19 10 12 14 16 R , and R , where R , R , R and R are independently hydrogen, alkyl, alkenyl, alkynyl, halo, haloalkoxy, hydroxy, alkoxy, amino, alkylamino, dialkylamino, haloalkyl, 8 8 8 8 8’ 8 8’ 19 -NHS(O) R , -CN, -C(O)R , -C(O)OR , -C(O)NR R and -NR C(O)R and where R is hydrogen, alkyl, or alkenyl; X is alkyl, halo, haloalkyl, or haloalkoxy; 1 2 3 4 5 6 8 8’ 8 8 R , R , R , R , R and R are independently hydrogen, halo, nitro, -NR R , -OR , -NHS(O) R , 8 8 8’ 8 8 8 8’ 8 8’ -CN, -S(O) R , -S(O) NR R , -C(O)R , -C(O)OR , -C(O)NR R , -NR C(O)OR , 8 8’ 8” 8 8’ 8 8’ 25 25a 25b -NR C(O)NR R , -NR C(O)OR , -NR C(O)R , -CH N(R )(NR R ), 25 25a 25b 25 25a -CH NR C(=NH)(NR R ), -CH NR C(=NH)(N(R )(NO )), 2 2 2 25 25a 25 25 -CH NR C(=NH)(N(R )(CN)), -CH NR C(=NH)(R ), 25 25a 25b -CH NR C(NR R )=CH(NO ), alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, or heterocycloalkyl; where the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, and heterocycloalkyl are independently optionally substituted with one, two, three, four, five, six or seven groups independently selected from halo, alkyl, haloalkyl, nitro, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, -OR , 8 8’ 8 9 9 8 8 -NR R , -NR S(O) R , -CN, -S(O) R , -C(O)R , -C(O)OR , 8 8’ 8 8’ 8” 8 8’ 8 8’ 1 2 -C(O)NR R , -NR C(O)NR R , -NR C(O)OR and -NR C(O)R ; or one of R and R together with the carbon to which they are attached, R and R together with the carbon to which they are attached, and R and R together with the carbon to which they are attached form C(O) or C(=NOH); m is 0, 1, or 2; R is hydrogen, halo or alkyl; 8 8’ 8” each R , R and R is independently selected from hydrogen, hydroxy, optionally substituted alkoxy, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl; where the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are independently optionally substituted with one, two three, four, or five groups independently selected from alkyl, halo, hydroxy, hydroxyalkyl, optionally substituted alkoxy, alkoxyalkyl, haloalkyl, carboxy, alkoxycarbonyl, alkenyloxycarbonyl, optionally substituted cycloalkyl, optionally substituted cycloalkyloxycarbonyl, optionally substituted aryl, optionally substituted aryloxy, optionally substituted aryloxycarbonyl, optionally substituted arylalkyl, optionally substituted arylalkyloxy, optionally substituted arylalkyloxycarbonyl, nitro, cyano, optionally substituted heterocycloalkyl, 31 31 optionally substituted heteroaryl, -S(O)R (where n is 0, 1, or 2 and R is optionally substituted alkyl, optionally substituted aryl, optionally substituted heterocycloalkyl, or 34 34a 34 34a optionally substituted heteroaryl), -NR SO R (where R is hydrogen or alkyl and R 35 35a is alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl), -SO NR R (where 35 35a R is hydrogen or alkyl and R is alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, or 32 32a 32 32a heterocycloalkyl), -NR C(O)R (where R is hydrogen or alkyl and R is alkyl, 30 30’ 30 30’ alkenyl, alkoxy, or cycloalkyl), -NR R (where R and R are independently 33 33a 33 hydrogen, alkyl, or hydroxyalkyl), and -C(O)NR R (where R is hydrogen or alkyl and R is alkyl, alkenyl, alkynyl, or cycloalkyl); and each R is independently selected from alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl; where the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are independently optionally susbstituted with one, two, three, four, or five groups selected from halo, hydroxy, alkyl, haloalkyl, haloalkoxy, amino, alkylamino, and dialkylamino; (ii): A is heteroarylene optionally substituted with one, two, three, or four groups selected from R , 12 14 16 19 10 12 14 16 R , R , R and R where R , R , R and R are independently hydrogen, alkyl, alkenyl, alkynyl, halo, haloalkoxy, hydroxy, alkoxy, cyano, amino, alkylamino, dialkylamino, haloalkyl, alkylsulfonylamino, alkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, alkenyloxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, or alkylcarbonylamino; where R is hydrogen, alkyl, or alkenyl; 10 12 and where each alkyl and alkenyl, either alone or as part of another group within R , R , 14 16 19 R , R , and R , is independently optionally substituted with halo, hydroxy, or alkoxy; X is alkyl, halo, haloalkyl, or haloalkoxy; 1 2 3 4 3 6 8 8’ 8 8 R , R , R , R , R and R are independently hydrogen, halo, nitro, -NR R , -OR , -NHS(O) R , 8 8 8’ 8 8 8 8’ 8 8’ -CN, -S(O) R , -S(O) NR R , -C(O)R , -C(O)OR , -C(O)NR R , -NR C(O)OR , 8 8’ 8” 8 8’ 8 8’ 25 25a 25b -NR C(O)NR R , -NR C(O)OR , -NR C(O)R , -CH2N(R )(NR R ), 25 25a 25b 25 25a -CH NR C(=NH)(NR R ), -CH NR C(=NH)(N(R )(NO )), 2 2 2 25 25a 25 25 -CH NR C(NH)(N(R )(CN)), -CH NR C(=NH)(R ), 25 25a 25b -CH NR C(NR R )=CH(NO ), alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, or heterocycloalkyl, where the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, and heterocycloalkyl are independently optionally substituted with one, two, three, four, five, six or seven groups independently selected from halo, alkyl, haloalkyl, nitro, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, -OR , 8 8’ 8 9 9 8 8 -NR R , -NR S(O) R , -CN, -S(O) R , -C(O)R , -C(O)OR , 8 8’ 8 8’ 8” 8 8’ 8 8’ 1 2 -C(O)NR R , -NR C(O)NR R , -NR C(O)OR and -NR C(O)R ; or one of R and R together with the carbon to which they are attached, R and R together with the carbon to which they are attached, and R and R together with the carbon to which they are attached form C(O) or C(=NOH); m is 1 or 2; R is hydrogen, halo or alkyl; and 8 8’ 8” each R , R and R is independently selected from hydrogen, hydroxy, optionally substituted alkoxy, alkyl, haloalkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, where the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are independently optionally substituted with one, two three, four, or five groups independently selected from alkyl, halo, hydroxy, hydroxyalkyl, optionally substituted alkoxy, alkoxyalkyl, haloalkyl, carboxy, carboxy ester, nitro, cyano, - 31 31 S(O)nR (where n is 0, 1, or 2 and R is optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, 36 36a 36 or optionally substituted heteroaryl), -NR S(O) R (where R is hydrogen, alkyl, or alkenyl and R is alkyl, alkenyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted 37 37a 37 37a heteroaryl), -S(O) NR R (where R is hydrogen, alkyl, or alkenyl and R is alkyl, alkenyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl), optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted aryloxy, optionally substituted arylalkyloxy, 32 32 optionally substituted heteroaryl, -NHC(O)R (where R is alkyl, alkenyl, alkoxy, or 30 30’ 30 30’ cycloalkyl) and -NR R (where R and R are independently hydrogen, alkyl, or 33 33 hydroxyalkyl), and -C(O)NHR (where R is alkyl, alkenyl, alkynyl, or cycloalkyl); (iii): A is , where R is hydrogen, alkyl, alkenyl, alkynyl, halo, haloalkoxy, hydroxy, alkoxy, amino, alkylamino, dialkylamino, haloalkyl, -NHS(O) R , -CN, 8 8 8 8’ 8 8’ 10a -C(O)R , -C(O)OR , -C(O)NR R and -NR C(O)R ; R is hydrogen, alkyl, or alkenyl; and Y is =CH- or =N-; X is alkyl, halo, haloalkyl, or haloalkoxy; 1 2 3 4 5 6 8 8’ 8 8 R , R , R , R , R and R are independently hydrogen, halo, nitro, -NR R , -OR , -NHS(O) R , 8 8 8’ 8 8 8 8’ 8 8’ -CN, -S(O) R , -S(O) NR R , -C(O)R , -C(O)OR , -C(O)NR R , -NR C(O)OR , 8 8’ 8” 8 8’ 8 8’ 25 25a 25b -NR C(O)NR R , -NR C(O)OR , -NR C(O)R , -CH2N(R )NR R ), 25 25a 25b 25 25a -CH NR C(=NH)(NR R ), -CH NR C(=NH)(N(R )(NO )), 2 2 2 25 25a 25 25 -CH NR C(=NH)(N(R )(CN)), -CH NR C(=NH)(R ), 25 25a 25b -CH NR C(NR R )=CH(NO ), alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, or heterocycloalkyl, where the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, and heterocycloalkyl are independently optionally substituted with one, two, three, four, five, six or seven groups independently selected from halo, alkyl, haloalkyl, nitro, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, 8 8 8’ optionally substituted arylalkyl, optionally substituted heteroaryl, -OR , -NR R , 8 9 9 8 8 8 8’ 8 8’ 8” -NR S(O) R , -CN, -S(O) R , -C(O)R , -C(O)OR , -C(O)NR R , -NR C(O)NR R , 8 8’ 8 8’ 1 2 -NR C(O)OR and -NR C(O)R ; or one of R and R together with the carbon to which 3 4 5 they are attached, R and R together with the carbon to which they are attached, and R and R together with the carbon to which they are attached form C(O) or C(NOH); m is 1 or 2; R is hydrogen, halo or alkyl; and 8 8’ 8” each R , R and R is independently selected from hydrogen, hydroxy, optionally substituted alkoxy, alkyl, haloalkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, where the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are independently optionally substituted with one, two three, four, or five groups independently selected from alkyl, halo, hydroxy, hydroxyalkyl, optionally substituted alkoxy, alkoxyalkyl, haloalkyl, carboxy, carboxy ester, nitro, cyano, - 31 31 S(O) R (where n is 0, 1, or 2 and R is optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, 36 36a 36 or optionally substituted heteroaryl), -NR S(O) R (where R is hydrogen, alkyl, or alkenyl and R is alkyl, alkenyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted 37 37a 37 37a heteroaryl), -S(O) NR R (where R is hydrogen, alkyl, or alkenyl and R is alkyl, alkenyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl), optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted aryloxy, optionally substituted arylalkyloxy, 32 32 optionally substituted heteroaryl, -NHC(O)R (where R is alkyl, alkenyl, alkoxy, or 30 30’ 30 30’ cycloalkyl) and -NR R (where R and R are independently hydrogen, alkyl, or 33 33 hydroxyalkyl), and -C(O)NHR (where R is alkyl, alkenyl, alkynyl, or cycloalkyl); (iv): 40 40a A is or , where R and R are independently hydrogen or alkyl; X is alkyl, halo, haloalkyl, or haloalkoxy; 1 2 3 4 5 6 8 8’ 8 8 R , R , R , R , R and R are independently hydrogen, halo, nitro, -NR R , -OR , -NHS(O) R , 8 8 8’ 8 8 8 8’ 8 8’ -CN, -S(O) R , -S(O) NR R , -C(O)R , -C(O)OR , -C(O)NR R , -NR C(O)OR , 8 8’ 8” 8 8’ 8 8’ 25 25a 25b -NR C(O)NR R , -NR C(O)OR , -NR C(O)R , -CH N(R )(NR R ), 25 25a 25b 25 25a -CH NR C(=NH)(NR R ), -CH NR C(=NH)(N(R )(NO )), 2 2 2 25 25a 25 25 -CH NR C(=NH)(N(R )(CN)), -CH NR C(=NH)(R ), 25 25a 25b -CH NR C(NR R )=CH(NO ), alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, or heterocycloalkyl, where the alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, and heterocycloalkyl are independently optionally substituted with one, two, three, four, five, six or seven groups independently selected from halo, alkyl, haloalkyl, nitro, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, -OR , - 8 8’ 8 9 9 8 8 NR R , -NR S(O) R , -CN, -S(O) R , -C(O)R , -C(O)OR , - 8 8’ 8 8’ 8” 8 8’ 8 8’ 1 2 C(O)NR R , -NR C(O)NR R , -NR C(O)OR and -NR C(O)R ; or one of R and R together with the carbon to which they are attached, R and R together with the carbon to which they are attached, and R and R together with the carbon to which they are attached form C(O) or C(NOH); m is 1 or 2; R is hydrogen, halo or alkyl; and 8 8’ 8” R , R and R are independently selected from hydrogen, hydroxy, optionally substituted alkoxy, alkyl, haloalkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, where the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are independently optionally substituted with one, two three, four, or five groups independently selected from alkyl, halo, hydroxy, hydroxyalkyl, optionally substituted alkoxy, alkoxyalkyl, 31 31 haloalkyl, carboxy, carboxy ester, nitro, cyano, -S(O) R (where n is 0, 1, or 2 and R is optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkyl, 36 36a optionally substituted heterocycloalkyl, or optionally substituted heteroaryl), -NR S(O) R 36 36a (where R is hydrogen, alkyl, or alkenyl and R is alkyl, alkenyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally 37 37a 37 37a substituted heteroaryl), -S(O) NR R (where R is hydrogen, alkyl, or alkenyl and R is alkyl, alkenyl, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl), optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted aryloxy, optionally substituted arylalkyloxy, 32 32 optionally substituted heteroaryl, -NHC(O)R (where R is alkyl, alkenyl, alkoxy, or 30 30’ 30 30’ cycloalkyl) and -NR R (where R and R are independently hydrogen, alkyl, or 33 33 hydroxyalkyl), and -C(O)NHR (where R is alkyl, alkenyl, alkynyl, or cycloalkyl).
78. The use of any one of Claims 59-70, wherein the MEK inhibitor is a compound of the formula (II): (II) or a pharmaceutically acceptable salt or solvate thereof, wherein: Z is CR or N; Z is CR or N; Z is CR or N; Z is CR or N; 1 2 3 4 where one or two of Z , Z , Z , and Z are N; 1 2 3 4 R , R , R and R are independently selected from H, halo, CN, CF , -OCF , -NO , 3 3 2 14 15 11 14 15 11 14 15 11 12 -(CR R ) C(=Y)R , -(CR R ) C(=Y)OR , -(CR R ) C(=Y)NR R , n n n 14 15 11 12 14 15 11 14 15 11 14 15 12 11 -(CR R ) NR R , -(CR R ) OR , -(CR R ) SR , -(CR R ) NR C(=Y)R , n n n n 14 15 12 11 14 15 13 11 12 14 15 12 11 -(CR R ) NR C(=Y)OR , -(CR R ) NR C(=Y)NR R , -(CR R ) NR SO R , n n n 2 14 15 11 14 15 11 14 15 11 12 -(CR R ) OC(=Y)R , -(CR R ) OC(=Y)OR , -(CR R ) OC(=Y)NR R , n n n 14 15 11 14 15 11 12 14 15 11 12 -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y)(OR )(OR ), -(CR R ) OP(OR )(OR ), n 2 n n 14 15 11 14 15 11 14 15 11 12 14 15 11 -(CR R )nS(O)R , -(CR R )nS(O)2R , -(CR R )n S(O)2NR R , -(CR R )nS(O)(OR ), 14 15 11 14 15 11 14 15 11 -(CR R ) S(O) (OR ), -(CR R ) SC(=Y)R , -(CR R ) SC(=Y)OR , n 2 n n 14 15 11 12 -(CR R ) SC(=Y)NR R , C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, n 1 12 2 8 2 8 heterocyclyl, aryl, and heteroaryl; 1 11 W is or ; R and R are independently selected from H or C -C alkyl; 1 12 1 11 11 11 12 11 11 1 11 X is selected from R , -OR , -NR R , -S(O)R , and -S(O) R ; when X is R or 11 11 11 1 5 -OR , R or -OR of X and -R are optionally taken together with the nitrogen atom to which they are attached to form a 4-7 membered saturated or unsaturated ring having 0-2 additional heteroatoms selected from O, S and N, wherein said ring is optionally substituted with one or more groups selected from halo, CN, CF , -OCF , -NO , oxo, -Si(C -C alkyl), 3 3 2 1 6 19 20 16 19 20 16 19 20 16 17 -(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR , -(CR R ) C(=Y’)NR R , n n n 19 20 16 17 19 20 16 19 20 16 19 20 16 17 -(CR R ) NR R , -(CR R ) OR , -(CR R ) -SR , -(CR R ) NR C(=Y’)R , n n n n 19 20 16 17 19 20 18 16 17 19 20 17 16 -(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R , -(CR R ) NR SO R , n n n 2 19 20 16 19 20 16 19 20 16 17 -(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR , -(CR R ) OC(=Y’)NR R , n n n 19 20 16 19 20 16 17 19 20 16 17 -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ), -(CR R ) OP(OR )(OR ), n 2 n n 19 20 16 19 20 16 19 20 16 17 19 20 16 -(CR R ) S(O)R , -(CR R ) S(O) R , -(CR R ) S(O) NR R , -(CR R ) S(O)(OR ), n n 2 n 2 n 19 20 16 19 20 16 19 20 16 19 20 -(CR R ) S(O) (OR ), -(CR R ) SC(=Y’)R , -(CR R ) SC(=Y’)OR , -(CR R ) n 2 n n n 16 17 21 SC(=Y’)NR R , and R ; X is selected from carbocyclyl, heterocyclyl, aryl, and heteroaryl; 11 12 13 R , R and R are independently H, C -C alkyl, C -C alkenyl, C -C alkynyl, 1 12 2 8 2 8 carbocyclyl, heterocyclyl, aryl, or heteroaryl, 11 12 or R and R together with the nitrogen to which they are attached form a 3-8 membered saturated, unsaturated or aromatic ring having 0-2 heteroatoms selected from O, S and N, wherein said ring is optionally substituted with one or more groups selected from halo, CN, CF , -OCF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), -S(C -C alkyl), -NH , 3 3 2 1 6 1 6 1 6 2 -NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C alkyl), 1 6 1 6 2 2 1 6 2 2 1 6 -C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C alkyl), 2 1 6 1 6 2 1 6 1 6 -NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), -SO NH , 1 6 2 1 6 1 6 2 1 6 2 2 -SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl), 2 1 6 2 1 6 2 2 1 6 -OC(O)N(C1-C6 alkyl)2, -OC(O)O(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -NHC(O)N(C1-C6 alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) , 2 1 6 1 6 1 6 1 6 2 -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C 1 6 1 6 2 1 6 1 6 alkyl)C(O)O(C -C alkyl); 14 15 R and R are independently selected from H, C -C alkyl, aryl, carbocyclyl, 1 12 heterocyclyl, and heteroaryl; m and n are independently selected from 0, 1, 2, 3, 4, 5, or 6; Y is independently O, NR , or S; wherein each said alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl 1 2 3 4 5 6 1 2 11 12 13 14 15 of R , R , R , R , R , R , X , X , R , R , R , R , and R is independently optionally substituted with one or more groups independently selected from halo, CN, CF , -OCF , -NO , 3 3 2 19 20 16 19 20 16 oxo, -Si(C -C alkyl), -(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR , 1 6 n n 19 20 16 17 19 20 16 17 19 20 16 19 20 16 -(CR R ) C(=Y’)NR R , -(CR R ) NR R , -(CR R ) OR , -(CR R ) -SR , n n n n 19 20 16 17 19 20 16 17 19 20 18 16 17 -(CR R ) NR C(=Y’)R , -(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R , n n n 19 20 17 16 19 20 16 19 20 16 -(CR R ) NR SO R , -(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR , n 2 n n 19 20 16 17 19 20 16 19 20 16 17 -(CR R ) OC(=Y’)NR R , -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ), n n 2 n 19 20 16 17 19 20 16 19 20 16 -(CR R ) OP(OR )(OR ), -(CR R ) S(O)R , -(CR R ) S(O) R , n n n 2 19 20 16 17 19 20 16 19 20 16 19 20 -(CR R ) S(O) NR R , -(CR R ) S(O)(OR ), -(CR R ) S(O) (OR ), -(CR R ) n 2 n n 2 n 16 19 20 16 19 20 16 17 21 SC(=Y’)R , -(CR R ) SC(=Y’)OR , -(CR R ) SC(=Y’)NR R , and R ; 16 17 18 each R , R and R is independently H, C -C alkyl, C -C alkenyl, C -C alkynyl, 1 12 2 8 2 8 carbocyclyl, heterocyclyl, aryl, or heteroaryl, wherein said alkyl, alkenyl, alkynyl,carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more groups selected from halo, oxo, CN, -OCF , CF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), -S(C -C alkyl), 3 3 2 1 6 1 6 1 6 -NH , -NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C alkyl), 2 1 6 1 6 2 2 1 6 2 2 1 6 -C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C alkyl), 2 1 6 1 6 2 1 6 1 6 -NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), -SO NH , 1 6 2 1 6 1 6 2 1 6 2 2 -SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl), 2 1 6 2 1 6 2 2 1 6 -OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C 1 6 2 1 6 1 6 1 6 alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) , 2 1 6 1 6 1 6 1 6 2 -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C 1 6 1 6 2 1 6 1 6 alkyl)C(O)O(C -C alkyl); 16 17 or R and R together with the nitrogen to which they are attached form a 3-8 membered saturated, unsaturated or aromatic ring having 0-2 heteroatoms selected from O, S and N, wherein said ring is optionally substituted with one or more groups selected from halo, CN, -OCF , CF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), -S(C -C alkyl), -NH , 3 3 2 1 6 1 6 1 6 2 -NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C alkyl), 1 6 1 6 2 2 1 6 2 2 1 6 -C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C alkyl), 2 1 6 1 6 2 1 6 1 6 -NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), -SO NH , 1 6 2 1 6 1 6 2 1 6 2 2 -SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl), 2 1 6 2 1 6 2 2 1 6 -OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C 1 6 2 1 6 1 6 1 6 alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) , 2 1 6 1 6 1 6 1 6 2 -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C 1 6 1 6 2 1 6 1 6 alkyl)C(O)O(C -C alkyl); 19 20 R and R are independently selected from H, C -C alkyl, -(CH ) -aryl, -(CH ) - 1 12 2 n 2 n carbocyclyl, -(CH ) -heterocyclyl, and -(CH ) -heteroaryl; 2 n 2 n R is C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, heterocyclyl, aryl, or 1 12 2 8 2 8 heteroaryl, wherein each member of R is optionally substituted with one or more groups selected from halo, CN, -OCF3, CF3, -NO2, C1-C6 alkyl, -OH, -SH, -O(C1-C6 alkyl), -S(C1-C6 alkyl), -NH , -NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C 2 1 6 1 6 2 2 1 6 2 2 1 6 alkyl), -C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C 2 1 6 1 6 2 1 6 1 6 alkyl), -NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), 1 6 2 1 6 1 6 2 1 6 -SO NH , -SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl), 2 2 2 1 6 2 1 6 2 2 1 6 -OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C 1 6 2 1 6 1 6 1 6 alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) , 2 1 6 1 6 1 6 1 6 2 -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C 1 6 1 6 2 1 6 1 6 alkyl)C(O)O(C -C alkyl); each Y’ is independently O, NR , or S; and R is H or C -C alkyl. 1 12
79. The use of any one of Claims 59-70, wherein the MEK inhibitor is a compound of the formula (III): (III) or a pharmaceutically acceptable salt or solvate thereof, wherein: Z is CR or N; 1 A A A R is H, C -C alkyl, halo, CF , CHF , CN, OR or NR R ; 1 3 3 2 1’ A A A R is H, C -C alkyl, halo, CF , CHF , CN, OR , or NR R ; 1 3 3 2 wherein each R is independently H or C -C alkyl; Z is CR or N; 3 3 1 2 3 Z is CR or N; provided that only one of Z , Z and Z can be N at the same time; R and R are independently selected from H, halo, CN, CF , -OCF , -NO , 3 3 2 14 15 11 14 15 11 14 15 11 12 -(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR , -(CR R ) C(=Y’)NR R , n n n 14 15 11 12 14 15 11 14 15 11 14 15 12 11 -(CR R ) NR R , -(CR R ) OR , -(CR R ) SR , -(CR R ) NR C(=Y’)R , n n n n 14 15 12 11 14 15 13 11 12 14 15 12 11 -(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R , -(CR R ) NR SO R , n n n 2 14 15 11 14 15 11 14 15 11 12 -(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR , -(CR R ) OC(=Y’)NR R , n n n 14 15 11 14 15 11 12 14 15 11 12 -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ), -(CR R ) OP(OR )(OR ), n 2 n n 14 15 11 14 15 11 14 15 11 12 14 15 11 -(CR R ) S(O)R , -(CR R ) S(O) R , -(CR R ) S(O) NR R , -(CR R ) S(O)(OR ), n n 2 n 2 n 14 15 11 14 15 11 14 15 11 -(CR R ) S(O) (OR ), -(CR R ) SC(=Y’)R , -(CR R ) SC(=Y’)OR , n 2 n n 14 15 11 12 -(CR R ) SC(=Y’)NR R , C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, n 1 12 2 8 2 8 heterocyclyl, aryl, and heteroaryl; R is H, C -C alkyl or C -C carbocyclyl; 1 6 3 4 Y is W-C(O)- or W’; 1 11' W is or ; R is H or C -C alkyl; 1 12 1 11’ 11’ 1 11’ 1 X is selected from R and -OR ; when X is R , X is optionally taken together with R and the nitrogen atom to which they are bound to form a 4-7 membered saturated or unsaturated ring having 0-2 additional heteroatoms selected from O, S and N, wherein said ring is optionally substituted with one or more groups selected from halo, CN, CF , -OCF , -NO , 3 3 2 19 20 16 19 20 16 19 20 16 17 oxo, -(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR , -(CR R ) C(=Y’)NR R , n n n 19 20 16 17 19 20 16 19 20 16 19 20 16 17 -(CR R ) NR R , -(CR R ) OR , -(CR R ) -SR , -(CR R ) NR C(=Y’)R , n n n n 19 20 16 17 19 20 18 16 17 19 20 17 16 -(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R , -(CR R ) NR SO R , n n n 2 19 20 16 19 20 16 19 20 16 17 -(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR , -(CR R ) OC(=Y’)NR R , n n n 19 20 16 19 20 16 17 19 20 16 17 -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ), -(CR R ) OP(OR )(OR ), n 2 n n 19 20 16 19 20 16 19 20 16 17 19 20 16 -(CR R ) S(O)R , -(CR R ) S(O) R , -(CR R ) S(O) NR R , -(CR R ) S(O)(OR ), n n 2 n 2 n 19 20 16 19 20 16 19 20 16 19 20 -(CR R ) S(O) (OR ), -(CR R ) SC(=Y’)R , -(CR R ) SC(=Y’)OR , -(CR R ) n 2 n n n 16 17 21 SC(=Y’)NR R , and R ; each R is independently H, C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, 1 12 2 8 2 8 heterocyclyl, aryl, or heteroaryl; 11 12 13 R , R and R are independently H, C -C alkyl, C -C alkenyl, C -C alkynyl, 1 12 2 8 2 8 carbocyclyl, heterocyclyl, aryl, or heteroaryl, 11 12 or R and R together with the nitrogen to which they are attached form a 3-8 membered saturated, unsaturated or aromatic ring having 0-2 heteroatoms selected from O, S and N, wherein said ring is optionally substituted with one or more groups selected from halo, CN, CF , -OCF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), -S(C -C alkyl), -NH , 3 3 2 1 6 1 6 1 6 2 -NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C alkyl), 1 6 1 6 2 2 1 6 2 2 1 6 -C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C alkyl), 2 1 6 1 6 2 1 6 1 6 -NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), -SO NH , 1 6 2 1 6 1 6 2 1 6 2 2 -SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl), 2 1 6 2 1 6 2 2 1 6 -OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C 1 6 2 1 6 1 6 1 6 alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) , 2 1 6 1 6 1 6 1 6 2 -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C 1 6 1 6 2 1 6 1 6 alkyl)C(O)O(C -C alkyl); 14 15 R and R are independently selected from H, C -C alkyl, aryl, carbocyclyl, 1 12 heterocyclyl, and heteroaryl; R O N O NH NH W’ is ; wherein is 7 7 7 R R R N 7 N N X 7 N X 7 X 7 N 7 N N R R R R R X N N N N N N N N N R N N N N N R O N HN O N N NH N N 7 O 7 N N NN each X is independently O, S, or NR ; each R is independently selected from H, halo, CN, CF , -OCF , -NO , 3 3 2 14 15 11 14 15 11 14 15 11 12 -(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR , -(CR R ) C(=Y’)NR R , n n n 14 15 11 12 14 15 11 14 15 11 14 15 12 11 -(CR R ) NR R , -(CR R ) OR , -(CR R ) SR , -(CR R ) NR C(=Y’)R , n n n n 14 15 12 11 14 15 13 11 12 14 15 12 11 -(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R , -(CR R ) NR SO R , n n n 2 14 15 11 14 15 11 14 15 11 12 -(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR , -(CR R ) OC(=Y’)NR R , n n n 14 15 11 14 15 11 12 14 15 11 12 -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ), -(CR R ) OP(OR )(OR ), n 2 n n 14 15 11 14 15 11 14 15 11 12 14 15 11 -(CR R ) S(O)R , -(CR R ) S(O) R , -(CR R ) S(O) NR R , -(CR R ) S(O)(OR ), n n 2 n 2 n 14 15 11 14 15 11 14 15 11 -(CR R ) S(O) (OR ), -(CR R ) SC(=Y’)R , -(CR R ) SC(=Y’)OR , n 2 n n 14 15 11 12 -(CR R ) SC(=Y’)NR R , C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, n 1 12 2 8 2 8 heterocyclyl, aryl, and heteroaryl; each R is independently selected from C -C alkyl, aryl, carbocyclyl, heterocyclyl, and 1 12 heteroaryl; 9 14 15 11 14 15 11 R is selected from H, -(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR , 14 15 11 12 14 15 11 12 14 15 11 14 15 11 -(CR R ) C(=Y’)NR R , -(CR R ) NR R , -(CR R ) OR , -(CR R ) SR , n q q q 14 15 12 11 14 15 12 11 14 15 13 11 12 -(CR R ) NR C(=Y’)R , -(CR R ) NR C(=Y’)OR , -(CR R ) NR C(=Y’)NR R , q q q 14 15 12 11 14 15 11 14 15 11 -(CR R ) NR SO R , -(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR , q 2 q q 14 15 11 12 14 15 11 14 15 11 12 -(CR R ) OC(=Y’)NR R , -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ), q q 2 q 14 15 11 12 14 15 11 14 15 11 14 15 -(CR R ) OP(OR )(OR ), -(CR R ) S(O)R , -(CR R ) S(O) R , -(CR R ) q n n 2 n 11 12 S(O) NR R , C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, heterocyclyl, aryl, and 2 1 12 2 8 2 8 heteroaryl; R is H, C -C alkyl or C -C carbocyclyl; 1 6 3 4 (R ) X is ; R is H, halo, C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, heteroaryl, 1 6 2 8 2 8 19 20 16 17 19 20 16 heterocyclyl, -OCF , -NO , -Si(C -C alkyl), -(CR R ) NR R , -(CR R ) OR , or 3 2 1 6 n n 19 20 16 -(CR R ) -SR ; R is H, halo, C -C alkyl, carbocyclyl, CF , -OCF , -NO , -Si(C -C alkyl), 1 6 3 3 2 1 6 19 20 16 17 19 20 16 19 20 16 -(CR R ) NR R , -(CR R ) OR , -(CR R ) -SR , C -C alkenyl, C -C alkynyl, n n n 2 8 2 8 heterocyclyl, aryl, or heteroaryl; p is 0, 1, 2 or 3; n is 0,1, 2 or 3; q is 2 or 3; wherein each said alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl 1 2 3 4 5 6 6’ 7 8 9 10 11 11’ 12 13 14 15 A of R , R , R , R , R , R , R , R , R , R , R , R , R , R , R , R , R and R is independently optionally substituted with one or more groups independently selected from halo, CN, CF , 19 20 16 19 20 16 -OCF , -NO , oxo, -Si(C -C alkyl), -(CR R ) C(=Y’)R , -(CR R ) C(=Y’)OR , 3 2 1 6 n n 19 20 16 17 19 20 16 17 19 20 16 19 20 16 -(CR R ) C(=Y’)NR R , -(CR R ) NR R , -(CR R ) OR , -(CR R ) SR , n n n n 19 20 16 17 19 20 16 17 19 20 18 16 17 -(CR R )nNR C(=Y’)R , -(CR R )nNR C(=Y’)OR , -(CR R )nNR C(=Y’)NR R , 19 20 17 16 19 20 16 19 20 16 -(CR R ) NR SO R , -(CR R ) OC(=Y’)R , -(CR R ) OC(=Y’)OR , n 2 n n 19 20 16 17 19 20 16 19 20 16 17 -(CR R ) OC(=Y’)NR R , -(CR R ) OS(O) (OR ), -(CR R ) OP(=Y’)(OR )(OR ), n n 2 n 19 20 16 17 19 20 16 19 20 16 -(CR R ) OP(OR )(OR ), -(CR R ) S(O)R , -(CR R ) S(O) R , n n n 2 19 20 16 17 19 20 16 19 20 16 -(CR R ) S(O) NR R , -(CR R ) S(O)(OR ), -(CR R ) S(O) (OR ), n 2 n n 2 19 20 16 19 20 16 19 20 16 17 21 -(CR R ) SC(=Y’)R , -(CR R ) SC(=Y’)OR , -(CR R ) SC(=Y’)NR R , and R ; n n n 16 17 18 each R , R and R is independently H, C -C alkyl, C -C alkenyl, C -C alkynyl, 1 12 2 8 2 8 carbocyclyl, heterocyclyl, aryl, or heteroaryl, wherein said alkyl, alkenyl, alkynyl,carbocyclyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one or more groups selected from halo, CN, -OCF , CF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), -S(C -C alkyl), -NH , 3 3 2 1 6 1 6 1 6 2 -NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, -CO (C -C alkyl), 1 6 1 6 2 2 1 6 2 2 1 6 -C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C alkyl), 2 1 6 1 6 2 1 6 1 6 -NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), -SO NH , 1 6 2 1 6 1 6 2 1 6 2 2 -SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl), 2 1 6 2 1 6 2 2 1 6 -OC(O)N(C1-C6 alkyl)2, -OC(O)O(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -NHC(O)N(C1-C6 alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) , 2 1 6 1 6 1 6 1 6 2 -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C 1 6 1 6 2 1 6 1 6 alkyl)C(O)O(C -C alkyl); 16 17 or R and R together with the nitrogen to which they are attached form a 3-8 membered saturated, unsaturated or aromatic ring having 0-2 heteroatoms selected from O, S and N, wherein said ring is optionally substituted with one or more groups selected from halo, CN, -OCF , CF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), -S(C -C alkyl), -NH , 3 3 2 1 6 1 6 1 6 2 -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -SO2(C1-C6 alkyl), -CO2H, -CO2(C1-C6 alkyl), -C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C alkyl)C(O)(C -C alkyl), 2 1 6 1 6 2 1 6 1 6 -NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C alkyl)SO (C -C alkyl), -SO NH , 1 6 2 1 6 1 6 2 1 6 2 2 -SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , -OC(O)NH(C -C alkyl), 2 1 6 2 1 6 2 2 1 6 -OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C 1 6 2 1 6 1 6 1 6 alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C alkyl)C(O)N(C -C alkyl) , 2 1 6 1 6 1 6 1 6 2 -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , -NHC(O)O(C -C alkyl), and -N(C -C 1 6 1 6 2 1 6 1 6 alkyl)C(O)O(C -C alkyl); 19 20 R and R are independently selected from H, C -C alkyl, -(CH ) -aryl, -(CH ) - 1 12 2 n 2 n carbocyclyl, -(CH ) -heterocyclyl, and -(CH ) -heteroaryl; 2 n 2 n R is C -C alkyl, C -C alkenyl, C -C alkynyl, carbocyclyl, heterocyclyl, aryl, or 1 12 2 8 2 8 heteroaryl, wherein each member of R is optionally substituted with one or more groups selected from halo, oxo, CN, -OCF , CF , -NO , C -C alkyl, -OH, -SH, -O(C -C alkyl), 3 3 2 1 6 1 6 -S(C -C alkyl), -NH , -NH(C -C alkyl), -N(C -C alkyl) , -SO (C -C alkyl), -CO H, 1 6 2 1 6 1 6 2 2 1 6 2 -CO (C -C alkyl), -C(O)NH , -C(O)NH(C -C alkyl), -C(O)N(C -C alkyl) , -N(C -C 2 1 6 2 1 6 1 6 2 1 6 alkyl)C(O)(C -C alkyl), -NHC(O)(C -C alkyl), -NHSO (C -C alkyl), -N(C -C 1 6 1 6 2 1 6 1 6 alkyl)SO (C -C alkyl), -SO NH , -SO NH(C -C alkyl), -SO N(C -C alkyl) , -OC(O)NH , 2 1 6 2 2 2 1 6 2 1 6 2 2 -OC(O)NH(C -C alkyl), -OC(O)N(C -C alkyl) , -OC(O)O(C -C alkyl), -NHC(O)NH(C -C 1 6 1 6 2 1 6 1 6 alkyl), -NHC(O)N(C -C alkyl) , -N(C -C alkyl)C(O)NH(C -C alkyl), -N(C -C 1 6 2 1 6 1 6 1 6 alkyl)C(O)N(C -C alkyl) , -NHC(O)NH(C -C alkyl), -NHC(O)N(C -C alkyl) , 1 6 2 1 6 1 6 2 -NHC(O)O(C -C alkyl), and -N(C -C alkyl)C(O)O(C -C alkyl); 1 6 1 6 1 6 each Y’ is independently O, NR , or S; and R is H or C -C alkyl. 1 12
80. The use of any one of Claims 59-70, wherein the MEK inhibitor is a compound of the formula (IV): (IV) or a pharmaceutically acceptable salt or solvate thereof, wherein: each dashed line ( ) represents an optional bond, provided that one and only one nitrogen of the ring is double-bonded; 1 2 9 10 R , R , R and R are independently selected from hydrogen, halogen, cyano, nitro, 3 3 3 trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -OR , -C(O)R , -C(O)OR , 4 6 3 4 6 3 4 4 3 3 4 -NR C(O)OR , -OC(O)R , -NR SO R , -SO NR R , -NR C(O)R , -C(O)N R R , 5 3 4 5 3 4 3 4 -NR C(O)NR R , -NR C(NCN)NR R , - NR R , C -C alkyl, C -C alkenyl, C -C 1 10 2 10 2 10 alkynyl, C -C cycloalkyl, C -C cycloalkylalkyl, -S(O) (C -C alkyl), 3 10 3 10 j 1 6 -S(O)j(CR R ) -aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, 4 5 4 4 5 4 5 heterocyclylalkyl, -O(CR R ) -aryl, -NR (CR R ) -aryl, -O(CR R ) -heteroaryl, m m m 4 4 5 4 5 4 4 5 -NR (CR R ) -heteroaryl, -O(CR R ) -heterocyclyl and -NR (CR R ) -heterocyclyl; m m m where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, 4 6 3 4 3 3 3 4 6 4 3 -NR SO R , -SO NR R , -C(O)R , -C(O)OR , -OC(O)R , -NR C(O)OR , -NR C(O)R , 3 4 3 4 5 3 4 5 3 4 3 -C(O)NR R , -NR R , -NR C(O)NR R , -NR C(NCN)NR R , -OR , aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R is selected from hydrogen, trifluoromethyl, C -C alkyl, C -C alkenyl, C -C alkynyl, 1 10 2 10 2 10 C -C cycloalkyl, C -C cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, 3 10 3 10 heterocyclyl, and heterocyclylalkyl; where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR’SO R””, -SO NR’R”, -C(O)R’, -C(O)OR’, -OC(O)R’, -NR’C(O)OR””, -NR’C(O)R”, -C(O)NR’R”, -SR’, -S(O)R””, -SO R””, -NR’R”, -NR’C(O)NR”R’”, -NR’C(NCN)NR”R’”, -OR’, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R’, R”, R’” independently are selected from hydrogen, lower alkyl, lower alkenyl, aryl and arylalkyl; R”” is selected from lower alkyl, lower alkenyl, aryl and arylalkyl; or any two of R’, R”, R’” or R”” can be taken together with the atom to which they are attached to form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; or R and R can be taken together with the atom to which they are attached to form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR’SO R””, -SO NR’R”, - C(O)R’, -C(O)OR’, -OC(O)R’, -NR’C(O)OR””, -NR’C(O)R”, -C(O)NR’R”, -SO R””, -NR’R”, -NR’C(O)NR”R’”, -NR’C(NCN)NR”R’”, -OR’, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; or R and R independently represent hydrogen or C -C alkyl; or R and R together with the atom to which they are attached form a 4 to 10 membered carbocyclic, heteroaryl or heterocyclic ring, each of which is optionally substituted with one to three groups independently selected from halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR’SO R””, -SO NR’R”, -C(O)R’, -C(O)OR’, -OC(O)R’, -NR’C(O)OR””, -NR’C(O)R”, -C(O)NR’R”, -SO R””, -NR’R”, -NR’C(O)NR”R’”, -NR’C(NCN)NR”R’”, -OR’, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R is selected from trifluoromethyl, C -C alkyl, C -C cycloalkyl, aryl, arylalkyl, heteroaryl, 1 10 3 10 heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, where each alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, -NR’SO R””, -SO NR’R”, -C(O)R’, -C(O)OR’, -OC(O)R’, -NR’C(O)OR””, -NR’C(O)R”, -C(O)NR’R”, -SO R””, -NR’R”, -NR’C(O)NR”R’”, -NR’C(NCN)NR”R’”, -OR’, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R is selected from hydrogen, C -C alkyl, C -C alkenyl, C -C alkynyl, C -C cycloalkyl, 1 10 2 10 2 10 3 10 C3-C10 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, 4 6 3 4 3 3 3 trifluoromethoxy, azido, -NR SO R , -SO NR R , -C(O)R , -C(O)OR , -OC(O)R , 4 6 4 3 3 4 6 3 4 5 3 4 -NR C(O)OR , -NR C(O)R , -C(O)NR R , -SO R , -NR R , -NR C(O)NR R , 5 3 4 3 -NR C(NCN)NR R , -OR , aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; 3 3 4 4 3 W is selected from heteroaryl, heterocyclyl, -C(O)OR , -C(O)NR R , -C(O)NR OR , -C(O)R OR , -C(O)(C -C cycloalkyl), -C(O)(C -C alkyl), -C(O)(aryl), 3 10 1 10 -C(O)(heteroaryl) and -C(O)(heterocyclyl); each of which is optionally substituted with 3 4 3 2 1-5 groups independently selected from -NR R , -OR , -R , and C -C alkyl, C -C 1 10 2 10 alkenyl, and C -C alkynyl, each of which is optionally substituted with 1 or 2 groups 2 10 3 4 3 independently selected from -NR R and-OR ; R is selected from hydrogen, -SCF , -Cl, -Br, -F, cyano, nitro, trifluoromethyl, difluoromethoxy, 3 3 3 4 6 3 trifluoromethoxy, azido, -OR , -C(O)R , -C(O)OR , -NR C(O)OR , -OC(O)R , 4 6 3 4 4 3 3 4 5 3 4 3 4 -NR SO R , -SO NR R , -NR C(O)R , -C(O)NR R , -NR C(O)NR R , -NR R , and C - 2 2 1 C alkyl, C -C alkenyl, C -C alkynyl, C -C cycloalkyl, C -C cycloalkylalkyl, 10 2 10 2 10 3 10 3 10 -S(O) (C -C alkyl), -S(O) (CR R ) -aryl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, j 1 6 j m 4 5 4 4 5 heterocyclyl, heterocyclylalkyl, -O(CR R ) -aryl, -NR (CR R ) -aryl, 4 5 4 4 5 4 5 -O(CR R ) -heteroaryl, -NR (CR R ) -heteroaryl, -O(CR R ) -heterocyclyl and m m m 4 4 5 -NR (CR R ) -heterocyclyl, where each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclyl portion is optionally substituted with one to five groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethoxy, 4 6 3 4 3 3 3 trifluoromethoxy, azido, -NR SO R , -SO NR R , -C(O)R , -C(O)OR , -OC(O)R , 4 6 4 3 3 4 3 4 5 3 4 -NR C(O)OR , -NR C(O)R , -C(O)NR R , -NR R , -NR C(O)NR R , 5 3 4 3 -NR C(NCN)NR R , -OR , aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; m is O, 1, 2, 3, 4 or 5; and j is 1 or 2.
81. The use of any one of Claims 59-70, wherein the MEK inhibitor is a compound of the formula (V): or a pharmaceutically acceptable salt or solvate thereof, wherein: X and X are the same or different and each is a carbon atom or a nitrogen atom, a moiety is ; 1 2 6 R , R , and R are the same or different and each is a C alkyl group, a C alkenyl group, 1-6 2-6 wherein the C alkyl group and the C alkenyl group are optionally substituted by 1 to 1-6 2-6 3 substituents selected from the following group A, or , wherein m is 0 or an integer of 1 to 4, ring Cy is a C carbon ring group or a heterocyclic group, wherein the heterocyclic 3-12 group is a saturated or unsaturated ring group having, besides carbon atom, 1 to 4 hetero atoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, the C carbon ring group and the heterocyclic group are optionally substituted 3-12 by 1 to 5 substituents selected from the following group B; 3 4 5 R , R , and R are the same or different and each is a hydrogen atom; a hydroxyl group; a C alkyl group, optionally substituted by 1 to 3 substituents selected from the following group A; a C alkenyl group, optionally substituted by 1 to 3 substituents selected from the following group A; a C3-12 carbon ring group, optionally substituted by 1 to 5 substituents selected from the following group B; or a heterocyclic group, wherein the heterocyclic group is a saturated or unsaturated ring group having, besides carbon atom, 1 to 4 hetero atoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, and is optionally substituted by 1 to 5 substituents selected from the following group B; R and R are optionally linked to form a C alkylene group; or R and R are optionally linked to form a C ι- alkylene group; wherein group A is a group consisting of: 1) a halogen atom, 2) a nitro group, 3) a cyano group, 4) a C alkyl group, A1 A1 5) -OR wherein R is a hydrogen atom or a C alkyl group, A2 A2 6) -SR wherein R is a hydrogen atom or a C alkyl group, A3 A4 A3 A4 7) -NR R wherein R and R are the same or different and each is a hydrogen atom or a C1-4 alkyl group, A5 A5 8) -COOR wherein R is a hydrogen atom or a C alkyl group, A6 A7 A6 A7 9) -NR COR wherein R is a hydrogen atom or a C alkyl group, R is a C alkyl 1-4 1-4 group, a C carbon ring group or a heterocyclic group, 3-12 A8 A9 A8 A9 10) -NR COOR wherein R and R are the same or different and each is a hydrogen atom or a C alkyl group, 11) a C carbon ring group, and 3-12 12) a heterocyclic group, wherein the heterocyclic group is a saturated or unsaturated ring group having, besides carbon atom, 1 to 4 hetero atoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, A1 A2 A3 A5 A6 A7 each of the C1-4 alkyl groups of the above-mentioned 4), R , R , R , R , R , R , A8 A9 R and R is optionally substituted by the same or different 1 to 3 substituents selected from the following group C, and each of the C carbon ring groups of the above-mentioned 11) and R , and the 3-12 heterocyclic groups of 12) and R is optionally substituted by the same or different 1 to 5 substituents selected from the following group C; group B is a group consisting of: 1) a halogen atom, 2) a nitro group, 3) a cyano group, 4) a C alkyl group, 5) a C alkenyl group, 6) a C alkynyl group, B1 B1 7) -OR wherein R is a hydrogen atom or a C alkyl group, B2 B2 8) -SR wherein R is a hydrogen atom or a C alkyl group, B3 B4 B3 9) -NR R wherein R is a hydrogen atom, a C alkyl group, a C carbon ring 1-4 3-12 group or a heterocyclic group, and R is a hydrogen atom or a C alkyl group, B5 B6 B5 B6 10) -NR COR wherein R is a hydrogen atom or a C alkyl group, and R is a hydrogen atom, a C alkyl group, a C carbon ring group or a heterocyclic group, 1-4 3-12 B7 B8 B7 B8 11) -NR COOR wherein R and R are the same or different and each is a hydrogen atom or a C alkyl group, B9 B10 B11 B9 B10 B11 12) -NR CONR R wherein R , R and R are the same or different and each is a hydrogen atom or a C1-4 alkyl group, B12 B13 B14 B12 B13 B14 13) -NR CONR OR wherein R , R and R are the same or different and each is a hydrogen atom or a C alkyl group, B15 B16 B15 B16 14) -NR SO R wherein R is a hydrogen atom or a C alkyl group, and R is a 2 1-4 C alkyl group, a C carbon ring group or a heterocyclic group, 1-4 3-12 B17 B17 15) -SO -R wherein R is a C alkyl group or a heterocyclic group, 2 1-4 B18 B19 B18 B19 16) -SO NR R wherein R and R are the same or different and each is a hydrogen atom or a C alkyl group , B20 B21 B20 B21 17) -P(=O)(R )(R ) wherein R and R are the same or different and each is a C alkyl group, B22 B22 18) -COOR wherein R is a hydrogen atom or a C1-4 alkyl group, B23 B24 B23 B24 19) -CONR R wherein R and R are the same or different and each is a hydrogen atom or a C alkyl group, B25 B26 B27 B25 B26 B27 20) -NR SO NR R wherein R , R and R are the same or different and each is a hydrogen atom or a C alkyl group, B28 B29 B30 B31 B28 B29 B30 B31 21) -NR SO NR CONR R wherein R , R , R and R are the same or different and each is a hydrogen atom or a C alkyl group, 22) a C carbon ring group, and 3-12 23) a heterocyclic group; wherein each of the “C alkyl group” of the above-mentioned 4), and the C alkyl 1-8 1-4 B1 B31 groups for R to R is optionally substituted by the same or different 1 to 3 substituents selected from the above-mentioned group A, each of the C alkenyl group of 5) and the C alkynyl group of 6) is optionally substituted by the same or different 1 to 3 substituents selected from the above-mentioned group A, the heterocyclic group is a saturated or unsaturated ring group having, besides carbon atom, 1 to 4 hetero atoms selected from an oxygen atom, a nitrogen atom and a sulfur B3 B6 atom, and each of the C carbon ring group of the above-mentioned 22), R , R 3-12 B16 B3 B6 B16 and R , and the heterocyclic group of the above- mentioned 23), R , R , R and R is optionally substituted by the same or different 1 to 5 substituents selected from the following group C; group C is a group consisting of: 1) a halogen atom, 2) a cyano group, 3) a C alkyl group, C1 C1 4) -OR wherein R is a hydrogen atom or a C alkyl group, C2 C3 C2 C3 5) -NR R wherein R and R are the same or different and each is a hydrogen atom or a C alkyl group, C4 C4 6) –COOR wherein R is a hydrogen atom or a C alkyl group, and 7) an oxo group.
82. The use of any one of Claims 59-70, wherein the MEK inhibitor is a compound of the formula (VI): (VI) or a pharmaceutically acceptable salt or ester thereof, wherein: R1 is selected from the group consisting of bromo, iodo, ethynyl, cycloalkyl, alkoxy, azetidinyl, acetyl, heterocycyl, cyano, straight-chained alkyl and branched-chain alkyl; R2 is selected from the group consisting of hydrogen, chlorine, fluorine, and alkyI; R3 is selected from the group consisting of hydrogen, chlorine, and fluorine; R4 is selected from the group consisting of hydrogen, optionally substituted aryl, alkyl, and cycloalkyl; R5 is selected from the group consisting of hydrogen and ; wherein R6 is selected from the group consisting of hydroxyl, alkoxy, cycloalkyl, optionally substituted alkyl, optionally substituted aryl, and optionally substituted heteroaryl; R7 and R8 are independently selected from the group consisting of hydrogen and optionally substituted alkyl; or R6 and R7 can together form a cycloalkyl group and R8 is hydrogen.
83. The use of any one of Claims 59-70, wherein the MEK inhibitor is a compound of the formula (VII): (VII) or a pharmaceutically acceptable salt or ester thereof, wherein: R1 is selected from the group consisting of halogen, ethynyl, and cycloalkyl; R2 is selected from the group consisting of hydrogen and CH(R3)(R4); R3 is selected from the group consisting of lower alkyl, lower alkoxy, optionally substituted aryl, and optionally substituted heteroaryl; R4 is selected from the group consisting of hydrogen and lower alkyl; R5 is hydrogen or, taken together with R2 and the carbon to which R2 and R5 are attached, forms lower cycloalkyl; and R6 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl.
84. The use of any one of Claims 59-70, wherein the MEK inhibitor is a compound selected from the group consisting of: , , , and or a pharmaceutically acceptable salt or solvate thereof.
85. The use of claim 84, wherein the MEK inhibitor is a compound selected from the group consisting of: , and or a pharmaceutically acceptable salt or solvate thereof.
86. The use of any one of Claims 59-70, wherein the PD-1 axis binding antagonist is an antibody.
87. The use of claim 85, wherein PD-L1 on the cancer cell surface is inhibited from transducing a signal to the intracellular pathway.
88. The use of claim 85, wherein the antibody is capable of inhibiting binding between PD- L1 and PD-1 and/or between PD-L1 and B7-1.
89. The use of claim 21 or 73, wherein the antibody is a monoclonal antibody.
90. The use of claim 21 or 73, wherein the antibody is an antibody fragment selected from the group consisting of Fab, Fab’-SH, Fv, scFv, and (Fab’) fragments.
91. The use of claim 21 or 73, wherein the antibody is a humanized antibody.
92. The use of claim 21 or 73, wherein the antibody is a human antibody.
93. The use of claim 73, wherein the antibody comprises a heavy chain comprising HVR-H1 sequence of SEQ ID NO:15, HVR-H2 sequence of SEQ ID NO:16, and HVR-H3 sequence of SEQ ID NO:3; and a light chain comprising HVR-L1 sequence of SEQ ID NO:17, HVR-L2 sequence of SEQ ID NO:18, and HVR-L3 sequence of SEQ ID NO:19.
94. The use of claim 73, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:24 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:21.
95. The use of any one of claims 1-81, wherein the PD-1 axis binding antagonist is to be administered intravenously, intramuscularly, subcutaneously, topically, orally, transdermally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally.
96. The use of any one of claims 1-82, wherein the PD-1 axis binding antagonist and/or the MEK inhibitor are present in the medicament in an effective amount.
97. Use of a kit comprising a PD-1 axis binding antagonist in the manufacture of a medicament for treating or delay progression of cancer in an individual, wherein the PD-1 axis binding antagonist is for use in combination with a MEK inhibitor.
98. Use of a kit comprising a PD-1 axis binding antagonist and a MEK inhibitor in the manufacture of a medicament for treating or delay progression of cancer in an individual.
99. Use of a kit comprising a MEK inhibitor in the manufacture of a medicament for treating or delay progression of cancer in an individual, wherein the MEK inhibitor is for use in combination with a PD-1 axis binding antagonist.
100. The use of any one of Claims 97-99, wherein the PD-1 axis binding antagonist is an anti-PD-L1 antibody.
101. The use of any one of Claims 97-99, wherein the PD-1 axis binding antagonist is an anti-PD-1 antibody.
102. The use of any one of Claims 97-99, wherein the PD-1 axis binding antagonist is an anti-PD-1 immunoadhesin.
103. A use as claimed in any one of claims 1-102, substantially as herein described with reference to any example thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161574406P | 2011-08-01 | 2011-08-01 | |
US61/574,406 | 2011-08-01 | ||
PCT/US2012/049233 WO2013019906A1 (en) | 2011-08-01 | 2012-08-01 | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ620411A NZ620411A (en) | 2016-07-29 |
NZ620411B2 true NZ620411B2 (en) | 2016-11-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10646567B2 (en) | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | |
US20220105180A1 (en) | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors | |
NZ620411B2 (en) | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors | |
TWI835048B (en) | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |